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By
Vishvas Garg
Bachelor of Pharmacy
Master of Business Administration
Doctor of Philosophy
ABSTRACT
Background/Purpose: Knee osteoarthritis (KOA) affects 13.8% of the US
population aged ≥26, causing significant burden-of-illness. We examined the costeffectiveness of conventional medicines such as non-steroidal anti-inflammatory drugs
(NSAIDs) and celecoxib and complementary and alternative medicines (CAM) therapies
to treat KOA from the US health care payers’ and patients’ perspectives and from 24week, 2-year, and 10-year time-horizons.
Methodology: We constructed a Markov cohort model (10-year analysis) and a
decision-tree model (24-week and 2-year analyses). All costs were obtained from the
published literature (converted to 2012 USD) and included both direct and indirect health
care costs of medications, drugs associated adverse events, and total knee replacement
surgery. Effectiveness was measured in Quality-adjusted life-years (QALYs) gained.
Clinical efficacies for treatment strategies under study were obtained from the
Glucosamine/CS Arthritis Intervention Trial (GAIT). Cost-effectiveness were estimated
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by severity of baseline knee pain, categorized based on the data from GAIT into overall,
mild pain only, and moderate-to-severe pain groups. Multiple published sources were
used to obtain rest of the modeling parameters. Base-case results were varied in both oneway and probabilistic sensitivity analysis.
Results: We found that, in general, CAM therapies are cost-effective than
conventional medicines to treat KOA in the US, with CS being the most cost-effective
treatment. With CS as the reference, glucosamine was the most cost-effective, except for
in mild pain only KOA patients group from 24-week time-horizon where celecoxib was
the most cost-effective. Among the moderate-to-severe pain group, combination therapy
of glucosamine and CS was the most cost-effective. A major driver of cost-effectiveness
of CAM therapies over conventional medicines was the exclusion of the risk of adverse
events associated with the former because of the lack of evidence.
Conclusion: CAM therapies are cost-effective than conventional medicines in
treating KOA, both because of adverse events associated with latter and their higher drug
utilization costs. Decision-makers could inform their treatment selection decisions from
the findings of our study; however, future research is required to examine the long-term
effectiveness and safety of CAM therapies in treating KOA.
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CHAPTER 1: INTRODUCTION
This chapter is divided into four sections. In the first section, we provide
background of our study. In the second section, we discuss the specific aims and
objectives for this study. These are followed by the theoretical framework for our study
in section three. This chapter is concluded by providing significance of this study in
section four.
Background
Knee osteoarthritis (KOA) has substantial burden-of-illness in the United States
(US). It is the most common form of osteoarthritis, affecting 13.8% of the US population
aged 26 or more.1 Patients with KOA have significantly higher health care resource
utilization, in comparison to healthy controls.2, 3 More than half of KOA patients undergo
total knee replacement (TKR) surgery during their life-time.3 Further, the KOA patients
have 6.0 times (95% CI=4.7 to 7.4) higher rates of physicians visits and 28% more
hospitalizations.2 KOA is a debilitating illness that significantly lowers both physical and
mental quality-of-life of patients suffering from it.4
Although there is no currently known cure for KOA, its treatment options are
focused on pain reduction, maintaining or improving joint mobility, and limiting
functional impairment.5 These treatment options include pharmacological modalities and
complementary and alternate medicine (CAM) therapies such as glucosamine and
chondroitin sulfate (CS). A commonly prescribed class of pharmacological modalities to
treat KOA is the non-steroidal anti-inflammatory drugs (NSAIDs). These NSAIDs
include both selective (e.g., celecoxib—a cyclooxygenase-2 [COX-2] only inhibitor) and
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non-selective NSAIDs (e.g., diclofenac and naproxen—both cyclooxygenase-1 [COX-1]
and COX-2 inhibitors).6-8 The efficacies of these NSAIDs to manage KOA are wellestablished in several randomized, double-blinded, placebo-controlled, multi-center
clinical trials.9-24
On the other hand, the effectiveness of commonly used CAM therapies such as
glucosamine and CS to treat KOA is currently debated. A recent meta-analysis of ten
randomized clinical trials with a total sample size of 3803 patients found no significant
differences in joint pain reduction or joint space narrowing benefits between placebo and
glucosamine, CS, or combination therapy of glucosamine and CS among the KOA
patients.25 However, this study is criticized for not studying the effect of CAM therapies
on joint replacement rates and for using artificially back transformed effect sizes in
making pool estimations for meta-analysis calculations.26, 27 This study also didn’t
consider the risk reduction in TKR surgery (5-year relative risk=0.43; 95% CI=0.2-0.92)
among those in the glucosamine group (who had taken 1500 mg glucosamine sulfate for
12-36 months) compared with placebo.28 Moreover, another meta-analysis found effect
size of 0.35 (95% CI=0.14 to 0.56) in favor of glucosamine.29
Despite several controversies surrounding the effectiveness of CAMs therapies
(as described above), these are widely used to treat KOA in the US.30 A recent marketing
study reported 2008 sales of glucosamine totaling to $872 million in the US and $4
billion globally.31 Another study reported 47% of KOA patients using CAM therapies at
least once to treat their illness..32 The National Health Interview Survey of 2007 further
found a total of $14.8 billion were spent out-of-pocket on the non-vitamin, non-mineral,
natural products that includes glucosamine and CS.30
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The Glucosamine/CS Arthritis Intervention Trial (GAIT)—largest clinical trial
examining efficacy of CAM therapies to treat KOA—compared celecoxib, glucosamine,
CS, combination of glucosamine and CS, and placebo in a multi-center double-blind
randomized study.21 A total of 1583 individuals with symptomatic KOA were randomly
assigned to receive daily doses of 1500 mg of glucosamine, 1200 mg of CS, both
glucosamine and CS, 200 mg of celecoxib, or placebo for 24 weeks. The primary
outcome measure was at least 20% reduction in pain from baseline enrollment, measured
using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
pain sub-scale. KOA patient groups were stratified by severity of knee pain at the
baseline into mild and moderate to severe. Overall, glucosamine, CS, or their
combination therapies were not significantly different from placebo in pain reduction,
p>0.05. Among the moderate to severe pain stratum group of patients, however, the
combination of glucosamine and CS was significantly better than placebo in treating
KOA. On the other hand, celecoxib was better than placebo in both overall analysis and
in mild-to-moderate pain stratum groups, but not in moderate-to-severe pain stratum.
A 2-year follow-up study of the GAIT—the ancillary structure modifying study—
was also conducted on a sub-group of original participants.24, 33 For this follow-up study,
a total of 662 participants were randomly assigned to glucosamine (n=134), CS (n=126),
combination of glucosamine and CS (n=129), celecoxib (n=142), and placebo groups
(n=131). The primary outcome measure was the loss of joint space width (JSW) in the
medial tibiofemoral joint compartment. The reduction in WOMAC pain sub-scale scores
from baseline at 2 years was also recorded as a secondary outcome measure in this
follow-up study. No significant differences were found between placebo and celecoxib,
3

glucosamine, CS, and combination of glucosamine and CS in reducing the loss of JSW or
change in WOMAC pain sub-scale scores at 2-year follow-up, p>0.05.
Cost-effectiveness analysis is an important tool to compare health technologies
based on their effectiveness and costs.34, 35 An increasing number of both private and
public healthcare systems in the US are utilizing the findings of these cost-effectiveness
analyses to make their coverage decisions.36-39 Requirements to examine the costeffectiveness of CAM therapies in the US have been raised previously.40 Currently,
several US health plans provide coverage for CAM therapies, including herbal
supplements.41-4343,61,62 Physicians practicing in the US also have positive believes
regarding benefits of CAM therapies in treating KOA; a recent survey concluded 39% of
the rheumatologists in the US believe glucosamine and/or CS to be at least moderately
beneficial.44 A systematic review of PubMed was conducted (1996 to February 2013) to
identify cost-effectiveness analyses comparing cost-effectiveness of glucosamine, CS,
their combined therapy, celecoxib, NSAIDs, and placebo. From this search, no studies
were found that have compared the cost-effectiveness of aforementioned therapies. Our
study fills the knowledge gap in cost-effectiveness of CAM therapies and conventional
medicines to treat KOA.
Specifically, the purpose of our study was to examine the cost-effectiveness of
1500 mg of glucosamine daily, 1200 mg of CS daily, combination of glucosamine 1500
mg and CS 1200 mg daily, 200 mg of celecoxib daily, US Food and Drug Administration
(FDA) approved NSAIDs, and placebo in treating KOA. Separate analyses were
conducted from health care payers’ and patients perspectives. Time-horizons for our
study were 24-weeks, 2 years, and 10 years. The costs measures included costs of
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conventional drugs and CAM therapies utilization, drugs associated adverse events
treatment, physician’s office visits, and TKR surgery among the KOA patients. The
effectiveness was measured as quality-adjusted life-years (QALYs) gained, based on its
endorsement for the “reference case” cost-effectiveness analysis by the US Panel on
Cost-Effectiveness in Health and Medicine (USPCEHM) and the National Institute of
Clinical Excellence (NICE) of the United Kingdom (UK).34, 45 Health utility values to
estimate QALYs were obtained by mapping the short form (SF)-36 scores recorded in the
GAIT study to SF-6 dimensions (SF-6D) instrument.
Two decision-analytic models—a decision-tree and a Markov cohort model—
were constructed for the purpose of our study. While the decision-tree model was used
for 24-week and 2-year analyses, Markov cohort model was utilized for 10-year timehorizon. One-way sensitivity analysis was performed on all model parameters.
Probabilistic sensitivity analysis (PSA) was also conducted to account for the presence of
second-order uncertainty in modeling parameters. The results were reported as
incremental cost-effectiveness ratios.
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Specific Aim and Objectives
The specific aim of our study was to compare the cost-effectiveness of CAM
therapies (i.e., glucosamine, CS, and their combination) with conventional medicines
(i.e., celecoxib and NSAIDs) and placebo in treating KOA from the perspectives of US
health care payers’ and patients’ and from time-horizons of 24 weeks, 2 years, and 10
years.
Objective 1: To compare the incremental cost-effectiveness of CAM therapies
(i.e., glucosamine, CS, and their combination) with conventional medicines (i.e.,
celecoxib and NSAIDs) for the treatment of KOA from the US health care payers’
perspective and 10-year horizon, through a Markov model based analysis.
Ha=CAM therapies (i.e., glucosamine, CS, and their combination) are costeffective at an incremental threshold of $50,000/QALY gained compared to conventional
medicines (i.e., celecoxib and NSAIDs) for the treatment of KOA from the US health
care payers perspective and 10-year horizon
Objective 2: To compare the incremental cost-effectiveness of CAM therapies
(i.e., glucosamine, CS, and their combination), celecoxib, and placebo for treatment of
KOA from the US health care payers’ perspective and 24-week time-horizon, among the
GAIT trial participants.
Ha=CAM therapies (i.e., glucosamine, CS, and their combination) were costeffective among the GAIT trials participants at an incremental threshold of
$50,000/QALY gained compared to conventional medicines (i.e., celecoxib and
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NSAIDs) for the treatment of KOA from the US health care payers perspective and 24week horizon
Objective 3: To compare the incremental cost-effectiveness of CAM therapies
(i.e., glucosamine, CS, and their combination), celecoxib, and placebo for treatment of
KOA from the US patients’ perspective and 24-week time-horizon, among the GAIT trial
participants.
Ha=CAM therapies (i.e., glucosamine, CS, and their combination) were costeffective among the GAIT trials participants at an incremental threshold of
$50,000/QALY gained compared to conventional medicines (i.e., celecoxib and
NSAIDs) for the treatment of KOA from the US patients’ perspective and 24-week
horizon
Objective 4: To compare the incremental cost-effectiveness of CAM therapies
(i.e., glucosamine, CS, and their combination), celecoxib, and placebo for treatment of
KOA from the US health care payers’ perspective and 2-year time-horizon, among the
GAIT trial participants.
Ha=CAM therapies (i.e., glucosamine, CS, and their combination) were costeffective among the GAIT trials participants at an incremental threshold of
$50,000/QALY gained compared to conventional medicines (i.e., celecoxib and
NSAIDs) for the treatment of KOA from the US health care payers perspective and 2year horizon
Objective 5: To compare the incremental cost-effectiveness of CAM therapies
(i.e., glucosamine, CS, and their combination), celecoxib, and placebo for treatment of
7

KOA from the US patients’ perspective and 2-year time-horizon, among the GAIT trial
participants.
Ha=CAM therapies (i.e., glucosamine, CS, and their combination) were costeffective among the GAIT trials participants at an incremental threshold of
$50,000/QALY gained compared to conventional medicines (i.e., celecoxib and
NSAIDs) for the treatment of KOA from the US patients’ perspective and 2-year horizon
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Theoretical Framework
Cost-effectiveness analysis of health technologies informs resource allocation
decisions. The theoretical foundations of cost-effectiveness analysis can be traced to a
variety of fields such as decision analysis, operations research, and, most recently,
welfare economics. The focus of this section is on welfare economics as the theoretical
basis of cost-effectiveness analysis, since the USPCEHM deems welfare economics to
provide a comprehensive framework that answers more theoretical questions arising in
cost-effectiveness analysis than any other alternatives.34 For instance, welfare economics
provides guidance on several elements of cost-effectiveness analysis including how
society should value resource costs and select discount rates for analysis.
Welfare economics is concerned with the means by which we can assess the
desirability of alternative resource allocation. Welfare economics is based on two
assumptions:
1. Individuals maximize a well-defined preference function. This means that an
individual’s sense of well-being (health utility function) depends on material
consumption, among other things.
2. The overall welfare of the society is a function of these individuals’ preferences.
Therefore, in order to measure the societal well-being, it is required to first measure
the well-beings of individuals and thereafter aggregate these to the societal level.34 In
welfare economics, the individuals’ preferences are represented by individuals’ utility
function that relates their well-being to their levels of consumption of several goods and
services.46
9

Although several economics methods could be used to model individuals’
preferences for the purpose of cost-effectiveness analysis, expected utility theory (EUT)
is the principal approach as both health status and the effects of health care interventions
involve substantial uncertainty.47 According to the expected utility theory, alternative
actions are characterized by a set of possible outcomes and a set of probabilities
associated with each outcome. Each outcome can be assigned a quantitative
representation of individuals’ preferences, i.e. health utilities. The probability of an
outcome when multiplied by its health utility, i.e. individuals’ preference, provides the
respective expected utility of that outcome. These numerical utility values, in theory,
represent both ordinal rankings of outcomes and strength of individuals’ preference for
these outcomes under uncertainty.
The ultimate goal of welfare economics is to maximize the social utility function,
defined as the aggregate of individuals’ utility preferences. However, currently there is no
consensus on how to combine individuals’ preferences to form the social utility function.
Nonetheless, the currently used benchmark concept behind determining the social utility
function is Pareto optimality.48 According to this concept, a resource is considered to be
Pareto-optimal when it is not possible to make anyone better without making at least one
other worse off.. On the other hand, if the resource relocation makes at least one person
better off without others being worse off, it is said to be Pareto improvement. Therefore,
in absence of knowledge of the social utility function, but not of the individuals’
preferences, the Pareto criterion can be used to determine if social welfare has improved.
In the real-world, however, it is rarely possible to benefit someone without
harming others; for example, in order to implement a public health program taxes or
10

other mechanisms are used that impose costs on some people to benefit others. A less
restrictive standard, called compensation test (also known as potential Pareto
improvement or Kaldor-Hicks criterion), is used in situations that have both gainers and
losers. Under this theory, social welfare can still be improved if the gainers are willing to
pay enough to compensate the losers. The welfare economics provides the conditions
under which the theoretical bases of cost-effectiveness ratios are in the theory of
compensation test. Garber and Phelps work show that individuals optimally set priorities
for health care expenditures by selecting those with cost/quality-adjusted life-year
(QALY) ratios less than some threshold. For this reason, the USPCEHM and the National
Institute of Clinical Excellence of the UK has endorsed QALYs as the effectiveness
measure for the “reference case” during the cost-effectiveness analysis. The QALYs
gained was also used as the primary outcome measure in this study.
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Study Significance
Significant of Cost-Effectiveness Analysis for Healthcare Decision-Makers
CEAs are widely utilized in the US as well as the rest of the world for the purpose
of health technology assessments. The 2009 report of the Institute of Medicine justifies
use of economic analysis, especially CEA, in comparative effectiveness research stating
that the overall value of a strategy can be understood best only by considering costs and
benefits together.49 A real-world example of use of CEA in health technology assessment
in the US is its incorporation into the Academy of Managed Care Pharmacy (AMCP)
drug dossiers. These drug dossiers are frequently utilized by managed care organizations
(87.5%) to inform their formulary decisions.50 Submitted by pharmaceutical companies,
these dossiers commonly contain CEA studies (39.3%) and budget-impact models
(53.5%) to describe value of a drug.
In another example, the UK Department of Health has commissioned the National
Institute of Clinical Excellence (NICE) to make health technology assessments on the
basis of both clinical effectiveness and cost-effectiveness.51 The NICE believes that on its
own the clinical effectiveness is insufficient for maintaining or introducing any health
technology and that cost must also be taken into account.52
Significance of Current Study for Health Care Policy and Decision-Makers
Comparing glucosamine and CS, alone as well as combination therapies, to
conventional medicines, our study is the first to provide evidence on the incremental costeffectiveness of these agents for health care policy makers as well as for the clinical
decision-makers such as the rheumatologists.
12

Currently billions of dollars are spend on CAM therapies in the US. A total of
$33.9 billion were spent out-of-pocket on CAM therapies in 2007, equaling to 11.2% of
the total out-of-pocket health care expenditures in the US.30 Of these out-of-pocket
expenditures, 43.7% of the total amount was spent on non-vitamin, non-mineral natural
products that include glucosamine and CS. Globally, the glucosamine market was valued
at $4 billion in 2008, with the US sales totaling to $872 million.31
Several health plans in the US also currently provide coverage for the CAM
therapies, including various herbal supplements.41-43,61,62 For example, the Blue Cross
Blue Shield provides discounts on herbal supplements as well as other CAM therapies to
its beneficiaries in various states, including Illinois, South Carolina, and Idaho.43, 53, 54
The Kaiser Permanente of Ohio also provides discounts on various herbal supplements.41
The clinical decision-makers in the US are also currently divided on the efficacy
of CAM therapies to treat KOA. In a survey of 345 rheumatologists in the US, 39% of
the physicians were reported to believe glucosamine and/or CS to be at least moderately
beneficial in treating KOA.44 When asked about recommending glucosamine and/or CS
to the patients, 57% of these rheumatologists said that they were likely to recommend
these agents to their patients.
There is an unmet and important need to evaluate therapeutic approaches for
osteoarthritis in terms of their cost-effectiveness.55 The evidence from randomized
clinical trials is central to efficacy testing. However, failing to translate the endpoints
from these trials into measures that are valued by patients, providers, insurers, and the
general public could lead to misleading decisions.56 Since an increasing number of health
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care payers are utilizing evidence from cost-effectiveness analyses in their decisionmaking, the findings from our study could be crucial to such stakeholders.
Significance of Current Study to the Literature
A systematic review of PubMed was conducted to identify studies that have
compared the cost-effectiveness of glucosamine, CS, their combination, celecoxib, and
NSAIDs from 1966 to February 2013. The MeSH terms “knee osteoarthritis”, “costbenefit analysis”, “glucosamine”, “chondroitin sulfate”, “celecoxib”, and “non-steroidal
anti-inflammatory agents” were separately combined with the keywords “costeffectiveness analysis”, “cost-utility analysis”, and “quality-adjusted life-years.” The
Boolean operators AND, OR, and NOT were used to combine the above listed MeSH
terms and keywords. No other limits were applied to the search strategy.
No studies comparing the cost-effectiveness of glucosamine, CS, their
combination, celecoxib, NSAIDs were found. Nonetheless, some cost-effectiveness
analysis studies were found that compared the incremental cost-effectiveness of celecoxib
with other therapies.57-67 Further, one study comparing the incremental cost-effectiveness
of glucosamine with paracetamol and placebo was also identified.68, 69 Glucosamine was
found to be highly cost-effective in this study, by dominating the paracetamol strategy
and with incremental cost-effectiveness of €4,285/quality-adjusted life-year (QALY)
gained in comparison to placebo. Further details of these studies are provided in the
literature review section, under sub-section “cost-effectiveness of glucosamine, CS,
combination of glucosamine and CS, and celecoxib in KOA.”
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Our study was the first cost-effectiveness analysis to compare cost-effectiveness
of glucosamine, CS, their combination therapy, celecoxib, NSAIDs, and placebo. In fact,
our study was the first to compare the cost-effectiveness of any selective or NSAIDs with
CAM therapies. It was also the first study to compare cost-effectiveness of CS or
combination of glucosamine and CS with each other and with other therapy options in the
treatment of KOA.
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CHAPTER 2: LITERATURE REVIEW
This chapter is divided into ten sections. In the first section, we begin by
providing the overview of KOA that constitutes its epidemiology, pathophysiology,
classification and etiology, diagnosis and treatment. In sections two to five, we discuss
celecoxib, NSAIDs, glucosamine, and CS as treatment options for KOA in terms of their
respective approved doses, indications, mode of administration, contraindications,
associated serious warnings and precautions, and clinical efficacies. Section six provides
review of the cost-effectiveness of celecoxib, NSAIDs, glucosamine, CS, and
combination of glucosamine and CS in treating KOA. Sections seven and eight provide
review of the structure, scoring, and psychometric properties of the Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC) and Medical Outcomes Study 36item Short Form Health Survey (SF-36), respectively. Section nine describes the
Glucosamine/chondroitin sulfate Arthritis Intervention Trial (GAIT), which is the source
of clinical data in our study. Finally, this chapter is concluded by a summary of the
literature review section.

16

Overview of KOA
Epidemiology
KOA is the most common type of osteoarthritis in the US, affecting 13.8% of the
US population aged 26 or more.1 The incidence and prevalence of KOA (age and sexstandardized) in the US are 240 and 900 cases per 100,000 person years, respectively.70, 71
This prevalence increases throughout the elderly years, more so in women than in men,
reaching to 37.4% among persons aged 60 years or more.71, 72 Women have significantly
more Kellgren-Lawrence Grade 3-4 changes (12.9% vs. 6.5% in men); however,
symptomatic KOA do not differ by gender.71 In recent years, the prevalence of KOA has
increased dramatically, doubling among women and tripling among men during the
period of the last 20 years.73
Pathophysiology
KOA, initially believed to be the result of aging, is now proven to result from
complex interactions of multiple physical and biochemical factors.74, 75 Abnormal or
compromised cartilage of knee joint, alone or in combination with abnormal stresses on
knee joint, initiate a cascade of proliferative and inflammatory processes that lead to
further damage this joint.76 Proinflammatory mediators fuel changes in the synovial
membrane and alter the chondrocyte metabolism, causing progression of KOA.76, 77
Classification and Etiology
KOA is most commonly classified by Kellgren-Lawrence scale that divides KOA
into five grades (0, normal to 4, severe).78-80 The World Health Organization (WHO) has
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also adopted these classification criteria for the radiological classification of KOA as the
standard for epidemiological studies of this pathology.81
Based on its etiology, KOA can also be classified into primary (idiopathic) and
secondary osteoarthritis.82 While the etiology of idiopathic KOA is unknown, the
common causes of secondary KOA are post-traumatic, congenital, malposition, postoperative, metabolic abnormalities, endocrine disorders, and aseptic osteonecrosis
conditions.82
Diagnostic Evaluation
The major elements to diagnose KOA are history, physical examination, and
imaging studies of the patients.82 Historical criteria that are specific to KOA are presence
of pain (beginning of movement, during movement, permanent/nocturnal, or early
morning), loss of function (stiffness, limited range of joint movement, impaired daily
activities), and other symptoms, including crepitation, elevated sensitivity to cold and/or
damp weather, and stepwise progression of disease. Physical examination includes
findings on inspection and palpation, testing of range of movement, and special
functional tests (for example, ligament stability, meniscus test, and gait analysis).
Imaging studies by X-ray are used for both primary diagnosis and to assess the
progression of the disease. Other radiological studies to diagnose KOA include MRI, to
demonstrate the hyaline cartilage, 99mTc bone scanning, to assess metabolic activity in the
subchondral bone, and ultrasonography, to demonstrate the soft-tissues and fluid-filled
spaces.
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Treatment of KOA
KOA is not a curable disease at present; therefore, its treatment is intended to
reduce pain, maintain and/or improve joint mobility, and limit functional impairment.5
The recommended approaches for treating KOA include nonpharmacological modalities,
pharmacological modalities, surgical modalities, and CAM therapies (Table 1).83
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Table 1: Treatment Modalities for KOA.5, 83, 84
Non-pharmacological Modalities
Patient education
Self-management programs
Personalized social support through telephone contact
Weight loss
Aerobic exercise programs
Physical therapy range-of-motion exercises
Muscle-strengthening exercises
Assistive devices for ambulation
Patellar taping
Appropriate footwear
Lateral-wedged insoles bracing
Occupational therapy
Joint protection and energy conservation
Assistive devices for activities of daily living
Pharmacological Modalities
Acetaminophen as initial oral analgesic for treatment of mild to moderate pain
NSAIDs at lowest effective dose in symptomatic KOA patients
Topical NSAIDs and capsaicin as adjunctives and alternatives to oral analgesic/antiinﬂammatory agents in KOA
IA Corticosteroids injections
IA Hyaluronate injections
Weak opioids and narcotic analgesics
Surgical Modalities
Knee replacement surgery
Complementary and Alternate Medicines Therapies
Acupuncture
Dietary supplements
Glucosamine
CS
Methylsulfonylmethane
Risedronate
Diacerein
CS=Chondroitin Sulfate; KOA=Knee osteoarthritis; IA=Inferior alveolar; NSAIDs= Nonsteroidal anti-inflammatory drugs
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Glucosamine as a Treatment Option for KOA
Approved Indications and Usage
In the US, glucosamine is considered a dietary supplement and is currently not
approved by the FDA for diagnosis, treatment, cure or prevention of any disease. In most
of the European Union (EU), however, glucosamine hydrochloride is approved as a
medical drug, indicated for the relief of symptoms in mild to moderate KOA.85
Dosage and Administration of Glucosamine in KOA
In the EU, the approved dosage of glucosamine is 1250 mg/day, taken orally. No
specific dosage of glucosamine is approved or recommended by the US FDA. Previous
clinical trial studies of glucosamine have used its daily doses ranging from 1200 mg to
1500 mg.21, 24, 69, 86-98
Available Dosage Forms and Strengths
In EU and the US, glucosamine is available as a tablet (400 mg, 625 mg, and
1500 mg) as well as in the power form for oral solution (1178 mg, 1500 mg).99
Contraindications
Glucosamine is contraindicated in patients: (1) with known hypersensitivity to
glucosamine or any other ingredient of glucosamine; (2) shellfish allergy; (3) who suffer
from impaired glucose intolerance; (4) who have known risk factor for cardiovascular
disease; and (5) who suffer from asthma.99
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Serious Warnings and Precautions
Glucosamine may be associated with risk of the following adverse events,
however no conclusive evidence currently exists: asthma attack, rise of blood sugar level
in people with diabetes, and shellfish allergy.99
Clinical efficacy of Glucosamine in KOA
Several randomized, double-blind, placebo-controlled, clinical trials have
examined the efficacy of glucosamine in treating KOA.21, 24, 69, 86-98 Many of these studies
found glucosamine to be significantly better than placebo (p<0.05) to treat KOA.69, 87-96
Most widely used primary outcome measures in these clinical trials of glucosamine are
the mean loss of joint space width (JSW), change in Lequesne index score, change in
WOMAC pain sub-scale score, change in visual analogue scale (VAS) score, and
patient’s global assessment of response to therapy (PGART). Table 2 displays the
summaries of all published randomized clinical trial studies of glucosamine.
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Table 2: Comparison of Efficacy of Glucosamine with Placebo.*
Study Duration
Treatment
Total Sample
Primary
(in weeks)
size
Endpoint(s)
Crolle
3
Glucosamine 30
Symptom
et al.
1500 mg/d
score
87
1980
reduction
Placebo
Pujalte 6-8
Glucosamine 20
Pain
et al.
1500 mg/d
reduction
198092
Placebo
Drovant 4
Glucosamine 80
Symptom
i et al.
1500 mg/d
score
198088
reduction
Placebo
Vajarad 9
One intra54
Pain
ul
articular
reduction
198196
glucosamine
injection/wee
k for 5 weeks
Placebo
Rovati
4
Glucosamine 252
Lequesne
et al.
1500 mg/d
index
95
1992
reduction of
at least 3
Placebo
Reichel
Glucosamine 155
Lequesne
t et al
intramuscular
index
199494
injection
reduction of
twice a week
at least 3
for 6 weeks
8
Placebo
Noack
Glucosamine 252
Lequesne
et al.
1500 mg/d
index
90
1994
reduction of
at least 3
4
Placebo
Rindon 8
Glucosamine 98
Pain score
e et al.
1500 mg/d
reduction on
2000+98
VAS scale
Placebo
Reginst 162
Glucosamine 212
Loss of
er et al.
1500 mg/d
mean JSW
93
2000

23

Results
80%

21%
80%

20%
71%

88%

54%
52%

37%
55%

33%
52%

37%
24%

16%
-0.06 mm (0.22 to 0.09)

Study

Duration
(in weeks)

Treatment

Total Sample
size

Primary
Endpoint(s)

Placebo

Pavelka
et al.
200291

162

Glucosamine
1500 mg/d

202

Loss of
mean JSW

80

PGART

205

WOMAC
pain score

Placebo

Hughes
et al.+
200297

6 months

Glucosamine
1500 mg/d
Placebo

McAlin
don et
al.+
200489

12

Glucosamine
1500 mg/d

Cibere
et al.+
200486

6 months

Placebo
Glucosamine
1500 mg/d

137

Proportion
of patients
with disease
flare after
drug
discontinuat
ion

Herrero
Beaum
ont et
al.
200769

6 months

Placebo
Glucosamine
1500 mg/d

210

Change in
Lequesne
index

Placebo

Clegg
24
et al.
2006+21

Glucosamine
1500 mg/d

630

Patients
with 20%
decrease in
WOMAC
pain score

Placebo

Results
-0.31 mm
(95% CI=0.48 to -0.13)
0.04 mm
(95% CI=0.06 to 0.14)
-0.19
mm(95%
CI=-0.29 to
0.09)
Mean
difference=
0.15 mm
(95% CI=8.78 to 9.07)
2.0±3.4

2.5±3.8
45%

42%
-3.1 (95%
CI=-3.8 to 2.3)

-1.9 (95%
CI=-2.6 to 1.2)
64.0%

60.1%

24

Study

Duration
Treatment
(in weeks)
Sawitzk 108
Glucosamine
e et al.
1500 mg/d
2008+24
Placebo

Total Sample
size
147

Primary
Results
Endpoint(s)
Mean
-0.153 (95%
change in
CI=-0.379 to
JSW
0.074)
-0.055 (95%
CI=-0.279 to
0.170)

*=Efficacy results from only glucosamine and placebo arms of the trials are reported.
+=No significant difference between placebo and glucosamine on primary outcome measure at
p<0.05
JSW=Joint space width; PGART=Patient global assessment of response to therapy; VAS=Visual
analogue scale; WOMAC=Western Ontario and McMaster Universities Osteoarthritis Index

In summary, glucosamine is currently not approved by the US FDA and is
marketed as a dietary supplement in the US. In EU, however, glucosamine is approved in
most of the countries as a medical drug to treat KOA patients with mild to moderate pain.
The recommended daily dose of glucosamine in EU to treat KOA is 1500 mg/day, taken
orally. Many randomized, double-blinded, placebo-controlled, clinical trials have
examined efficacy of glucosamine for relief of symptoms of KOA. Based on these
studies, currently, the efficacy of glucosamine to treat KOA is not well-established.
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CS as a Treatment Option for KOA
Approved Indications and Usage
CS is currently used as a dietary supplement in both the US and the Europe.100
However, the European League Against Rheumatism (EULAR) recommends CS as a
symptomatic slow acting drug for all forms of osteoarthritis.101
Dosage and Administration of CS in KOA
Currently, there is no US FDA or European Medicine Agency (EMA) approved
or recommended dose of CS. In clinical trials studies, however, the commonly used doses
of CS have ranged from 800 mg to 1200 mg per day, taken orally. 22,25,103-108
Available Dosage Forms and Strengths
Currently, there is no officially approved dosage form and strength of CS.
Nonetheless, CS is commonly available as tablets or capsules in strengths 400 mg, 800
mg, and 1200 mg.102
Contraindications
CS is contraindicated in patients: (1) with prostate cancer, or at increased risk of
prostate cancer, (2) with hypersensitivity to CS products, (3) who have shellfish allergy,
or (4) who suffer from asthma.103
Serious Warnings and Precautions
The CS is deemed to be well-tolerated for up to 3 years, as no conclusive
evidence currently exist that associates risk of any serious adverse events with it.103, 104
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Clinical efficacy of CS in KOA
Several randomized, double-blinded, placebo-controlled, clinical trials have
examined the clinical efficacy of CS in treating KOA, Table 3.21, 24, 105-110 Some of these
studies found CS to be significantly better than placebo (p<0.05) for the treatment of
KOA.105-110 Overall, however, the efficacy of CS to treat KOA is currently not wellestablished, as reported in an recent meta-analysis.25 Most commonly used primary
outcome measures in clinical trial studies of CS are change in Lequesne index scores,
change in VAS pain scores, joint space narrowing, and change in WOMAC pain subscale scores.
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Table 3: Comparison of Clinical Efficacy of Chondroitin Sulfate with Placebo.
Study
Duration
Treatment
Total
Primary
Results
N
Endpoint(s)
Uebelhart
et al.
1998105

12
months

CS 800 mg/d

42

Change in
degree of
spontaneous
joint pain

Placebo
Bourgeois
et al.
1998106

3 months

CS 1200 mg/d

Bucsi et al.
1998107

6 months

Placebo
CS 800 mg/d

80

Change in
Lequesne index

Michel et
al. 2005108

24
months

Placebo
CS 800 mg/d

300

Mean change in
JSW

130

Lequesne Index

CS 800 mg/d

104

Lequesne Index

Placebo
CS 1200 mg/d

621

Patients with
20% decrease in
WOMAC pain
score

Mazieres et 6 months
al.+ 2001109

Conrozier
et al.
1998110

12
months

Clegg et al.
2006+21

24 weeks

Sawitzke et
al. 2008+24

24
months

Placebo
CS 1000 mg/d
for 3 months
Placebo for 3
months

Placebo
CS 1200 mg/d

127

141

Placebo

Change in
Lequesne index,
change in pain
score on VAS

Mean change in
JSW

At 6 months:
57%

At 6 months:
25%
45%, 50%

10%, 20%
58%

3%
0.00±0.53 mm
0.14±0.61 mm
CS group had
nonsignificantly
better
outcomes than
placebo group
Functional
impairment
was reduced by
50%
65.4%

60.1%
Difference
from placebo:
-0.059 (95%
CI=-0.287 to
0.169)

*=Results from only glucosamine and placebo arms of the trials are reported.
+=No significant difference between placebo and glucosamine on primary outcome measure at
p<0.05
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CS=Chondroitin Sulfate; JSW=Joint Space Narrowing; VAS=Visual Analogue Scale; WOMAC=
Western Ontario and McMaster Universities Osteoarthritis Index

In summary, CS is currently used as an oral dietary supplement in both the US
and EU. Several randomized clinical trials have examined the efficacy of CS to treat
KOA. Based on the findings from these clinical trials, the efficacy of CS to manage
symptoms of KOA is currently not well-established.21, 24, 25, 105-111
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Celecoxib as a Treatment Option for KOA
Approved Indications and Usage
Celecoxib is a selective NSAID (i.e., a COX-2 only inhibitor) approved by the US
FDA for relief of signs and symptoms of osteoarthritis, rheumatoid arthritis (including
juvenile rheumatoid arthritis), and ankylosing spondylitis.8 Celecoxib is also approved for
the management of acute pain in adults and treatment of primary dysmenorrhea. It was
the first selective COX-2 inhibitor to be introduced into the clinical practice.112
Dosage and Administration of Celecoxib in KOA
Celecoxib is recommended in oral doses of 200 mg once a day or 100 mg twice a
day for relief of signs and symptoms of KOA.8 These doses can be administered without
regards to the timings of meals.
Available Dosage Forms and Strengths
Celecoxib is marketed as capsules of strength 50 mg, 100 mg, 200 mg, and 400
mg.8
Contraindications
Celecoxib is contraindicated in patients: (1) with known hypersensitivity to
celecoxib, aspirin, or other NSAIDs; (2) who have demonstrated allergic-type reactions
to sulfonamides; (3) who have experienced asthma, urticaria, or allergic-type reactions
after taking aspirin or other NSAIDs; and (4) for the treatment of peri-operative pain in
the setting of coronary artery bypass graft (CABG) surgery.8
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Serious Warnings and Precautions
Celecoxib is associated with risk of serious and fatal cardiovascular thrombotic
events, myocardial infarction, and stroke.8 It is also associated with serious
gastrointestinal (GI) adverse events including bleeding, ulceration, and dyspepsia.8
Clinical efficacy of Celecoxib in KOA
Several randomized clinical trials have examined the efficacy of celecoxib to treat
KOA.9-11, 13-24, 113 All of these clinical trial studies have found celecoxib to be
significantly better than placebo to treat KOA (p<0.05). Table 4 summarizes the
published studies that have examined the clinical efficacy of oral celecoxib with placebo
in randomized, double-blind, placebo-controlled, clinical trials for the treatment of
symptomatic KOA.
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Table 4: Comparison of Efficacy of Oral Celecoxib with Placebo.*
Study
Duration Treatment
N
Primary
Mean change
(in weeks)
Endpoint(s)
(improvement)
From Baseline
Birbara et
6
Cel 200 mg/d 157
PGART
2.29
al. 20059
Placebo
78
1.61
Birbara et
6
Cel 200 mg/d 169
PGART
2.28
al. 20059
Placebo
85
1.61
Gibofsky et 6
Cel 200 mg/d 189
VAS,
34 mm, -22.1
al. 200310
WOMAC
Placebo
96
21.2 mm, -12.6
McKenna
6
Cel 200 mg/d 63
VAS,
39 mm, -26, 79
et al.
WOMAC,
200111
PGA
improvement
%
Placebo
60
25 mm, 18, 50
Smugar et
6
Cel 200mg/d 456
WOMAC pain -37.5
al. 2006113
score
Placebo
150
-25.0
Smugar et
6
Cel 200mg/d 460
WOMAC pain -33.0
al. 2006113
score
Placebo
151
-21.0
Pincus et
6
Cel 200 mg/d 370
Patients
54%
al. 200413
preferences for
treatment
Placebo
354
24%
Bensen et
12
Cel 100 mg/d
PGA,
27, 9.5±1.11
al. 199914
Cel 200 mg/d
WOMAC total 35, -13.3±1.17
score
Cel 400 mg/d
36, -12.0±1.22
Placebo
24, -6.1±1.09
McKenna
6
Cel 200 mg/d 201
VAS,
-34.9±28.1, et al.
WOMAC,
18.8±17.5, 50%
200111
PGA
improvement
%
Placebo
200
-23.1±28.0, 11.5±17.8, 34%
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Study

Rother et
al. 200715

Duration
(in weeks)
6

Treatment

N

Primary
Endpoint(s)

Cel 200 mg/d 132

WOMAC pain
score,
WOMAC
physical
function score,
PGA excellent
%

Placebo

127

Bingham
III et al.
200716

26

Cel 200 mg/d 241

Bingham
III et al.
200716

26

Placebo
127
Cel 200 mg/d 247

Placebo
117
Cel 200 mg/d 444

Fleischman
n et al.
200617

Placebo

Lehmann
et al.
200518

13

WOMAC pain
score,
WOMAC
physical
function score,
PGA

0.14, -0.08, 0.06

VAS, PGA,
WOMAC pain
score,
WOMAC total
score

-24.5±27.38, 3.5±4.11, 16.0±18.19

PGA,
WOMAC total
score

Placebo
Sheldon et
al. 200519

13

Cel 200 mg/d 393

Placebo

382
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-12.4±20.8, 12.3±19.2, 5±3.9
-3.12, -1.74, -4.05

WOMAC pain
score,
WOMAC
physical
function score,
PGA

231

Cel 200 mg/d

Mean change
(improvement)
From Baseline
-20.7±22.7, 18.1±22.5,
14±10.6

VAS,
WOMAC
functional
score

-16.1±27.45, 2.3±3.90, 9.3±16.15
-22.9±24.64, 14.7±15.81
-18.9±24.70, 11.3±18.27
-24.1±26.40, 10.8±13.07

-18.1±25.51, 6.3±11.80

Study

Tannenbau
m et al.
200420

Duration
(in weeks)
13

Treatment

Cel 200 mg/d 481

Placebo

Hochberg
et al.
201123

12

12

Primary
Endpoint(s)
VAS, PGA,
WOMAC pain
score, and
WOMAC total
score

243

Cel 200 mg/d 243

Placebo

Hochberg
et al.
201123

N

WOMAC pain
score,
WOMAC
function score,
and PGA

124

Cel 200 mg/d 245

WOMAC pain
score,
WOMAC
function score,
and PGA

122

Sawitzke et 108
al. 200824
Clegg et al.
200621

DeLemos
et al.
201122

Cel 200 mg/d 80

24

Placebo
70
Cel 200 mg/d 318

12

Placebo
313
Cel 200 mg/d 202

Placebo

200

Mean change
in JSW
Patients with
20% decrease
in WOMAC
pain score
WOMAC pain
score,
WOMAC
function score,
and PGA

Mean change
(improvement)
From Baseline
-25.2±24.7, 22.4±25.7, 3.1±3.8, 13.4±15.8
-19.8±26.1, 15.7±26.1, 2.4±3.8, 9.4±16.1
-41.1±26.2, 36.0±26.4,
22.4 ±28.7

-34.0± 25.3, 28.9±24.9,
12.4±28.9
-43.6±25.2, 37.7±27.5,
26.4±30.3

-37.3±26.1, 30.9±28,
22.4±31.3
-0.055 mm (95%
CI=-0.279, 0.170)
70.1%

60.1%
130.0±9.0,
429.2±29.3,
28.6±2.0

94.9±8.9,
290.1±29.1,
20.2±2.0

*=Results from only celecoxib and placebo arms of the trials are reported.
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Cel=Celecoxib; CI=Confidence interval; JSW=Joint space width; PGA=Patient global assessment
score; PGART=Patient global assessment of response to therapy; VAS=Visual analogue scale;
WOMAC=Western Ontario and McMaster Universities Osteoarthritis Index

In summary, celecoxib is currently approved by the US FDA for symptomatic
pain relief in KOA patients. The recommended daily doses of celecoxib to treat KOA are
200 mg, taken orally. Several randomized, double-blind, placebo-controlled, clinical
trials have established the efficacy of celecoxib to relief symptoms of KOA.
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NSAIDs as Treatment Options for KOA
The discussion in this section is focused on the US FDA approved prescription
NSAIDs all of which are listed in Table 5.114
Table 5: List of FDA Approved Non-selective Non-Steroidal Anti-inflammatory Drugs
for Prescription.
FDA Approved Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
Diclofenac
Flurbiprofen
Naproxen
Diflunisal
Indomethacin
Oxaprozin
Etodolac
Ketoprofen
Piroxicam
Fenoprofen
Meloxicam
Sulindac

Approved Indications and Usage
The NSAIDs class of drugs are approved by the US FDA to treat pain and redness,

swelling, and heat (inflammation) from medical conditions such as arthritis, including
KOA, and menstrual cramps.114
Dosage and Administration of NSAIDs in KOA
Different NSAIDs have different FDA approved doses for treating KOA, as
displayed in Table 6.115
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Table 6: FDA Approved Dosages of NSAIDs in Treatment of KOA.
Drug
Recommended FDA Dosage to Treat KOA
Diclofenac
100-150 mg/day in divided doses (50 mg BID, TID or 75 mg BID)
Diflunisal
500-1000mg/day in two divided doses
Etodolac
300 mg BID, TID or 400 mg BID or 500 mg BID
Fenoprofen
Up to 3,200 mg/day (3 to 4 times a day)
Flurbiprofen
200-300 mg/day
Ibuprofen
400 to 800 mg orally every 6 to 8 hours
Indomethacin
Up to 150-200 mg/day
Ketoprofen
Up to 200 mg/day (75 mg TID or 50 mg BID)
Ketorolac
10 mg 4 times a day orally as needed
Mefenamic acid 500 mg orally followed by 250 mg every 6 hours as needed
Meloxicam
Up to 15 mg/day
Nabumetone
Up to 2000 mg per day
Naproxen
Up to 500 mg/day in divided doses, BID
Oxaprozin
1200 mg/day in divided doses, BID
Piroxicam
20 mg/day
Sulindac
300 mg/day, BID
BID=Twice a day; FDA=Food and Drug Administration; KOA=Knee osteoarthritis; TID=Thrice
a day

Available Dosage Forms and Strengths
The US FDA approved dosage forms and strengths of NSAIDs vary by specific
drugs. These agents are available in dosage forms such as tablets, capsules, suspension,
and power. Their approved strengths vary from 7.5 mg for meloxicam to 600 mg
oxaprozin.115
Contraindications
Similar to celecoxib, NSAIDs are contraindicated in patients : (1) with known
hypersensitivity to aspirin or any NSAIDs; (2) who have demonstrated allergic-type
reactions to sulfonamides; (3) who have experienced asthma, urticaria, or allergic-type
reactions after taking aspirin or other NSAIDs; and (4) for the treatment of peri-operative
pain in the setting of CABG surgery.114
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Serious Warnings and Precautions
Similar to celecoxib, NSAIDs are associated with risk of serious cardiovascular
events, including heart failure, stroke, and myocardial infarction. These NSAIDs are also
associated with risk of serious GI events, including dyspepsia, peptic ulcer, and bleeding
and perforation.114
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Cost-Effectiveness of Glucosamine, CS, Combination of Glucosamine and CS, and
Celecoxib in KOA
Based on a systematic review of PubMed, to our knowledge, no previously
published study has compared the cost-effectiveness of glucosamine, CS, their
combination, celecoxib, and NSAIDs in treating KOA. However, a few published studies
have compared the cost-effectiveness of celecoxib with other treatment options (Table 7).
One study has also compared the cost-effectiveness of glucosamine with paracetamol
(acetaminophen) and placebo.68 The focus of this section is on describing these published
studies.
Celecoxib as the Primary Study Comparator
A total of 11 studies have previously compared the cost-effectiveness of celecoxib
with other treatment strategies in osteoarthritis patients (hip and/or knee), Table 7.57-67
Treatment options compared with celecoxib in these studies included NSAIDs (alone or in
combination with Misoprostol [Arthrotec], proton pump inhibitors, histamine-2 receptor
antagonists, and prophylaxis), acetaminophen, rofecoxib, and hyalouronan. Countries of
focus in these studies were Mexico, Netherlands, United States, Taiwan, Canada,
Switzerland, Sweden, and Norway. All except for one study utilized decision-tree models
for conducting cost-effectiveness analysis—this one exception used an Markov model.63
All except two studies were conducted from the 6-months’ time-horizon. These rest of
the two studies were conducted from the life-time of the patients.59 Perspectives under
evaluation were health care payers’ and societal.
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Table 7: Summary of Published Literature on Cost-Effectiveness of Celecoxib and Glucosamine.
Author, year
Comparators
Primary
Methodology
Base Case
outcome
Results
measure
Celecoxib as the Primary Comparator
Iris et al. 200857
Cost per
Celecoxib
 Celecoxib
 Time horizon: 6
number
of
dominated the
months
 NSAIDs
 Decision-tree model rest of the two
 Acetaminop patients with
pain
control
comparators
hen
 Perspective: health
care payer
 Country: Mexico
Al et al. 200858
Celecoxib ICER
 Celecoxib
 Cost/number
 Time horizon: 6
was
of averted GI
months
 NSAIDs
events
 Decision-tree model €56,667/life-year
 NSAIDs +
saved
Misoprostol  Cost/life Perspective:
years
saved
societal
 NSAIDs +
H2RA
 Country:
Netherlands
 NSAIDs +
PPI
 Arthrotec
59
Loyd et al. 2007
 Celecoxib
 Cost/QALY
 Time horizon: life- Celecoxib ICER
was
gained
time
 NSAIDs
 Decision-tree model $31,097/QALY
gained in
 Perspective:
comparison to
societal
NSAIDs
 Country: United
States
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Comments

 Patient population:
OA of knee or hip
 Study funded by
pharmaceutical
company (Pfizer)
 Patient population:
OA or RA
 Study funded by
pharmaceutical
company (Pfizer)

 Patient population:
OA patients aged
60 years or more
 Study funded by
pharmaceutical
company (Pfizer)

Author, year

Comparators

Schaefer et al. 200460

 Celecoxib
 Rofecoxib
 NSAIDs

Spiegel et al. 200361

 Celecoxib
 NSAIDs

Yen et al. 200462

 Celecoxib
 NSAIDs
 Hyalourona
n

Primary
outcome
measure
 Cost per
clinically
significant
upper GI
event averted
(CSUGIE)
 Cost per
QALY
gained
 Cost per
QALY
gained

 Cost per
QALY
gained

Methodology

Base Case
Results

Comments

Celecoxib:
 Time horizon: 1
year
 Cost/CSUGIE=
$7,476
 Decision-tree model
 Cost/QALY
 Perspective:
gained=
Veterans Affairs
<$50,000
Administration
 Country: United
States

 Patient population:
OA patients with
previous history of
perforation/
ulcer/bleed

 Time horizon: Lifetime
 Decision-tree model
 Perspective: Health
care payer
 Country: United
States
 Time horizon: 6
months
 Decision-tree model
 Perspective:
Societal
 Country: Taiwan

 Patient population:
OA or RA patients
 No funding source
declared
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Celecoxib ICER
was
$275,809/QALY
gained in
comparison to
NSAIDs

Celecoxib ICER
was
$21,226/QALY
gained in
comparison to
NSAIDs

 Patient population:
60-years old
women with knee
OA
 Study funded by a
governmental
organization

Author, year
Maetzel et al. 200363

Kamath et al. 200364

Comparators
 Celecoxib
 Rofecoxib
 NSAIDs

 Celecoxib
 Rofecoxib
 NSAIDs
 NSAIDs +
prophylaxis
 Acetaminop
hen

Primary
outcome
measure
 Cost per
QALY
gained

 Cost/number
of upper GI
events
averted
 Cost/number
of patients
achieving
pain relief

Methodology

Base Case
Results

Comments

 Time horizon: 5years
 Markov model
 Perspective: Health
care payers
 Country: Canada

 In averagerisk patients:
Celecoxib was
dominated by

 Patient population:
OA or RA patients
with no prior
history of GI
events (averagerisk) or prior
history of GI
events (high-risk)
 Study funded by a
governmental
organization

 Time horizon: 6
months
 Decision-tree model
 Perspective: Health
care payer
 Country: United
States

 For GI events
avoided:
Acetaminophe
n dominates
all other
strategies
 For pain
relief:
Acetaminophe
n, followed by
Rofecoxib
have lowest
ICER

41

NSAIDs

 In high-risk
patients:
Celecoxib was
cost-effective
at <$Can
50,000 per
QALY gained

 Patient population:
patients with
symptomatic knee
OA
 Study funded by a
private
organization

Author, year
Chancellor et al. 200165

+Haglund et al. 200066

Comparators
 Celecoxib
 NSAIDs
 NSAIDs +
Misoprostol
 NSAIDs +
H2RA
 NSAIDs +
PPI
 NSAIDs +
Misoprostol
 Celecoxib
 NSAIDs
 NSAIDs +
Misoprostol
 NSAIDs +
H2RA
 NSAIDs +
PPI
 Arthrotec

Primary
outcome
measure
 Cost/number
of averted GI
events

 Cost/number
of averted GI
events
 Cost/lifeyears saved

Methodology

Base Case
Results

Comments

 Time horizon: 6
 Cost/number of
months
averted GI
events:
 Decision-tree model
Celecoxib
 Perspective: Health
dominated
care payers
NSAIDs alone
 Country:
Switzerland

 Patient population:
OA or RA
 Study funded by
pharmaceutical
company (Pfizer)

 Time horizon: 6
months
 Decision-tree model
 Perspective: Health
care payers
 Country: Sweden

 Patient population:
OA and RA
patients
 No funding source
declared
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Celecoxib
dominated all
other
comparators

Author, year

Comparators

+Svarvar et al. 200067

 Celecoxib
 Rofecoxib
 NSAIDs
 NSAIDs +
Misoprostol
 NSAIDs +
H2RA
 NSAIDs +
PPI
 Arthrotec

Glucosamine as the primary
Comparator
Scholtissen et al. 201068

 Glucosamin
e
 Paracetamol
 Placebo

Primary
outcome
measure
 Cost per
number of
averted GI
events
 Cost per lifeyears saved

 Cost/QALY
gained

Methodology
 Time horizon: 6
months
 Decision-tree model
 Perspective: Health
care payers
 Country: Norway

 Time horizon: 6
months
 Clinical trial data69
 Perspective: Health
care payers
 Country: Spain

Base Case
Results
Celecoxib
dominated all
other
comparators

ICER:
 Glucosamine
dominated
paracetamol
 Glucosamine
vs. placebo:
€4,285/QALY
gained

Comments
 Patient population:
OA and RA
patients
 No funding source
declared

 Patient population:
patients with knee
OA
 Study funded by a
grant from
ESCEO-Amgen

+=Only osteoarthritis results are reported.
GI=Gastrointestinal; H2RA=Histamine-2 receptor antagonists; ICER=Incremental cost-effectiveness ratio; NSAIDs=Non-steroidal antiinflammatory drugs; OA=Osteoarthritis; PPI=Proton pump inhibitor; QALY=Quality-adjusted life-years; RA=Rheumatoid Arthritis

The findings on cost-effectiveness of celecoxib vary by studies. Celecoxib dominated all other treatment strategies in four
studies;57, 65-67 whereas, it was dominated by NSAIDs 63 and acetaminophen in one study each.64
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Glucosamine as the Primary Study Comparator
Only one published study has previously examined the cost-effectiveness of
glucosamine. Scholtissen et al. compared the cost-effectiveness of glucosamine with
paracetamol and placebo in treating KOA, based on the data from a randomized clinical
trial.68, 69 This cost-effectiveness analysis study was conducted from 6 months’ timehorizon and health care payers’ perspective of the Spanish population. No decisionanalytic model was used in this study. Cost/QALY gained was used as the primary
outcome measure of effectiveness in this study. Glucosamine was found to be highly
cost-effective, by dominating the paracetamol strategy and with incremental costeffectiveness ratio of €4,285/QALY gained in comparison to placebo.
In summary, to our knowledge, no published study has compared the costeffectiveness of celecoxib, glucosamine, CS, and combination of glucosamine and CS.
We found a few cost-effectiveness studies that have compared celecoxib to other
treatment strategies such as the NSAIDs alone or in combination with other agents (e.g.,
rofecoxib and hyalouronan). The findings on cost-effectiveness of celecoxib vary by
studies. We also found one study that compared the incremental cost-effectiveness of
glucosamine with paracetamol and placebo. This study concluded glucosamine to be a
highly cost-effective therapy option in treating KOA. No published study has compared
the cost-effectiveness of CS or alone or in combination with glucosamine.
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Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
The WOMAC was developed in 1980s as a disease-specific clinical index for
assessing the pain, stiffness, and physical function among the osteoarthritis patients.116 It
is widely used and easily-administered instrument to evaluate the outcomes of KOA
patients.117 WOMAC is also incorporated into the clinical trials guidelines of the
Osteoarthritis Research Society International (OARSI) as an index relevant to outcome
measurement in osteoarthritis.118
Structure
The WOMAC consists of 24 items divided into 3 sub-scales:
1) Pain (5 items): during walking on flat surface, using stairs, in bed, sitting or lying,
and standing upright
2) Stiffness (2 items): after first awakening and later in the day
3) Physical function (17 items): descending stairs, ascending stairs, rising from
sitting, standing, bending, walking on flat surface, getting in/out of the bath,
sitting, getting on/off toilet, heavy domestic duties, light domestic duties,
shopping, rising from bed, lying in bed, putting on socks/stockings, taking off
socks or stockings, getting in/out of a car or bus.
Scoring
The WOMAC is currently available in two versions: Likert scale and visual
analogue scale (VAS). The possible ranges of scores on the Likert scale version of
WOMAC are: 0 to 20 (pain); 0 to 8 (stiffness); and 0 to 68 (physical function). On the
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other hand, the possible ranges of scores on the VAS version of the WOMAC for each
item are from 0 to 100. Therefore, the possible ranges of total scores on the three subscales are: 0 to 500 (pain); 0 to 200 (stiffness); and 0 to 1700 (physical function). The
WOMAC 3.1 Veterans Affairs (VA) 100 mm VAS version was used in the GAIT study.
Psychometric Properties
A recent systematic review of 43 published articles examined the reliability,
validity, and responsiveness of the WOMAC instrument in measuring outcomes among
hip osteoarthritis or KOA patients.117
Reliability, test-retest:
Overall, the test-retest reliability of the WOMAC meets the minimum
standards.119-124 One study examining this psychometric property of the WOMAC found
the global score on test-retest reliability to be 0.64, with sub-scale scores being 0.64,
0.61, and 0.72 for pain, stiffness, and physical function, respectively.125 Another study
reported internal consistencies for WOMAC sub-scales to be 0.83 (pain), 0.87 (stiffness),
and 0.96 (physical function).121
Reliability, internal consistency:
Findings from several studies suggest that the WOMAC sub-scales are internally
consistent and that the items on each sub-scale are related to each other.117, 126 One such
study reported internal consistency of the pain sub-scale to be 0.89, as estimated through
the Chronbach’s alpha.125
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Reliability, rater:
The Intraclass correlation coefficients (ICCs) for WOMAC range from 0.53 to
0.78 and 0.62 to 0.90 for intra-rater reliability and inter-rater reliability of WOMAC,
respectively, in a study of patients undergoing hip replacement.127
Validity, face:
The WOMAC has been face validated through the expert opinion of
rheumatologists and epidemiologists, reviews of previous instruments, and survey of hip
osteoarthritis and KOA patients.128
Validity, criterion:
Several studies have examined and established the criterion validity for
WOMAC.129-131 For example, one study with knee arthroplasty patient population found
statistically significant Spearman correlations between patient satisfaction and
WOMAC’s pain (r =0.67), stiffness (r =0.63), and function (r =0.64) subscales.129
Validity, construct:
Convergent construct validity for WOMAC has also been examined and
established by several studies.122, 123, 131-136
Validity, known-group:
One study has examined the known-group validity of WOMAC scale.131 Studying
the total knee arthroplasty population, this study found that WOMAC differentiates on
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the pain and physical function subscales and on the global scores in a variety of different
groups.
Responsiveness:
The WOMAC’s responsiveness varies by its sub-scales.117 For example, among
the six hip arthroplasty studies examining this property, the effect size for WOMAC’s
pain, stiffness, and physical function sub-scales were large and ranged from 1.7 to 2.58,
1.0 to 2.17, and 1.8 to 2.9, respectively.132, 133, 137-140
Utilization of WOMAC in GAIT
WOMAC scores were used as a secondary outcome measure in the GAIT study.
A complete WOMAC questionnare including patient assessments of pain, stiffness, and
function were done at each visit, i.e. at baseline; weeks 4, 8, 16, 24; and months 9, 12, 15,
18, 21 and 24.
In summary, WOMAC is a disease-specific clinical index used for assessing
disease status of the hip osteoarthritis or KOA patients. The WOMAC consists of 24
items divided into 3 sub-scales, i.e. pain, stiffness, and physical function. The WOMAC
is available in both the Likert scale and VAS formats. Both of these versions are well
validated and are tested for reliability and responsiveness in many studies.
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Medical Outcomes Study (MOS) 36-item Short Form Health Survey (SF-36)
Structure
The MOS SF-36 (better known as SF-36) is a generic quality-of-life index, with
36 items divided into 8 sub-domains (i.e., physical functioning, role-physical, bodily
pain, general health, vitality, social functioning, role-emotional, and mental health), Table
8.141-143 These sub-domains, in turn, can be summarized into two composite scores, i.e.
physical component summary (PCS) and mental component summary (MCS). Previous
studies based on factor analysis have confirmed that the physical and mental health
summary composite scores account for 80-85% of the reliable variance in the eight subdomains in the US general population,144 MOS patients, 102,105 and populations of other
countries.145-149 The SF-36 is available to administer by self, computer, or a trained
interviewer in person or by telephone, to persons age 14 and older.
Table 8: Structure of SF-36 Instrument.
Summary
Number
Meaning of Scores
Measures
of Items
Low
High
Physical
21
Component
Physical 10
Limited a lot in
Performs all types of
Functioning
performing all physical
physical activities
activities
Role-Physical 4
Problems with work or
No problems with work or
other daily activities due other daily activities due to
to physical health
physical health, past 4
weeks
Bodily pain 2
Very severe and
No pain or limitations due
extremely limiting pain
to pain, past 4 weeks
General Health 5
Believes personal health Believes personal health is
is poor and likely to get excellent
worse
Mental
14
Component
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Summary
Number
Meaning of Scores
Measures
of Items
Low
High
Vitality 4
Feels tired and worn out Feels full of pep and
all of the time
energy all of the time, past
4 weeks
Social 2
Extreme and frequent
Performs normal social
Functioning
interference with normal activities without
social activities
interference, past 4 weeks
Role-Emotional 3
Problems with work or
No problems with work or
other daily activities due other daily activities due to
to mental health
mental health, past 4 weeks
Mental Health 5
Feeling of nervousness
Feels peaceful, happy, and
and depression all of the calm all of the time, past 4
time
weeks

Scoring
Higher PCS and MCS summary scores on the SF-36 indicate better physical and
mental health status, respectively. The following description provides overview of the
scoring algorithm for the SF-36v2 (version 2). Items of the physical functioning subdomain consist of three levels, ranging from ‘limited a lot’ to ‘not limited at all’. Items on
the role physical sub-domain consist of five levels in the SF-36v2, varying from ‘all of
the time’ to ‘none of the time.’ This is different from the version 1 where these items use
to have only two levels, i.e. yes and no. Bodily pain sub-domain has six levels for the
first question (from none to very severe) and five levels for the second question (from
‘not at all’ to ‘extremely’). The general health sub-domain has five levels for all five
items. The vitality sub-domain has five levels in the SF-36v2 (ranging from ‘all of the
time’ to ‘none of the time’), differing from the six level items in the version 1 of this
instrument. Items in the social functioning sub-domains have five levels. Items on the
role emotional sub-domain also have five levels in the SF-36v2, ranging from ‘all of the
time’ to ‘none of the time.’ This is different from the version 1 of SF-36, in which these
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items had only two levels (yes and no). The mental health sub-domain has five level
items in both of the version 1 and 2 of the SF-36.
Psychometric Properties
Reliability, test-retest:
The SF-36’s test-retest reliability has been tested in more than 200 studies.150
Reliability statistics have exceeded the minimum standards of 0.70 or even 0.80 in most
of these studies.
Reliability, internal consistency:
Findings from a systematic review suggest that the median reliability for each of
the eight scales of the SF-36 are at least 0.80, except for the social functioning scale that
would found to have an median reliability of 0.76.151 These statistics indicate that the SF36 is internally consistent.
Reliability, rater:
Several studies have examined the inter- and intra-rater reliabilities of the SF36.152-157 Most of these studies have found moderate to high inter-and intra-rater
reliabilities for this quality-of-life instrument.
Validity, face:
The SF-36 has been compared to other widely used generic quality-of-life
instruments.158 Content of the SF-36 instrument includes eight of the most frequently
measured health concepts, ensuring its face validity.
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Validity, criterion:
Numerous studies have evaluated the criterion validity of the SF-36
instrument;141, 144, 148, 159-163 all of these studies found SF-36 to meet the standards of
criterion validity.
Validity, construct:
The construct validity of SF-36 has been examined by various studies.
102,105,109,120-124

These studies have reported that the SF-36’s construct validity varies from

0.85 (physical function) to 0.69 (general health) for the PCS and from 0.87 (mental
health) to 0.65 (vitality) for the MCS summary scores.
Validity, known-group:
Several studies have found evidence of known-group validity of the SF-36. A
recent systematic review focused on examining the use of SF-36 in schizophrenia
population found 11 studies comparing SF-36 scores with normative values.164 All of the
11 studies found statistically significant (p<0.05) differences in SF-36 composite scores
(PCS and MCS) and dimension scores between individuals with schizophrenia and
normative values. Two studies found significant difference for all eight sub-domains,
except for the bodily pain.165
Responsiveness:
The responsiveness of SF-36 has been examined and established in several
studies.166-170 For example, one study examined Sf-36’s responsiveness in four common
chronic conditions of low back pain, menorrhagia, suspected peptic ulcer, and varicose
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veins.166 This study found that the changes across health status were significantly
associated with the changes in SF-36 scores, establishing the responsiveness of SF-36.
In summary, the SF-36 is a generic quality-of-life instrument, with 36 items
divided into 8 sub-domains that can be summarized into two component scores, i.e. PCS
and MCS. Many studies have established the validity, reliability, and responsiveness of
the SF-36 instrument.
Estimation of Quality-Adjusted Life-years (QALYs) From SF-36
As described before in the introduction chapter, the individuals’ preferences are
represented by individuals’ utility function that relates their well-being to their levels of
consumption of several goods and services. In health economics, this preference-based
individuals’ utility function is known as health utility, which is used to estimate QALYs
for the purpose of a CEA study.
The SF-36 instrument cannot be directly used to estimate QALYs as the former is
not a preference-based instrument, but a descriptive one. Therefore, in order to estimate
QALYs from SF-36 its scores must be mapped on to a preference based instrument like
SF-6 Dimensions (SF-6D) or EuroQol 5-Dimensions (EQ-5D). Pickard et al. have
previous compared several mapping algorithms (n=9) for estimating preference-based
health utilities from the SF-36 and concluded Brazier Index to be the best.171, 172 Brazier
index is a preference-based measure of health from the SF-36 instrument that was derived
by mapping UK’s national population measures on to SF-6D through the standard gamble
approach.173 Further details of mapping SF-36 scores to SF-6D and, in turn, estimate
QALYs for the purpose of current study are provided in the methods section.
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Utilization of SF-36 in GAIT
SF-36 scores were used as a secondary outcome measure in the GAIT study. The
SF-36 scores were recorded at each visit, i.e. at baseline; weeks 4, 8, 16, 24; and months
9, 12, 15, 18, 21 and 24.

Glucosamine/chondroitin sulfate Arthritis Intervention Trial (GAIT)
GAIT was the largest clinical trial examining efficacy of CAM therapies to treat
KOA. This trial compared glucosamine, CS, their combination, celecoxib, and placebo
in a multi-center double-blind randomized study.21 All patients were screened at the
screening visit for several inclusion and exclusion criteria (Appendix 1). This was
followed by a randomization visit and follow-up visits at weeks 4, 8, 16, and 24 (GAIT
24-week study) and at months 9, 12, 15, 18, and 24 (GAIT 2-year follow-up study).
For the GAIT 24-week study, a total of 1583 individuals with symptomatic KOA
were randomly assigned to receive daily doses of 1500 mg of glucosamine, 1200 mg of
CS, both glucosamine and CS, 200 mg of celecoxib, or placebo for 24 weeks. KOA
patient groups were stratified by severity of knee pain at the baseline into mild and
moderate to severe. The primary outcome measure was at least 20% reduction in pain
from baseline enrollment, measured using the Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC) pain sub-scale. The secondary outcome
measures were: 1) WOMAC stiffness and function subscales, 2) patient’s global
assessment of disease status, 3) patient global assessment of response to therapy, 4)
investigator global assessment of disease status, 5) investigator global assessment of
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response to therapy, 6) study joint evaluation, 7) SF-36 scores, 8) modified health
assessment questionnaire (mHAQ), beck depression inventory, 9) use of rescue analgesic,
and 10) discontinuation of study medication due to adverse event. Overall, glucosamine,
CS, or their combination therapies were not significantly different from placebo in pain
reduction, p>0.05. Among the moderate to severe pain stratum group of patients,
however, the combination of glucosamine and CS was significantly better than placebo in
treating KOA. On the other hand, celecoxib was better than placebo in both overall
analysis and in mild-to-moderate pain stratum groups, but not in moderate-to-severe pain
stratum.
The GAIT 2-year follow-up study—the ancillary structure modifying study—was
conducted on a sub-group of original participants.24, 33 For this follow-up study, a total of
662 participants were randomly assigned to glucosamine (n=134), CS (n=126),
combination of glucosamine and CS (n=129), celecoxib (n=142), and placebo groups
(n=131). The primary outcome measure was the loss of joint space width (JSW) in the
medial tibiofemoral joint compartment. The reduction in WOMAC pain sub-scale scores
from baseline at 2 years was also recorded as a secondary outcome measure in this
follow-up study. No significant differences were found between placebo and celecoxib,
glucosamine, CS, and combination of glucosamine and CS in reducing the loss of JSW or
change in WOMAC pain sub-scale scores at 2-year follow-up, p>0.05.
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Summary of Literature Review
KOA has substantial burden of illness in the US, affecting 13.8% of the
population aged 26 years or more. Currently, there is no cure for KOA; all available
treatment options are intended to reduce pain, maintain and/or improve joint disability,
and limit functional impairment. Both CAM therapies and conventional medicines are
widely used in the US to treat KOA. Several previous clinical trials have examined and
established the efficacy and safety of conventional medicines such as celecoxib to treat
KOA. On the other hand, the efficacy and safety of CAM therapies like glucosamine and
CS is still debatable after several clinical trials. There is a high unmet need to compare
the cost-effectiveness of CAM therapies with conventional medicines in treating KOA in
the US.
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CHAPTER 3: METHODS AND MATERIALS
The aim of our study was to compare the incremental cost-effectiveness of
glucosamine, CS, combination of glucosamine and CS, celecoxib, NSAIDs and placebo
therapies to treat KOA. We begin this section by discussing the human subjects’ approval
for this study. This is followed by the discussion on research design and data sources;
study population; inclusion and exclusion criteria; sample size estimation; strategies to
manage KOA; model structure, description, and validation; study perspective, time
horizon and discounting rates; costs measures, effectiveness measures; health utilities;
transition probabilities and event rates; and sensitivity analysis. Wherever necessary, the
aforementioned sections have separate sub-sections for different study objectives to
differentiate between their respective applicable methodologies.

Human Subjects Approval
We submitted this study for the departmental review through the University of
New Mexico, College of Pharmacy. After seeking the departmental approval, this study
was submitted to the Human Research and Review Committee (HRRC) under the exempt
category. The HRRC approved this study on November 7, 2012. The approval letter for
this study is presented in Appendix 2.
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Research Design and Data Sources
Two decision-analytic models were constructed to examine the cost-effectiveness
of CAM therapies and conventional medicines in treating KOA: (1) A Markov cohort
model to compare the cost-effectiveness of CAM therapies and conventional medicines
from 10-year time-horizon, and (2) A decision-tree model to compare cost-effectiveness
of CAM therapies and conventional medicines from 24-weeks and 2-year time-horizons.
Below is a brief of all data sources utilized in this study; the specific details of these,
however, are provided in the later sections of this chapter.
For the Markov cohort model, efficacies of CAM therapies and conventional
medicines were based on 1-year WOMAC pain sub-scale reduction outcomes from the
GAIT study and were defined as at least 20% reduction in pain sub-scale scores from the
baseline, as described later in this chapter.174 Health utility values were estimated by
mapping SF-36 scores to the SF-6D instrument. Drug costs were obtained from the
published literature sources such as Red Book, Wal-Mart Prescription Program, and CVS
Generic Pharmacy.175-178 Published literature was also used to obtain risks rates of drugs
associated adverse events,63, 179-208 their costs59, 176, 209-216 and their health utility values,63,
217-222

and total knee replacement surgery rates and its costs. 39,40,63, 217-224
For the decision-tree model drug efficacies data were based on 24-week and 2-

year WOMAC pain sub-scale reduction outcomes from the GAIT study , for respective
time-horizons of 24-weeks and 2-year. Similar to the Markov model, the health utility
values were estimated by mapping SF-36 scores to the SF-6D instrument and the drug
costs were obtained from the published literature sources such as Red Book, Wal-Mart
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Prescription Program, and CVS Generic Pharmacy.175-178 Since no significant difference
in serious adverse events between CAM therapies and celecoxib was observed in the
GAIT study, none were modeled in the decision-tree.24, 33, 174
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Study Population, Inclusion and Exclusion Criteria
For Objective 1
The inclusion criteria used for our study population are being male or female, age
of at least 50 years, and clinical diagnosis of primary KOA. No other inclusion or
exclusion criteria apply to this study population, as multiple data sources from the
literature were utilized for objective 1.
For Objectives 2 to 5
Study population for objectives 2 & 3 and 4 & 5 consist of the GAIT 24-week and
GAIT 2-year follow-up studies participants, respectively.21, 33 The inclusion criteria for
our study are same as the inclusion and exclusion criteria from the GAIT study
(Appendix 1).21, 33
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Sample Size Estimation
We did not conduct formal sample size estimations and power for our study
because of the following reasons. First, the foundation of cost-effectiveness analysis is
based on the concepts of estimation rather than hypothesis testing.34, 225, 226 Unlike other
types of studies, the uncertainties in cost-effectiveness analysis studies are addressed
through sensitivity analysis rather than the formal power calculations.34 If any, the usage
of power calculations and sample size estimation in cost-effectiveness analyses are
limited to those studies that are conducted alongside clinical trials.227 Even the economic
evaluations alongside clinical trials are commonly underpowered, as recognized by a
recent good practices report by the International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) Randomized Clinical Trials (RCT) Cost-Effectiveness
Analysis Task Force.228 Further, all currently published literature on sample size
estimation and power calculation is based on cost-effectiveness analysis studies
conducted alongside clinical trials.227, 229-234 Our study was not a cost-effectiveness
analysis alongside a clinical trial because no cost data were collected in the GAIT study
and we utilized multiple data sources to populate our decision-analytic models.
Therefore, the sample size estimation formulas valid for cost-effectiveness analysis
studies alongside the clinical trials are not applicable to our study.
Second, to address the parameter uncertainty among the decision-model inputs,
we performed second order Monte Carlo simulation (probabilistic sensitivity analysis) on
all of our decision-analytic models. Further details on the probabilistic sensitivity analysis
are provided later in this chapter.
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Third, sample size estimation is most beneficial at the time of designing a study
so that sufficient study participants can be recruited accordingly.235 As the GAIT study is
already closed out, no further participants recruitment or data collection is possible at this
point.21 Therefore, estimation of sample size based on the cost-effectiveness ratios at this
stage for our study would not be fruitful, and, more importantly, would be of least
scientific importance.
Sample Size Estimation in GAIT Study
In the GAIT 24-weeks study, a total of 1583 patients with symptomatic KOA
were randomly assigned to glucosamine (n=317), CS (n=318), combination of
glucosamine and CS (n=317), celecoxib (n=318), or placebo (n=313).21 These group
assignments were based on the statistical power of 85% to detect at least one clinically
meaningful difference between the placebo group and groups of glucosamine, CS,
combination of glucosamine and CS, and celecoxib.21, 235 The rate of response for these
calculations was assumed to be 35% in placebo group and the overall rate of withdrawal
from study was assumed to be 20%.21
The GAIT 2-year ancillary structural study consisted of sub-population of GAIT
24-week study.24, 33 Nine of the sixteen centers from the latter participated in this 2-year
follow-up study (Arthritis Research Center, Wichita; University of Arizona; Case
Western Reserve University; Cedars-Sinai Medical Center; Indiana University;
University of California, Los Angeles; University of California, San Francisco;
University of Pittsburgh; and the University of Utah). For the 2-year follow-up study, a
total of 662 participants were randomly assigned to glucosamine (n=134), CS (n=126),
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combination of glucosamine and CS (n=129), celecoxib (n=142), and placebo (n=131)
groups.
Sample Size and Power Calculations Based on QALYs
As described before, no formal sample size and power calculations were
conducted in our study. Nonetheless, we here discuss if the currently available sample
size from the GAIT study was sufficient to determine the minimum important difference
(MID) in QALYs gained among the KOA patients for the study of objectives 2 to 5.
Walters and colleagues estimated the MID in SF-6D based health utility values
among the KOA patients from a prospective study.236 They found a difference of 0.032 to
be the MID, with standard deviation of 0.066 and 95% CI of 0.015 to 0.049. Based on
these statistics, the required sample size per group and the total required sample size (5
groups) are displayed in Table 9. These statistics indicate that the data available from the
GAIT study were sufficient to estimate MID in QALYs gained (mean=0.032, 95%
CI=0.015 to 0.049) at 90% power.
Table 9: Sample Size Estimation Based on QALYs.236
Power
MID*;
Required Sample Size
Mean (95% CI)
Per Group:
LCI, M, UCI
0.80
0.032
610, 136, 60
(0.015 to 0.049)
0.85
0.032
698, 156, 68
(0.015 to 0.049)
0.90
0.032
816, 182, 80
(0.015 to 0.049)
*Standard Deviation=0.066

Total Required
Sample Size:
LCI, M, UCI
3650, 680, 300
3490, 780, 340
4080, 910, 400

CI=Confidence Interval; LCI=Estimates as per the Lower Confidence Interval; M=Estimates as
per the mean; QALYs=Quality-Adjusted Life-years; UCI=Estimates as per the Upper Confidence
Interval
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KOA Treatment Strategies/Study Comparators
For Objective 1
We compared the incremental cost-effectiveness of 1500 mg of glucosamine
daily, 1200 mg of CS daily, combination of glucosamine 1500 mg and CS 1200 mg daily,
200 mg of celecoxib daily, and US FDA approved prescription NSAIDs in the treatment
of KOA. The list of these US FDA approved prescription NSAIDs is provided in Table
10.
Table 10: FDA Approved Dosages of NSAIDs in Treatment of KOA.
Drug
Recommended FDA Dosage to Treat KOA
Diclofenac
100-150 mg/day in divided doses (50 mg BID, TID or 75 mg BID)
Diflunisal
500-1000mg/day in two divided doses
Etodolac
300 mg BID, TID or 400 mg BID or 500 mg BID
Fenoprofen
Up to 3,200 mg/day (3 to 4 times a day)
Flurbiprofen
200-300 mg/day
Ibuprofen
400 to 800 mg orally every 6 to 8 hours
Indomethacin
Up to 150-200 mg/day
Ketoprofen
Up to 200 mg/day (75 mg TID or 50 mg BID)
Ketorolac
10 mg 4 times a day orally as needed
Mefenamic acid 500 mg orally followed by 250 mg every 6 hours as needed
Meloxicam
Up to 15 mg/day
Nabumetone
Up to 2000 mg per day
Naproxen
Up to 500 mg/day in divided doses, BID
Oxaprozin
1200 mg/day in divided doses, BID
Piroxicam
20 mg/day
Sulindac
300 mg/day, BID
BID=Twice a day; FDA=Food and Drug Administration; KOA=Knee osteoarthritis; TID=Thrice

a day
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For Objectives 2 to 5
We compared the incremental cost-effectiveness of 1500 mg of glucosamine
daily, 1200 mg of CS daily, combination of glucosamine 1500 mg and CS 1200 mg daily,
200 mg of celecoxib daily, and placebo in the treatment of KOA. These comparators are
per the dosage regimen used in the GAIT study protocol. Further details of the
aforementioned drugs dispensed to the blinded groups in the GAIT study are provided in
Table 11.
Table 11: Blinded Drugs Dispensed to the GAIT Study Participants.
Treatment
Strength
Dosage
Dose/Day (number of
Form
capsules/day)
Glucosamine
250 mg
Capsules
1500 mg (six capsules/day)
CS
200 mg
Capsules
1200 mg (six capsules/day)
Glucosamine +
250 mg
Capsules
Glucosamine: 1500 mg (six
CS
Glucosamine +
capsules/day) + CS: 1200 mg (six
200 mg CS
capsules/day)
Celecoxib
200 mg
Capsules
200 mg (one capsule/day)
Placebo I
0 mg
Capsules
0 mg (six capsules/day)
Placebo II
0 mg
Capsules
0 mg (one capsule/day)
CS=Chondroitin Sulfate; GAIT=Glucosamine/Chondroitin Arthritis Intervention Trial
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At each visit during the GAIT study, participants were dispensed two bottles of
the blinded drugs. The first bottle consisted of glucosamine, CS, combination of
glucosamine and CS, or placebo I to be taken three times a day. The second bottle
consisted of celecoxib or placebo II to be taken once a day. The details of the treatment
regimens during the GAIT study are provided in Table 12.

Table 12: Treatment Regimens for GAIT Study.
Treatment Treatment
Bottle 1 Dose/Day
(Dosage regimen: 2
Group
capsules 3 times a day)
1
Glucosamine
Glucosamine 1500 mg
2
CS
CS 1200 mg
3
Glucosamine + CS
Glucosamine 1500 mg +
CS 1200 mg
4
Celecoxib
Placebo I 0 mg
5
Placebo
Placebo I 0 mg

Bottle 2 Dose/Day
(Dosage regimen: one
capsule a day)
Placebo II 0 mg
Placebo II 0 mg
Placebo II 0 mg
Celecoxib 200 mg
Placebo II 0 mg

GAIT=Glucosamine/Chondroitin Arthritis Intervention Trial

Placebo was included as one of the comparators in our study as it is commonly
prescribed among the KOA patients and its use is viewed ethical among the US
physicians.237, 238 A recent survey of 679 internists and rheumatologists practicing in the
US found that 46-58% of these physicians prescribe placebo to their patients on a regular
basis.237 Majority of these physicians (62%) also believe the practice of prescribing
placebo to be ethically permissible. In addition, these physicians most commonly
describe placebo to their patients as potentially beneficial treatment (68%); only rarely do
they explicitly describe these as placebos (5%). Further, a systematic review of 22 studies
from 12 countries further found the use of placebos to range from 17% to 80% among
physicians.238
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Model Structure, Description, and Validation
Mathematical modeling is widely used in health economic evaluations of the
pharmaceuticals as well as of other health technologies.56 The types of decision-analytic
models used in our study for objective 1 was a Markov cohort model and two decisiontree models for examining objectives 2 to 5. Both of these types of models had provisions
for probabilistic sensitivity analysis.
Two different types of models (i.e., Markov and decision-tree models) were
constructed in this study for the following reason: The purpose of studying objective 1
was to compare the long-term (10 years) cost-effectiveness of CAM therapies with
conventional medicines in real-world where a patient may experience adverse events or
death during its treatment journey. On the other hand, the purpose of objectives 2 to 5
was to compare the cost-effectiveness of KOA treatment strategies by exclusively
simulating the world of GAIT clinical trial. For the same reason, no adverse events or
deaths were modeled in any decision-tree, as none occurred in the GAIT study.
Markov Cohort Model for Objective 1
A Markov cohort model was constructed to mathematically simulate clinical
scenarios of treating KOA patients with CAM therapies and conventional medicines from
10-year time-horizon (1-year Markov cycles) and healthcare payers’ perspective (Figure
1 to 4). Clinically diagnosed KOA patients entered the Markov model at age 50 years to
be allocated to one of the following treatment groups: celecoxib, NSAIDs, glucosamine,
CS, or combination of glucosamine and CS. Unlike the other four objectives, no placebo
arm was modeled in the Markov model because the purpose of the Markov model based
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analysis was to compare cost-effectiveness of FDA approved conventional medicines
with CAM therapies in a broader group of US population. Whereas, for decision-tree
model based analyses, the purpose was to examine which therapy (including placebo)
was most cost-effective in the GAIT study population. Patients entered different Markov
processes based on their initial allocations to CAM therapies or conventional medicines,
as displayed in Figure 1. No medication augmentation or switching was allowed in the
model.
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Figure 1: Schematic Diagram of the Markov Cohort Model.

Treatment
Allocation

Celecoxib

Markov Process # 1

non-selective NSAIDs

Markov Process # 1
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Markov Process # 2

Chondroitin Sulfate

Markov Process # 2

Glucosamine + CS

Markov Process #2

CS=Chondroitin Sulfate; NSAIDs=non-selective Non-Steroidal Anti-Inflammatory
Drugs

Patients allocated to conventional medicines, i.e. celecoxib or NSAIDs,
progressed through the Markov process displayed in Figure 2 (Markov Process # 1).
Beginning at the celecoxib/NSAIDs health state, the KOA patients progressed to one of
the following Markov health states: treatment success, TKR surgery, adverse events, and
death. Treatment success was defined as at least 20% reduction on WOMAC pain subscale scores from baseline at the end of one year, these data were obtained from 1-year
outcomes of the GAIT study. TKR surgery rates were obtained from a large US joint
replacement registry of the Kaiser Permanente and varied by age-groups and gender.
Included adverse events were serious cardiovascular (i.e., heart attack, stroke, myocardial
infarction, and hypertension) and GI adverse events (i.e., GI bleeding, peptic ulcer, and
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dyspepsia) for conventional medicines.63, 179-208 After experiencing a GI bleeding event,
KOA patients were modeled to be managed either in outpatient or inpatient settings, as
per the recommendations and previously published evidence.179-184 Among the inpatients,
the treatment of GI bleeding may have included surgery.63 Progressing through the
Markov process, death was modeled to occur because of one of the following five
reasons: heart failure, stroke, myocardial infarction, GI bleeding, and aging. A patient
may have progressed to death due to aging from any of the Markov health states. Death
was not modeled in any of the decision-tree models, as these models were exclusively
populated without any extrapolation from the GAIT study outcomes in which no deaths
occurred.185-196, 239, 240
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Figure 2: Markov Process (1-year cycles) for Conventional Medicines (Markov Process #
1 in figure 1).
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Figure 3: GI Bleeding Management Pathway

GI=Gastrointestinal

Patients allocated to CAM therapies, i.e. glucosamine, CS, or combination of
glucosamine and CS, entered the Markov process shown in Figure 4 (Markov process # 2
in Figure 1). Only difference between the Markov processes for conventional medicines
and CAM therapies is the absence of risks of adverse events associated with the latter
(The reasons for not associating any serious adverse events with CAM therapies are
described later in this chapter). In the Markov process for CAM therapies, KOA patients
began in the model at the CAM therapies health state and progressed to one of the
following: treatment success, TKR, and death. Treatment success was defined in the
same manner as for the conventional medicines group, i.e. at least 20% reduction on
WOMAC pain sub-scale scores from baseline to end of one year. TKR risks and death
rates were also based on same data sources as that for the conventional medicines group.
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Figure 4: Markov Process for CAM Therapies (Markov Process # 2 in figure 1).

CAM
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Dead

CAM=Complementary and alternate medicine
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Decision-Tree Model for Objectives 2 to 5
In addition to the Markov cohort model described earlier, two decision-tree
models were constructed to compare the cost-effectiveness of CAM therapies and
conventional medicines from 24-weeks and 2-year time-horizons (one decision-tree for
each). The schematic framework of these decision-tree models is displayed in Figure 5.
All KOA patients entered the model at the decision branch “treatment allocation.”
From this decision branch, patients were allocated to one of the following five branches,
as per their respective blinded treatment groups in the GAIT study: glucosamine, CS,
combination of glucosamine and CS, celecoxib, or placebo. From these five decision
branches patients progressed to either “compliant” or “non-compliant” chance
branches.21, 241, 242 Since the GAIT study was conducted in well-controlled clinical trial
settings, compliance rates during GAIT study may have differed from the real-world
settings. To account for potential bias in decision-tree model parameters due to this issue,
the compliance for all study parameters was arbitrarily assumed to be 75%. This estimate
was varied by ±25% in the sensitivity analysis.243
From the compliant/non-compliant event branches, the patients entered
“responders” or “non-responders” terminal chance branches. “Responders” were defined
as the patients that achieved at least 20% reduction on the WOMAC pain sub-scale scores
from baseline at the end of 24-weeks or 2-years, for the respective study time-horizons.21
Patients who did not achieve at least 20% reduction on the pain sub-scale of the
WOMAC instrument from baseline to endpoint were defined as “non-responders.”
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Figure 5: Schematic Diagram of the Decision-Tree Model.
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Models Validation
Health economic models were based on specific assumptions related to their
structure and parameters; therefore, model validation is important for decision-makers to
judge regarding applicability of these models while making their decisions.244, 245 Several
different types of model validations are required as it is not possible to specify a criterion
that a model must meet to be declared valid. Verification (internal validity) was
performed by examining all model equations and parameters against their sources, after
building the final decision-analytic models.245 Cross-validation was conducted by
comparing the study models with the previously published related cost-effectiveness
models.62, 63, 246, 247 External validation was conducted by extrapolating the decisionmodel to 1 year based on the data from the GAIT 24-weeks study and comparing these
results with the GAIT ancillary study results.
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Time Horizon, Study Perspective, and Discounting Rates
Our study was conducted from three different time-horizons: 24-weeks, 2-years,
and 10-years. The selection of first two time-horizons was as per the studied time periods
in the GAIT.24, 33, 174 The 10-year time horizon was used to compare long-term costeffectiveness of CAM therapies and conventional medicines among the KOA patients.
Separate cost-effectiveness analyses were conducted from healthcare payers and
patients perspectives for the purpose of 24-week and 2-year time-horizon analyses.
Healthcare payers’ perspective was used to study cost-effectiveness of CAM therapies
and conventional medicines from 10-year time-horizon.
The base case discounting rate of 3% was used in all of our analyses, as
recommended by the USPCEHM.34 This rate was varied from 0% to 5% in the sensitivity
analysis, as described later in this chapter.
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Cost Measures
All costs were estimated in the 2012 US dollars, adjusting previous years costs for
inflation through the consumer price index (CPI).34, 248 These costs include drug costs;
adverse events management costs for heart failure, stroke, myocardial infarction, GI
bleeding, peptic ulcer, dyspepsia, edema, and hypertension; and TKR surgery costs. For
objectives 3 and 5, we also included indirect healthcare costs incurred among the KOA
patients, as described later in this section. Any other health care costs excluded from our
study as they would be similar between all study comparators.21, 33, 249-251 Table 13 lists all
costs included in our study.
Drug Costs
Multiple literature sources were utilized to obtain annual drug costs for the study
comparators. Drug costs for celecoxib and NSAIDs were obtained from the generic
prescription drug programs of the Wal-Mart and CVS.175, 176 Drugs costs of glucosamine
and CS were obtained from the published literature.178 The average wholesale prices of
glucosamine and chondroitin combination therapy obtained from the Red Book was used
as its drug cost.176 Placebo costs were assumed to be equal to the mean of costs of all
other study comparators. Costs related to the physicians’ office visit were based on the
2012 Medicare fee schedule estimated using the Current Procedural Terminology (CPT)
codes.252, 253
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Adverse Events Costs
Heart Failure
Costs of heart failure treatment were obtained from the published literature and
were inclusive of 90-days post heart failure inpatient and outpatient management costs.209
These heart failure treatment costs were estimated from a large employer-based
commercial insurance database. From this database, the costs of treating heart failure
were measured as the total healthcare costs for patients with heart failure claims minus
the total healthcare costs among matched control groups without heart failure claims.
Stroke
Costs of treating stroke include separate short-term and long-term direct
healthcare expenditures.210, 211, 254 Short-term (i.e., day 0 to 30 post-stroke) direct
healthcare costs during hospitalization ranged from $8,531 to $24,526.65.210 Long-term
(i.e., after 30 days post-stroke) direct care stroke costs after hospital discharge ranged
from $5,482 to $27,195.211 All stroke related costs were estimated from large
retrospective claims databases.
Myocardial Infarction
Costs of treating myocardial infarction were obtained from the US estimates of an
international, multisite registry of patients presented with acute myocardial infarction.212
These costs were based on diagnosis-related group (DRG) codes and are adjusted to
reflect length of hospital stay and physicians’ efforts for each procedure performed.
These procedures include CABG, percutaneous transluminal coronary angioplasty
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(PTCA), coronary catheterization (CC), intra-aortic balloon pump (ABP), and automatic
implantable cardiac defibrillator (AICD).
GI Bleeding
Costs of treating GI bleeding included 12-month healthcare costs post a GI
bleeding event, estimated from a large US national health plan claims database.213 These
costs include total healthcare, medical, and pharmacy costs incurred in both inpatients
and ambulatory care settings for patients experienced a GI bleeding event.
Dyspepsia
Costs of managing dyspepsia were based on the American College of
Gastroenterology recommendations to treat dyspepsia.255 The dyspepsia treatment
strategy followed was of empiric trial of acid suppression with a proton pump inhibitors
(PPIs) for a month. All dyspeptic patients over 55 years of age additionally underwent
esophagogastroduodenoscopy (EDG). The cost of EDG was obtained from 2012
Medicare physicians fee reimbursement schedule.214 The cost of PPI was obtained from
the published literature.59
Peptic Ulcer
Similar to costs of managing dyspepsia, the costs of managing peptic ulcer were
based on the guidelines of the American Association of Family Physicians.256 All patients
with peptic ulcer discontinued NSAIDs/celecoxib, underwent test for Helicobactor Pylori
(H. Pylori) and took PPIs for 2 months. Furthermore, all patients aged over 55 years
underwent EDG. The cost of EDG and H. Pylori testing were based on the 2012
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Medicare physician fee reimbursement schedule and the cost of PPIs was obtained from
the published literature.59, 214
Edema
Costs of treating edema were also based on the treatment guidelines of the
American Association of Family Physicians.257 All patients experiencing edema
discontinued NSAIDs/celecoxib and were treated with diuretics for 4 to 6 weeks. Costs of
diuretics were based on the Wal-Mart Prescription Program.176
Hypertension
Hypertension management is based on the recommendations of the National
Institute of Clinical Excellence (NICE).258 All patients experiencing hypertension
continued on their KOA medications and were started on a concomitant anti-hypertensive
therapy.258-260 Costs of anti-hypertensive therapy were based on the Wal-Mart
Prescription Program for generic drugs.176
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Table 13: Model Inputs for Costs.
Parameter
Base Case (SA Range)
Drugs (annual)
Celecoxib $456.16
($339.76 to $957)
NSAIDs $40
($30 to $ 50)
Glucosamine $ 286.20
($214.65 to $429.30)
CS $ 227.88
($170.92 to $284.84)
Glucosamine + CS $ 499.44
($374.58 to $624.30)
Placebo $367.42
($274.97 to $573.86)
$75.77±25%
Physicians’ office visit cost (4
times/year)
Adverse Events Costs
Heart Failure
$7,926.67
($5,945.01 to $9,908.33)
Stroke
Short-term care (up to 30 days) $15,995.12
($11,997.01 to $19,993.75)
Long-term care (after 30 days) $21,713
($16,284.76 to $27,141.24)
Myocardial Infarction
$11,898.72
($8,924.04 to $14,873.40)
GI Bleeding
Inpatient Management $16,294.94
($12,223.20 $20,366.67)
Outpatient Management $5037.34
($3,778.01 to $6,296.67)
Peptic Ulcer
Esophagogastroduodenoscopy $315 ($256.28 to $373.72)
PPI for 2 months $40.4 ($33.0 to $49.2)
Test for Helicobacter Pylori $87.12 ($52.49 to $121.75)
Dyspepsia
Esophagogastroduodenoscopy $315 ($256.28 to $373.72)
PPI for one month $20.2 ($16.5 to $24.6)
Edema
Diuretics $4 ($2 to $ 5)
Hypertension
Anti-hypertensive drugs $40 ($30 to $50)
Total Knee Replacement

$11,660 ($5,830 to $17,490)
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Reference
CVS Generic
Pharmacy175
Wal-Mart Prescription
Program176
Gregory et al.178
Gregory et al.178
Red Book177
Assumption
CPT code: 99214252
Zhao et al.209
Qureshi et al.210
Kind et al.211
Kauf et al.212
Cryer et al213
Cryer et al213
HCPCS code=43235214
Loyd et al.59
HCPCS code=83013215
HCPCS code=43235214
Loyd et al.59
Wal-Mart Prescription
Program176
Wal-Mart Prescription
Program176
Robinson et al.216

CS=Chondroitin Sulfate; NSAIDs= Non-steroidal anti-inflammatory drugs; PPI=Proton pump
inhibitors; SA=Sensitivity analysis
Average length of stay for bleeding=5.56 days261

TKR Surgery Costs
Costs of TKR surgery were obtained from the claims records of commercial and
Medicare beneficiaries from 61 hospitals in the US.216 These costs include device costs as
well as procedure costs, adjusted for patient age, principal diagnoses (i.e., fracture,
osteoarthritis, rheumatoid arthritis, and osteonecrosis), number of comorbidities,
discharge destination, and number of in-hospital complications. Table 13 displays the
costs of TKR surgery.
Indirect Health Care Costs
To compare the cost-effectiveness of CAM therapies with conventional medicines
from patients’ perspective, in addition to all of the costs described eariler, we also
included indirect health care costs of treating KOA in the analysis (i.e., for examining
objectives 3 and 5).
Several studies have previously examined indirect healthcare costs incurred
among KOA patients in different countries; however, none of these studies are focused
on the US population.262-267 For the purpose of our analysis, we used indirect healthcare
costs estimated by Gupta et al in Canada because: (1) the Canadian healthcare systems
was assumed to most closely represent the US system and, (2) authors also reported their
findings in terms of US dollars. The annual average indirect healthcare costs were
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$13,624.37 (SD±$6,416.7). These indirect healthcare costs include formal and informal
productivity lost costs and caregiver time costs.
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Effectiveness Measure
Quality-adjusted life-years (QALYs) gained was used as the primary
effectiveness measure in our study. Selection of QALYs as the effectiveness measure for
our study is based on QALYs’ endorsement for “reference case” by the USPCEHM and
the NICE of the UK.34, 45 While using QALY as the effectiveness measure, the
assumption of the decision-makers objective of maximizing the health or health
improvements across the population subject to resource constraints is made.
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Health Utilities
Treatment Success, Respondents, Non-Respondents, Baseline, and No Treatment
Health utilities for all studied therapies (i.e., KOA treatment strategies) related
treatment success, response and, non-response were obtained from the GAIT study.
However, GAIT study did not collect any preference-based data, which are required to
estimate health utilities and, in turn, QALYs. As a result, data from the GAIT study could
not be directly converted into health utilities. Nonetheless, the short form (SF)-36, which
is a descriptive index, was used in the GAIT study to determine quality-of-life changes
among the GAIT study participants. In order to estimate QALYs from GAIT study, SF36 scores were mapped on SF-6 Dimensions (SF-6D), which is a preference-based
quality-of-life instrument. These SF-6D scores were then converted into health utilities
from which QALYs were estimated.
More specifically, in the first step Brazier’s index was used to map SF-36 scores
on SF-6D based preference-scores, thus estimating the patient-level health utility values
among the GAIT participants.172 In the second step, using the health utility values
obtained from the above procedure, QALYs gained were estimated among the GAIT
study participants.34, 268 In sensitivity analysis, these health utilities were varied by ±25%
to account for uncertainty in the parameters, as described later in this chapter.243
Several studies have previously mapped the descriptive SF-36 questionnaire on to
the preference-based measurements. Some examples include mapping SF-36 on to the
quality of well-being index,269 EuroQol-5D (EQ-5D),270 Health Utility Index (HUI),271
and Short Form-6 Dimensions (SF-6D).172 The published algorithm of converting SF-36
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scores to SF-6D based health utilities was utilized in this study.172 This was because a
recent study comparing multiple algorithms to convert SF-36 scores to preference-based
scores concluded Brazier’s index to have the strongest methodological and theoretical
basis among all other conversion algorithms.171
Brazier et al. derived preference-based measure of health (i.e., health utilities)
from the SF-36 instrument for use in economic evaluations.172 A sample of 249 states
from the SF-6D was valued by a representative sample of the UK’s national population
and mapped to the preference-based measures through standard gamble approach.173 A
trained and experienced interviewer conducted the interviews in the respondent’s own
home. Each respondent was asked to rank, and then value, six of the 249 sample SF-6D
states using a variant of the standard gamble technique. Several exploratory models
(mean and individual-level) were tested with the aim to construct model to predict health
states valuations based on the SF-6D. Appendix 3 displays the ordinary least squares
(OLS), random error, mean, and median models tested in the study. Appendix 3 also
displays the random error model and mean model with intercept forced to unity, as
recommended for estimating health utility values. Appendix 4 displays the random error
and mean models, with and without forcing intercept to unity. Based on the evaluation of
predictive ability of these models, Brazier and colleagues recommend using the mean
model with interaction effects that has the intercept forced to unity for the purpose of
estimating health utilities.
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The following equation summarizes this aforementioned recommended mean
model:
Health utility scores= 1 + (-0.053) PF2i + (−0.011)PF3 +
(−0.040)PF4 + (−0.054)PF5 + (−0.111)PF6 +
(−0.053)RL2 + (−0.055)RL3 + (−0.050)RL4 +
(−0.055)SF2 + (−0.067)SF3 + (−0.070)SF4 + (−0.087)SF5
+ (−0.047)PAIN2 + (−0.025)PAIN3 + (−0.056)PAIN4 +
(−0.091)PAIN5 + (−0.167)PAIN6 + (−0.049)MH2 +
(−0.042)MH3 + (−0.109)MH4 + (−0.128)MH5 +
(−0.086)VIT2 + (−0.061)VIT3 + (−0.054)VIT4 +
(−0.091)VIT5 + error
Where,
PF=Physical Functioning
RL=Role Limitation
SF=Social Functioning
Pain=Bodily Pain
MH=Mental health, and
VH=Vitality
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There were no significant differences (p<0.05) in baseline SF-36 scores between
glucosamine, CS, their combination, celecoxib, and placebo groups;21 therefore, an
overall baseline mean utility score, rather than differential means for each study
comparator, was used to populate the decision-analytic model for the purpose of our
analysis. Table 14 displays the mean health utility scores for baseline, treatment success,
and no treatment groups.
Table 14: Health Utility Values For Study Comparators Related Health States.
Health State
Utility Value
Data Source
(SA Range)
Baseline*
Responders*
At 24-Weeks

0.65 (0.49 to 0.81)

GAIT study at baseline

0.70 (0.52 to 0.87)

At 2-Years
Non-Responders*
At 24-Weeks

0.71 (0.53 to 0.89)

GAIT study 24-weeks
outcomes
GAIT study 2-years outcomes

At 2-Years
Annual Treatment
Success┼
No Treatment┼

0.64 (0.48 to 0.80)
0.70 (0.54 to 0.86)

GAIT study 24-weeks
outcomes
GAIT study 2-years outcomes
GAIT study 1-year outcomes

0.65 (0.51 to 0.79)

GAIT study 1-year outcomes

0.64 (0.48 to 0.80)

*=For decision-tree model
┼=For Markov model
GAIT=Glucosamine/chondroitin sulfate Arthritis Intervention Trial; SA=Sensitivity analysis
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Adverse Events
Health utility values for adverse event health states to populate the Markov cohort
model were obtained from the published literature (Table 15). All base case health utility
values were varied by ±25% in the sensitivity analysis to account for parameter
uncertainty.243
Separate health utility values were used for year one and thereafter for stroke and
myocardial infarction.218, 219, 223
Table 15: Model Inputs for Health Utility Values of Adverse Events.
Health State
Utility Value;
Reference
Base Case (SA Range)
Heart Failure
0.66 (0.58 to 0.75)
Miller et al.217
Stroke
Pickard et al.223
First Year 0.31 (0.16 to 0.46)
Subsequent Years 0.62 (0.31 to 0.93)
Myocardial Infarction
First Year 0.37 (0.28 to 0.46)
Squires et al.218
Subsequent Years 0.91 (0.68 to 1.00)
Crespin et al.219
GI Bleeding
0.46 (0.34 to 0.57)
Maetzel et al.63
Peptic Ulcer
0.55 (0.41 to 0.69)
Maetzel et al.63
Dyspepsia
0.73 (0.55 to 0.91)
Maetzel et al.63
Edema
0.98 (0.74 to 1.00)
Revicki et al.220
Hypertension
0.96 (0.72 to 1.00)
Mclntyre et al.221
Inpatient Treatment of Bleeding
0.31 (0.23 to 0.39)
Moore et al.222
Outpatient Treatment of Bleeding
0.38 (0.28 to 0.47)
Moore et al.222
Surgery Given Inpatient Treatment 0.20 (0.15 to 0.25)
Moore et al.222
of Bleeding
GAIT= Glucosamine/chondroitin sulfate Arthritis Intervention Trial; GI=Gastrointestinal;
KOA=Knee osteoarthritis; SA=Sensitivity analysis
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TKR Surgery
Health utility values for TKR surgery were obtained from a large randomized
clinical trial (n=2352 participants).224, 272, 273 These health utility values differed from
each other based on the number of years a KOA patient has spent in the post TKR
surgery health state. All base case health utility values were varied by ±25% in the
sensitivity analysis to account for parameter uncertainty.243 Table 16 displays values of
health utilities used in the Markov cohort model.
Table 16: Model Inputs for Health Utility Values.
Total Knee Replacement
Utility Value
(SA Range)
After 1 year 0.71 (0.53 to 0.88)
After 2 years 0.68 (0.51 to 0.85)
After 3 years 0.66 (0.49 to 0.82)
After 4 years 0.63 (0.47 to 0.79)
After 5 or more years 0.61 (0.46 to 0.76)

Reference
224, 272, 273
224, 272, 273
224, 272, 273
224, 272, 273
224, 272, 273

GI=Gastrointestinal; KOA=Knee osteoarthritis; SA=Sensitivity analysis
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Transition Probabilities and Event Rates
Treatment Success, Response, and No Response
Transition probabilities for treatment success health state in the Markov model
and event rates for response and no response branches in our decision-tree model were
based on the drug efficacies data obtained from the GAIT study.33, 174 Specifically,
transition probabilities for treatment success to populate the Markov model were based
on 1-year outcomes on WOMAC pain sub-scale as found in the GAIT study, as described
earlier in this chapter. Similarly, event rates for 24-weeks and 2-year time-horizon
decision-tree models were based on the WOMAC pain-subscale outcomes during the
respective GAIT study time-periods.
The treatment success for the Markov model and response/non-response for the
decision-tree model were defined as at least 20% reduction in WOMAC pain sub-scale
scores from baseline at 24-weeks, 1-year, and 2-years respectively for 24-weeks, 10-year
(1 year Markov cycles), and 2-year time-horizons decision-analytic models. This
definition is same as was used for the primary outcome measure in the GAIT study.24, 33,
174

Table 17 displays the transition probabilities for the Markov cohort model. With
rationale of utilizing the best available data source for population the models, 1-year, not
24-weeks, GAIT data were used reflecting longer-term efficacies of all KOA treatment
strategies in the Markov model. Separate transition probabilities were used for overall
KOA patients group, KOA patients with mild pain, and KOA patients with moderate to
severe pain at the baseline. Mild pain was defined as baseline WOMAC pain sub-scale
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score of 125 to 300. Similarly, moderate to severe pain was defined as baseline WOMAC
pain sub-scale score of 301 to 400.

Table 17: Markov Model Transition Probabilities For Treatment Success.
Study Comparators
Annual Transition Probability;
References
Base case* (SA Range)
Overall KOA Patients
Celecoxib 0.4584 (0.4446 to 0.4784)
GAIT study33, 174
NSAIDs 0.4584 (0.4446 to 0.4784)
Latimer et al.247
Glucosamine 0.4509 (0.4421 to 0.4762)
GAIT study33, 174
CS 0.4393 (0.4340 to 0.4567)
GAIT study33, 174
Glucosamine+ CS 0.4560 (0.4526 to 0.4729)
GAIT study33, 174
KOA Patients with Mild Pain┼
Celecoxib 0.4615 (0.4481 to 0.4788)
GAIT study33, 174
NSAIDs 0.4615 (0.4481 to 0.4788)
Latimer et al.247
Glucosamine 0.4529 (0.4440 to 0.4768)
GAIT study33, 174
CS 0.4395 (0.4350 to 0.4611)
GAIT study33, 174
Glucosamine+ CS 0.4399 (0.4376 to 0.4578)
GAIT study33, 174
KOA Patients with Moderate to Severe Pain‡
Celecoxib 0.4451 (0.4297 to 0.4747)
GAIT study33, 174
NSAIDs 0.4451 (0.4297 to 0.4747)
Latimer et al.247
Glucosamine 0.4399 (0.4318 to 0.4715)
GAIT study33, 174
CS 0.4387 (0.4307 to 0.4543)
GAIT study33, 174
Glucosamine+ CS 0.5124 (0.5050 to 0.5260)
GAIT study33, 174
*=based on change in WOMAC pain-subscale scores improvement from baseline at 1-year: base
case=20% (range=12% to 22%) in the GAIT study24, 33, 174, 274
┼=Mild pain stratum is defined as baseline WOMAC pain subscale score of 125 to 300.174
‡= Moderate to severe pain stratum is defined as baseline WOMAC pain subscale score of 301 to
400.174
CS=Chondroitin Sulfate; GAIT= Glucosamine/chondroitin sulfate Arthritis Intervention Trial;
KOA=Knee osteoarthritis; nsNSAIDs= non-steroidal anti-inflammatory drugs; SA=Sensitivity
analysis

Table 18 shows the response rates for the 24-week time-horizon study, to
populate the decision-tree model. Different response rates were used for the compliant
and non-compliant KOA patients in the decision-tree model. For the purpose of
estimating response rates, patients were defined as compliant if they were adherent to
their study medications 80% to 110% of the times during the study period.275 Similar to
93

the Markov model, separate rates of response were used for overall KOA patient group,
KOA patients with mild pain, and KOA patients with moderate to severe pain.
Table 18: Decision-Tree Model Rates for Study Comparators from 24-week TimeHorizon.
Study
Response Rates* (SA Range)
Comparators
Overall KOA
KOA Patients with
Mild to Moderate
Patients
Mild Pain┼
Pain KOA Patient ‡
Celecoxib
Compliant
78.17%
77.07%
82.50%
(75.13% to 82.74%) (74.52% to 80.89%) (77.50% to 90.00%)
Non-Compliant
53.68%
56.72%
44.44%
(51.58% to 57.89%) (53.73% to 61.19%) (44.44% to 48.15%)
Glucosamine
Compliant
78.95%
75.56%
91.43%
(77.19% to 81.29% ) (74.07% to 78.52%) (88.57% to 91.43%)
Non-Compliant
46.13%
50.00%
34.62%
(45.54% to 49.11%) (50.00% to 52.33%) (30.77% to 38.46%)
CS
Compliant
71.43%
72.66%
65.52%
(71.43% to 78.57%) (72.66% to 79.14%) (65.52% to 75.86%)
Non-Compliant
51.28%
50.56%
53.57%
(50.43% to 52.99%) (49.44% to 51.69%) (53.57% to 57.14%)
Glucosamine + CS
Compliant
70.00%
64.75%
87.80%
(69.44% to 75.56%) (64.75% to 69.78%) (85.37% to 95.12%)
Non-Compliant
56.19%
51.81%
72.73%
(55.24% to 60.95%) (51.81% to 55.42%) (68.18% to 81.82%)
Placebo
Compliant
69.89%
72.79%
58.97%
(69.89% to 76.34%) (72.79% to 77.55%) (58.97% to 71.79%)
Non-Compliant
40.00%
39.44%
44.44%
(37.78% to 45.56%) (38.03% to 45.07%) (38.89% to 50.00%)
*=based on change in WOMAC pain-subscale scores changes between baseline and 24 weeks:
base case=20% (range=12% to 22%) in the GAIT study24, 33, 174, 274
┼=Mild pain is defined as baseline WOMAC pain subscale score of 125 to 300.174
‡= Moderate to severe pain is defined as baseline WOMAC pain subscale score of 301 to 400.174
CS=Chondroitin Sulfate; KOA=Knee osteoarthritis; nsNSAIDs=NSAIDs non-steroidal antiinflammatory drugs; SA=Sensitivity analysis
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The response rates for all study comparators, stratified by compliance/noncompliance and pain stratum, from 2-year time-horizon are displayed in Table 19.
Table 19: Decision-Tree Model Rates for Study Comparators from 2-Year Time-Horizon.
Study
Response Rates* (SA Range)
Comparators
Overall KOA Patients KOA Patients with
KOA Patients with
┼
Mild Pain
Mild to Moderate
Pain‡
Celecoxib
Compliant
62.64%
57.33%
87.50%
(61.54% to 65.93%)
(56.00% to 61.33%) (87.50% to 87.50%)
Non-Compliant
50.00%
62.50%
16.67%§
(50.00% to 50.00%)
(62.50% to 62.50%) (16.67% to 16.67%)
Glucosamine
Compliant
77.14%
80.00%
66.67%
(77.14% to 78.57%)
(80.00% to 81.82%) (66.67% to 66.67%)
Non-Compliant
59.26%
68.18%
20.00%§
(55.56% to 59.26%)
(63.64% to 68.18%) (20.00% to 20.00%)
CS
Compliant
64.29%
65.00%
60.00%
(61.43% to 64.29%)
(61.67% to 65.00%) (60.00% to 60.00%)
Non-Compliant
41.67%
43.75%
37.50%§
(41.67% to 50.00%)
(43.75% to 56.25%) (37.50% to 37.50%)
Glucosamine +
CS
Compliant
54.24%
54.76%
52.94%
(50.85% to 61.02%)
(52.38% to 61.90%) (47.06% to 58.82%)
Non-Compliant
34.48%
33.33%
40.00%§
(34.48% to 34.48%)
(33.33% to 33.33%) (40.00% to 40.00%)
Placebo
Compliant
62.16%
59.32%
73.33%
(60.81% to 62.16%)
(57.63% to 59.32%) (73.33% to 73.33%)
Non-Compliant
54.17%
52.63%
75.00%§
(54.17% to 54.17%)
(52.63% to 52.63%) (75.00% to 75.00%)
*=based on change in WOMAC pain-subscale scores changes between baseline and 24 weeks:
base case=20% (range=12% to 22%) in the GAIT study24, 33, 174, 274
┼=Mild pain stratum is defined as baseline WOMAC pain subscale score of 125 to 300.174
‡= Moderate to severe pain stratum is defined as baseline WOMAC pain subscale score of 301 to
400.174

§=Cell count is less than 5
CS=Chondroitin Sulfate; KOA=Knee osteoarthritis; NSAIDs= non-steroidal anti-inflammatory
drugs; SA=Sensitivity analysis
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Adverse Events
PubMed literature searches were conducted to obtain transition probabilities for
adverse events for populating the Markov model. Based on these searches, data sources
for transition probabilities of adverse events associated with NSAIDs and celecoxib
included large clinical trials such as Celecoxib Long-term Arthritis Safety Study
(CLASS), Multinational Etoricoxib Versus Diclofenac Arthritis Long-Term Study
(MEDAL) study, and MONItor trends in CArdiovascular disease (MONICA) study and
large prospective cohort studies like the Framingham Heart Study.195-198, 239
Modeled adverse events include risk of serious cardiovascular (i.e., heart failure,
stroke, myocardial infarction, and hypertension) and GI (peptic ulcer, GI bleeding, and
dyspepsia) adverse events associated with NSAIDs and celecoxib. All KOA patients on
celecoxib or NSAIDs experiencing any adverse event except for hypertension and
dyspepsia were modeled to discontinue their medications.
Patients experiencing GI bleeding adverse events were modeled to be treated in
either outpatient or inpatient settings.179-184 If hospitalized, the patients were modeled to
undergo surgery to manage a GI bleeding event, based on the published rates of surgery
for GI bleeding after hospitalization.63 The risk of GI bleeding was modeled to increase
with age, based on the reviewed literature.204, 205, 207, 276-278
Increased risk of mortality after an event of GI bleeding, heart failure, stroke, or
myocardial infarction was incorporated in the model, based on the published literature.185193, 195, 196, 239
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Table 20: Transition Probabilities of Adverse Events.
Model Inputs for Adverse
Annual Transition
Events
Probability;
Base case (SA Range)
Heart Failure
Celecoxib 0.0044 (0.0032 to 0.0058)*
NSAIDs 0.0026 (0.0017 to 0.0037)
Stroke
Celecoxib 0.0100 (0.0087 to 0.0112)
NSAIDs 0.0296 (0.0259 to 0.0332)
Myocardial Infarction
Celecoxib 0.0112 (0.0084 to 0.0140)
NSAIDs 0.0129 (0.0097 to 0.0161)
GI Bleeding
Celecoxib 0.0134 (0.0075 to 0.0221)
NSAIDs 0.0270 (0.0216 t0 0.0334)
Peptic Ulcer
Celecoxib 0.0082 (0.0048 to 0.0114)
NSAIDs 0.0106 (0.0048 to 0.0159)
Dyspepsia
Celecoxib 0.0463 (0.0420 to 0.0506)*
NSAIDs 0.0704 (0.0650 to 0.0759)
Edema
Celecoxib 0.0106 (0.0086 to 0.0127)*
NSAIDs 0.0070 (0.0054 to 0.0088)
Hypertension
Celecoxib 0.0229 (0.0200 to 0.0260)*
NSAIDs 0.0153 (0.0129 to 0.0179)
Age-related increased risk of
0.0421 (0.0247 to 0.0592)
Bleeding/year
Hospitalization rate for bleeding 0.5934 (0.5507 to 0.6321)
Surgery after hospitalization for 0.0815 (0.0392 to 0.3002)
bleeding
Mortality for GI bleeding
0.0769
Mortality for post heart failure
0.3750
Mortality for post myocardial
infarction
Mortality post stroke

0.0344
0.3363

Reference

MEDAL study197
MEDAL study197
CLASS study198
CLASS study198
Caldwell et al.199
Rodirguez et al.200
CLASS study201
CLASS study201
202-208
202-208

MEDAL study197
MEDAL study197
MEDAL study197
MEDAL study197
MEDAL study197
MEDAL study197
204, 205, 207, 276-278

179-184

Maetzel et al.63
185-193

Framingham Heart
Study239
Framingham Heart
Study195
MONICA study196

Adverse event rates for glucosamine, chondroitin sulfate, and their combination therapy are
assumed to be zero in the model, based on previously published meta-analyses and analysis of the
Food and Drug Administration’s Adverse Event Reporting System database.
*=Transition probabilities for celecoxib were based on events rates for Etoricoxib
CLASS=Celecoxib Long-term Arthritis Safety Study; MEDAL= Multinational Etoricoxib Versus
Diclofenac Arthritis Long-Term Study; MONICA=MONItor trends in CArdiovascular disease;
NSAIDs= Non-Steroidal Anti-inflammatory Drugs; SA=Sensitivity Analysis
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No risk of serious adverse events associated with CAM therapies were incorporated
in the Markov model based on evidence from the following two sources:
1. Food and Drug Administration Adverse Event Reporting System (FAERS) database
The FDA’s post-marketing safety surveillance program plays a crucial role in
identifying the safety problems associated with a drug after its market launch. One of the
main tools employed by the FDA to support this surveillance program is MedWatch that
consists of voluntarily reported adverse drug reactions to the FDA by patients, health
professionals, pharmaceutical manufacturers, and other such sources.279, 280 The FAERS
is the electronic database that summarizes these adverse events MedWatch reports.279, 281
This FAERS database is updated quarterly and more than 300,000 MedWatch cases are
currently added each year.
We searched the FAERS database for glucosamine or CS associated adverse events
reported to the FDA. Specifically, the World Health Organization (WHO) drug dictionary
based preferred and trade names of glucosamine, CS, and combination of glucosamine
and CS were searched separately in the FAERS to review reports of serious adverse
events associated with these agents. The list of the trade and preferred names of these
CAM therapies searched in the FAERS is displayed in Table 21.
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Table 21: Search Terms Used in FAERS
Search Terms in FAERS
Glucosamine only
Terrastatin (glucosamine hydrochloride, nystatin, oxytetracycline)
Osteoeze bone & joint care (calcium carbonate, glucosamine hydrochloride,
phytomenadione, vitamin D NOS)
Glucosamine with methylsulfonylmethane (glucosamine,
methylsulfonylmethane)
Glucosamine with methylsulfonylmethane
Glucosamine sulfate with chondroitin
Glucosamine sulfate sodium chloride
Glucosamine sulfate potassium chloride
Glucosamine sulfate
Glucosamine hydrochloride
Glucosamine (cod-liver oil, glucosamine, minerals NOS, salmon oil,
vitamins NOS)
Glucosamine
Dona 200 tablet (glucosamine hydroiodide, glucosamine sulfate)
Dona (glucosamine sulfate)
Arthryl (acetyl-glucosamine, diethanolamine, sodium sulfate)
Arthrochoice (glucosamine, minerals NOS, vitamins NOS)
Aflexa (glucosamine hydrochloride, glucosamine sulfate)
CS only
Kashiwadol (chondroitin sulfate sodium, salicylate sodium)
Chondroitin sulfate sodium
Chondroitin sulfate
Chloroquine chondroitin sulfate
Blutal (chondroitin sulfate sodium, ferric chloride)
Combination of Glucosamine and CS
Osteo bi-flex (chondroitin sulfate, glucosamine hydrochloride)
Joint food (chondroitin sulfate, glucosamine sulfate)
Glucosamine with chondroitin sulfate (chondroitin sulfate, glucosamine)
Glucosamine with chondroitin sulfate/magnesium/vitamin C (ascorbic acid,
chondroitin sulfate, glucosamine sulfate, manganese)
Glucosamine with chondroitin sulfate/ magnesium/vitamin C
Glucosamine with chondroitin (chondroitin sulfate, glucosamine)
Glucosamine sulfate w/chondroitin
Flex-a-min (chondroitin sulfate, glucosamine sulfate,
methylsulfonylmethane)
Cosamin ds (ascorbic acid, chondroitin sulfate sodium, glucosamine
hydrochloride, manganese ascorbate)
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Term
Type
Preferred
Preferred
Preferred
Trade
Trade
Preferred
Preferred
Preferred
Preferred
Preferred
Preferred
Preferred
Trade
Preferred
Preferred
Preferred
Preferred
Preferred
Preferred
Preferred
Preferred
Preferred
Preferred
Preferred
Preferred
Trade
Preferred
Trade
Preferred
Preferred

Search Terms in FAERS
Cosamin (chondroitin sulfate, glucosamine hydrochloride, manganese
ascorbate)
Chondroitin with glucosamine (chondroitin, glucosamine)
Chondroitin sodium sulfate with glucosamine HCL (chondroitin sulfate
sodium, glucosamine hydrochloride)
Chondroitin sodium sulfate with glucosamine HCL
Blackmores joint glucosamine, chondroitin (chondroitin sulfate sodium,
glucosamine hydrochloride, manganese gluconate, sodium borate
decahydrate)

Term
Type
Preferred
Preferred
Preferred
Trade
Preferred

CS=Chondroitin Sulfate; FAERS=Food and Drug Administration Adverse Event Reporting
System; NOS=Not otherwise specified

Based on the analysis of the FAERS described above, no serious cardiovascular or GI
adverse events were found to be associated with glucosamine, CS, or their combination
therapies.
2. Meta-analyses of previously conducted clinical trials of one or more of glucosamine
and CS.25, 29
A recent meta-analysis of ten randomized clinical trials with a total sample size of
3803 patients reported no significantly higher risk of serious adverse events associated
with glucosamine, CS, or their combination therapies among the KOA patients.25 Similar
findings were reported in a previously published-meta-analysis study.29
Based on the evidence from the above described two sources, we assumed no risk of
serious cardiovascular and GI adverse events associated with CAM therapies in the
Markov cohort model.
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TKR Surgery
Transition probabilities for TKR surgery were obtained from on a large US joint
replacement registry of Kaiser Permanente.282 These transition probabilities for TKR
surgery vary by age and gender, as displayed in Table 22.
Table 22: Total Knee Replacement Surgery Rates in the US.
Age Group
Males (95% CI)
Females (95 % CI)
50 to 64 years
6.4% (3.0% to 9.7%)
8.1% (4.5% to 11.8%)
65 to 84 years
11.9% (6.7% to 17.0%)
10.9% (6.5% to 15.3%)
85 or more years
3.0% (1.7% to 4.3%)
2.7% (1.6% to 3.8%)
CI=Confidence interval
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Death Rates
KOA patients were modeled to die either because of adverse events (i.e., health
failure, stroke, myocardial infarction, and GI bleeding) or aging. The transition
probabilities for death due to adverse events were obtained from multiple literature
sources and are displayed in Table 20. The transition probabilities for death due to aging
were obtained from the National Vital Statistics Reports US life-tables.240 These
transition probabilities for death due to aging are shown in Table 23.
Table 23: Model Inputs for Age-Specific Mortality Rates, Based on US Life-tables.240
Age (in years)
Annual Probability of Death
0.004337
50
0.004709
51
0.005091
52
0.005474
53
0.005863
54
0.006275
55
0.006726
56
0.007220
57
0.007773
58
0.008389
59
0.009081
60
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Sensitivity Analysis
Parameter Sensitivity Analysis
We performed both one-way sensitivity analysis and probabilistic sensitivity
analysis on all modeling parameters. These parameters include costs, drug efficacies,
health utilities, adverse events probabilities, TKR surgery rates, medication compliance
rates, and discounting rates (for study of first objective). The sensitivity analysis ranges
for all of these parameters are listed in tables in earlier sections of this chapter.
Probabilistic sensitivity analysis (second-order Monte Carlo simulation) was also
performed to account for the parameter uncertainty in the decision-tree model inputs. The
parameter distributions used for conducting probabilistic sensitivity analysis are
displayed in Table 24.
Table 24: Parameters Distributions Used in PSA.
Type of Parameter
Type of Distribution
Transition Probabilities
Beta
Costs
Gamma
Health Utilities
Beta
Compliance
Log-normal
Discount Rate
Uniform
PSA=Probabilistic Sensitivity analysis.

The base case definition of treatment success in the Markov model and response
rate in the decision-tree model was at least 20% reduction on WOMAC pain sub-scale
from the baseline. In sensitivity analysis, this definition was varied from treatment
success/response being 12% to 22% reduction in WOMAC pain sub-scale from the
baseline. This variation is based on a prospective cohort study that estimated minimal
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clinically important differences (MCID) of effects measured by the WOMAC in patients
with osteoarthritis of the lower extremities.274
All health utility values and adverse event probabilities were varied by ±25%
from the base case in the sensitivity analysis to account for parameter uncertainties
arising due to factors such as differences in patient populations and in methods and
instruments of measurements. These variations of ±25% from baseline are as per the
good practices recommendations of the International Society for Pharmacoeconomics and
Outcomes Research-Society for Medical Decision Making (ISPOR-SMDM) modeling
task force.243
Rates for TKR surgery were varied per the 95% confidence interval reported in
the findings from the analysis based on a large US joint replacement registry of the
Kaiser Permanente.283 The base case medication compliance rate of 75% in the decisiontree model was varied from 50% (poor compliance) to 100% (excellent compliance) in
the sensitivity analysis. The base case discounting rate of 3% was varied from 0% to
5%.34
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Structural Sensitivity Analysis
In addition to performing the parameter sensitivity analysis, structural sensitivity
analysis was performed to account for the robustness of assumption of no risk of adverse
events associated with CAM therapies. In this regard, ICERs were estimated by
excluding all drug associated adverse events from the 10-year Markov models, thereby
leaving both CAM therapies and conventional medicines without any risk of adverse
events.
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CHAPTER 4: RESULTS
This chapter is divided into seven sections, describing results for objectives 1 to 5
of this study (one objective per section) and results for the structural sensitivity analysis.
Sections 1 to 5 are further divided into three sub-sections each providing study findings
for KOA patients: (1) overall, (2) with mild baseline pain (defined by WOMAC pain
subscale being between 150 and 300), and (3) with moderate to severe baseline pain
(defined by WOMAC pain subscale being between 301 and 400). Finally, this chapter is
concluded by a summary of findings section.

Section 1: Findings for Study Objective 1:
The first objective of our study was to compare the incremental cost-effectiveness
of CAM therapies (i.e., glucosamine, CS, and their combination therapy) with
conventional medicines (i.e., celecoxib and NSAIDs) to treat KOA from the US health
care payers’ perspective and 10-years horizon of the patients, through a Markov model
based analysis. Tables 25 to 30 display results for cost-effectiveness comparison of CAM
therapies with conventional medicines among different study groups of KOA patients.
Cost-Effectiveness of CAM Therapies vs. Conventional Medicines among Overall
KOA Patients Group
Table 25 displays the base case results for incremental cost-effectiveness of CAM
therapies and conventional medicines among the overall KOA patients group (i.e., KOA
patients with baseline WOMAC pain sub-scale scores between 150 and 400) from US
health care payers’ perspective and 10-year time-horizon. In general, CAM therapies
were found to be cost-effective than conventional medicines in treating KOA.
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Specifically, while both NSAIDs and celecoxib were dominated by CS in treating KOA
from the US health care payers’ perspective and 10-year time-horizon; the incremental
cost-effectiveness of glucosamine, in comparison to CS, was found to be
$120,367.90/QALY gained.
CS alone therapy was used as the reference group in our analysis based on the
recommendations of the USPCEHM—this panel recommends using that strategy as the
reference group which has the lowest total costs (i.e., CS alone therapy in our analysis).34
In this analysis, the absolute value of the cost-effectiveness of CS alone therapy was
found to be $1,332.32/QALY gained.

Table 25: Base Case Results for Cost-Effectiveness Analysis in Overall KOA Patients
Group from US Health care Payers’ Perspective and 10-year Time-Horizon, with
Chondroitin Sulfate as the Reference Group.
Study
Total Cost Total Incremental Incremental
ICER
Comparator
QALYs
Cost
QALYs
(Cost/QALY
gained┼
gained
gained)
CS
$7,571 5.6833
Glucosamine
$8,033 5.6872
$461
0.0038
$120,367
Glucosamine
+ CS
$9,719 5.6877
$1,686
0.0005
$3,250,047
Celecoxib
$19,759 4.8567
$10,040
-0.8310
-$12,083*
NSAIDs
$21,274 4.7765
$11,555
-0.9112
-$12,682*
*=Dominated therapies
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; NSAIDs= Non-steroidal
anti-inflammatory drugs; QALYs=Quality-adjusted life-years
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Sensitivity Analysis
In one-way sensitivity analysis, the following parameters were found to impact
the expected value of the cost-effectiveness model: discount rate; utilities of treatment
success, no response, and TKR surgery at baseline; transition probability of TKR surgery,
response to CS, and response to glucosamine; and cost of TKR surgery, glucosamine, and
CS.
Table 26 displays the detailed results of probabilistic sensitivity analysis on all
model inputs and Figure 6 presents its scatter plot based on 10000 second-order Monte
Carlo simulations.

Table 26: Probabilistic Sensitivity Analysis Results, in Overall KOA Patients Group from
US Health care Payers’ Perspective and 10-year Time-Horizon.

Cost

Parame
ters
Mean
SD
Min
2.50%
10%
Median
90%
97.50%
Max

CS
Glucosamine
$7,598
$8,057
$1,607
$1,612
$3,174
$3,588
$4,913
$5,352
$5,648
$6,114
$7,440
$7,917
$9,705
$10,168
$1,120
$11,627
$15,983
$16,349

Glucosamine
+ CS
NSAIDs
$9,748
$21,026
$1,679
$3,136
$5,246
$11,144
$6,883
$15,270
$7,707
$17,078
$9,608
$20,892
$11,962
$25,053
$13,398
$27,658
$18,067
$38,902

QALYs
gained┼

Celecoxib
$19,715
$2,306
$11,160
$15,537
$16,849
$19,602
$22,701
$24,624
$29,726

Mean
5.7070
5.7108
5.7113
4.8067
4.8799
SD
0.5131
0.5144
0.514498
0.4369
0.4231
Min
3.9063
3.9075
3.9064
3.3014
3.3411
2.50%
4.7156
4.7209
4.7193
3.9761
4.0712
10%
5.0526
5.0533
5.0528
4.2548
4.3425
Median
5.6973
5.7003
5.7015
4.7954
4.8699
90%
6.3811
6.3888
6.3854
5.3785
5.4341
97.50%
6.7147
6.7181
6.7187
5.6910
5.7156
Max
7.6564
7.6726
7.6702
6.5346
6.4528
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; NSAIDs= Non-steroidal anti-inflammatory drugs; QALYs=Qualityadjusted life-years
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Figure 6: Scatter Plot for Probabilistic Sensitivity Analysis Based on 10000 Simulations,
in Overall KOA Patients Group from US Health care Payers’ Perspective and 10-year
Time-Horizon.
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CS=Chondroitin Sulfate; Glu=Glucosamine; Glu + CS=Glucosamine and Chondroitin Sulfate
combined therapy; NSAIDs=non-selective Non-Steroidal Anti-Inflammatory Drugs;
QALYs=Quality-adjusted life-years

The above scatter plot can be interpreted as follows: the most cost-effective
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less
expensive) and right hand side from the X-axis (i.e., more effective).
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Figure 7 displays the cost-effectiveness acceptability curve for the above
described analysis, based on 10,000 simulations and variation of willingness-to-pay from
$0 to $500,000 per QALY gained.

Figure 7: Cost-Effectiveness Acceptability Curve, in Overall KOA Patients Group from
US Health care Payers’ Perspective and 10-year Time-Horizon.

CS=Chondroitin Sulfate; Glu=Glucosamine; Glu + CS=Glucosamine and Chondroitin Sulfate
combined therapy; NSAIDs=non-selective Non-Steroidal Anti-Inflammatory Drugs
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Cost-Effectiveness of CAM Therapies vs. Conventional Medicines among KOA
Patients with Mild Pain
In this sub-group analysis, cost-effectiveness of CAM therapies (i.e.,
glucosamine, CS, and combination of glucosamine and CS) was compared conventional
medicines (i.e., celecoxib and NSAIDs) in the treatment of KOA among those patients
that had mild knee pain at the baseline, defined by WOMAC pain sub-scale score of
between 150 and 300. The study time-horizon was 10 years and perspective was of the
US healthcare payers.
Table 27 displays the base case results for incremental cost-effectiveness of CAM
therapies and conventional medicines among the KOA patients group with mild baseline
pain from US health care payers’ perspective and 10-year time-horizon. In general, CAM
therapies were cost-effective than conventional medicines in treating KOA. Specifically,
both NSAIDs and celecoxib were dominated by CS in treating KOA from the US health
care payers’ perspective and 10-year time-horizon. The incremental cost-effectiveness of
glucosamine, in comparison to CS, was found to be $86,233.71/QALY gained.
CS alone therapy was used as the reference group in this analysis (reason is
described earlier in this chapter) and was found to have the absolute the costeffectiveness ratio of $1,333.12/QALY gained.
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Table 27: Base Case Results for Cost-Effectiveness Analysis, in Mild Pain Only KOA
Patients Group from US Health care Payers’ Perspective and 10-year Time-Horizon, with
Chondroitin Sulfate as the Reference Group.
Study
Total Cost Total Incremental Incremental
ICER
Comparator
QALYs
Cost
QALYs
(Cost/QALY
gained┼
gained
gained)
CS
$7,571 5.6799
Glucosamine
$8,033 5.6853
$461
0.0053
$86,233
Glucosamine
+ CS
$9,719 5.6801
$1,686
-0.0052
-$325,005*
Celecoxib
$19,770 4.8560
$11,737
-0.8292
-$14,155*
NSAIDs
$21,301 4.7754
$13,268
-0.9099
-$14,583*
*=Dominated therapies
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; NSAIDs= Non-steroidal
anti-inflammatory drugs; QALYs=Quality-adjusted life-years
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Sensitivity Analysis
In one-way sensitivity analysis, the following parameters were found to impact
the expected value of the cost-effectiveness model: discount rate; utilities of treatment
success, no response, and TKR surgery at baseline; transition probability of TKR surgery,
response to CS, and response to glucosamine; and cost of TKR surgery, glucosamine, and
CS. No other model parameters affect cost-effectiveness ratios.
Table 28 displays the detailed results of probabilistic sensitivity analysis on all
model inputs and Figure 8 presents its scatter plot based on 10000 second-order Monte
Carlo simulations.

Table 28: Probabilistic Sensitivity Analysis Results, in Mild Pain Only KOA Patients
Group from US Health care Payers’ Perspective and 10-year Time-Horizon.

Cost

Parame
ters
Mean
SD
Min
2.50%
10%
Median
90%
97.50%
Max

CS
Glucosamine
$7,587
$8,047
$1,602
$1,608
$3,174
$3,588
$4,911
$5,349
$5,644
$6,102
$7,435
$7,910
$9,689
$10,154
$11,198
$11,621
$15,983
$16,349

Glucosamine
+ CS
NSAIDs
$9,740
$21,040
$1,675
$3,137
$5,246
$11,169
$6,883
$15,270
$7,707
$17,084
$9,599
$20,905
$11,952
$25,072
$13,390
$27,662
$18,067
$38,953

QALYs
gained┼

Celecoxib
$19,716
$2,302
$12,406
$15,543
$16,847
$19,605
$22,701
$24,630
$29,745

Mean
5.7024
5.7078
5.7026
4.8050
4.8785
SD
0.5134
0.5150
0.5134
0.4381
0.4243
Min
3.9056
3.9071
3.9048
3.3006
3.3399
2.50%
4.7095
4.7145
4.7107
3.9712
4.0700
10%
5.0493
5.0518
5.0505
4.2520
4.3399
Median
5.6915
5.6972
5.6926
4.7932
4.8685
90%
6.3780
6.3860
6.3787
5.3782
5.4359
97.50%
6.7154
6.7200
6.7153
5.6992
5.7162
Max
7.6477
7.6672
7.6505
6.5334
6.4501
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; NSAIDs= Non-steroidal anti-inflammatory drugs; QALYs=Qualityadjusted life-years
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Figure 8: Scatter Plot for Probabilistic Sensitivity Analysis Based on 10000 Simulations,
in Mild Pain Only KOA Patients Group from US Health care Payers’ Perspective and 10year Time-Horizon.

CS=Chondroitin Sulfate; Glu=Glucosamine; Glu + CS=Glucosamine and Chondroitin Sulfate
combined therapy; NSAIDs=non-selective Non-Steroidal Anti-Inflammatory Drugs;
QALYs=Quality-adjusted life-years

The above scatter plot can be interpreted as follows: the most cost-effective
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less
expensive) and right hand side from the X-axis (i.e., more effective).
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Figure 9 displays the cost-effectiveness acceptability curve for the above
described analysis, based on 10,000 simulations and variation of willingness-to-pay from
$0 to $500,000 per QALY gained.

Figure 9: Cost-Effectiveness Acceptability Curve, in Mild Pain Only KOA Patients
Group from US Health care Payers’ Perspective and 10-year Time-Horizon.

CS=Chondroitin Sulfate; Glu=Glucosamine; Glu + CS=Glucosamine and Chondroitin Sulfate
combined therapy; NSAIDs=non-selective Non-Steroidal Anti-Inflammatory Drugs
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Cost-Effectiveness of CAM Therapies vs. Conventional Medicines among KOA
Patients with Moderate to Severe Pain
In this sub-group analysis, cost-effectiveness of CAM therapies (i.e.,
glucosamine, CS, and combination of glucosamine and CS) was compared conventional
medicines (i.e., celecoxib and NSAIDs) in treating KOA among those patients that had
moderate to severe knee pain at the baseline defined by WOMAC pain sub-scale score of
between 301 and 400. The study time-horizon was 10 years and perspective was of the
US healthcare payers’.
Table 29 displays the base case results for incremental cost-effectiveness of CAM
therapies and conventional medicines among the KOA patients group with moderate to
severe baseline pain from US health care payers’ perspective and 10-year time-horizon.
In general, CAM therapies were cost-effective than conventional medicines. Specifically,
both NSAIDs and celecoxib were dominated by CS in treating KOA from the US health
care payers’ perspective and 10-year time-horizon. The incremental cost-effectiveness of
combination of glucosamine and CS, in comparison to CS, was found to be
$73,006.69/QALY gained.
CS alone therapy was used as the reference group in this analysis (reason is
described earlier in this chapter) and was found to have the absolute the costeffectiveness ratio of $1,333.19/QALY gained.
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Table 29: Base Case Results for Cost-Effectiveness Analysis, in Moderate to Severe Pain
KOA Patients Group from US Health care Payers’ Perspective and 10-year TimeHorizon, with Chondroitin Sulfate as the Reference Group.
Study
Total Cost Total Incremental Incremental
ICER
Comparator
QALYs
Cost
QALYs
(Cost/QALY
gained┼
gained
gained)
CS
$7,572
5.6796
Glucosamine $8,033
5.6801 $461
0.0005
$962,943
Glucosamine
$9,719
5.709
$2,147
0.0294
$73,007
+ CS
Celecoxib
$19,795
4.8545 $10,076
-0.8545
-$11,791*
NSAIDs
$21,363
4.7728 $11,644
-0.9362
-$12437*
*=Dominated therapies
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; NSAIDs= Non-steroidal
anti-inflammatory drugs; QALYs=Quality-adjusted life-years
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Sensitivity Analysis
In one-way sensitivity analysis, the following parameters were found to impact
the expected value of the cost-effectiveness model: discount rate; utilities of treatment
success, no response, and TKR surgery at baseline; transition probability of TKR surgery,
response to combination therapy of glucosamine and CS; and cost of TKR surgery. No
other model parameters affect cost-effectiveness ratios.
Table 30 displays the detailed results of probabilistic sensitivity analysis on all
model inputs and Figure 10 presents its scatter plot based on 10000 second-order Monte
Carlo simulations.
Table 30: Probabilistic Sensitivity Analysis Results, in Moderate to Severe Pain KOA
Patients Group from US Health care Payers’ Perspective and 10-year Time-Horizon.

Cost

Parame
ters
Mean
SD
Min
2.50%
10%
Median
90%
97.50%
Max

CS
Glucosamine
$7,597
$8,056
$1,609
$1,614
$3,175
$3,589
$4,900
$5,350
$5,644
$6,107
$7,441
$7,917
$9,713
$10,179
$11,208
$11,631
$15,984
$16,350

Glucosamine
+ CS
NSAIDs
$9,749
$21,114
$1,681
$3,147
$5,247
$11,188
$6,891
$15,362
$7,704
$17,162
$9,607
$20,982
$11,971
$25,155
$13,398
$27,753
$18,067
$39,034

QALYs
gained┼

Celecoxib
$19,751
$2,313
$11,180
$15,555
$16,882
$19,635
$22,745
$24,679
$29,809

5.7048
5.7053
5.7338
4.8044
4.8791
Mean
0.5122
0.5125
0.5231
0.4375
0.4235
SD
3.9055
3.9061
3.9111
3.2990
3.3364
Min
4.7201
4.7193
4.7274
3.9709
4.0710
2.50%
5.0524
5.0538
5.0633
4.2515
4.3429
10%
5.6951
5.6967
5.7252
4.7940
4.8693
Median
6.3778
6.3789
6.4226
5.3748
5.4360
90%
6.7098
6.7155
6.7497
5.6921
5.7137
97.50%
7.6467
7.6553
7.7253
6.5288
6.4471
Max
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; NSAIDs= Non-steroidal anti-inflammatory drugs; QALYs=Qualityadjusted life-years
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Figure 10: Scatter Plot for Probabilistic Sensitivity Analysis Based on 10000 Simulations,
in Moderate to Severe Pain KOA Patients Group from US Health care Payers’
Perspective and 10-year Time-Horizon.
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CS=Chondroitin Sulfate; Glu=Glucosamine; Glu + CS=Glucosamine and Chondroitin Sulfate
combined therapy; NSAIDs=non-selective Non-Steroidal Anti-Inflammatory Drugs;
QALYs=Quality-adjusted life-years

The above scatter plot can be interpreted as follows: the most cost-effective
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less
expensive) and right hand side from the X-axis (i.e., more effective).

119

Figure 11 displays the cost-effectiveness acceptability curve for the above
described analysis, based on 10,000 simulations and variation of willingness-to-pay from
$0 to $500,000 per QALY gained.

Figure 11: Cost-Effectiveness Acceptability Curve, in Moderate to Severe Pain KOA
Patients Group from US Health care Payers’ Perspective and 10-year Time-Horizon.

CS=Chondroitin Sulfate; Glu=Glucosamine; Glu + CS=Glucosamine and Chondroitin Sulfate
combined therapy; NSAIDs=non-selective Non-Steroidal Anti-Inflammatory Drugs
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Section 2: Findings for Study Objective 2:
The second objective of our study was to compare the incremental costeffectiveness of CAM therapies (i.e., glucosamine, CS, and their combination therapy)
with celecoxib and placebo in treating KOA from the US health care payers’ perspective
and 24-week time-horizon. Tables 31 to 36 display results for cost-effectiveness
comparison of CAM therapies with celecoxib and placebo among different therapy
groups of KOA patients.
Cost-Effectiveness of CAM Therapies vs. Celecoxib among Overall KOA Patients
Group
Table 31 displays the base case results for incremental cost-effectiveness of CAM
therapies and conventional medicines among the overall KOA patients group (i.e., KOA
patients with baseline WOMAC pain sub-scale scores between 150 and 400) from US
health care payers’ perspective and 24-week time-horizon. Overall, CAM therapies were
cost-effective than conventional medicines in treating KOA. Specifically, the incremental
cost-effectiveness of glucosamine, in comparison to CS, was found to be
$11,215.38/QALY gained; whereas, while placebo was dominated, the cost effectiveness
of celecoxib was $106,225.00/QALY gained.
CS alone therapy was used as the reference group in this analysis (reason is
described earlier in this chapter) and was found to have the absolute the costeffectiveness ratio of $167.60/QALY gained.
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Table 31: Base Case Results for Cost-Effectiveness Analysis, in Overall KOA Patients
Group from US Health care Payers’ Perspective and 24-Week Time-Horizon, with
Chondroitin Sulfate as the Reference Group.
Study
Total Cost Total Incremental Incremental
ICER
Comparator
QALYs
Cost
QALYs
(Cost/QALY
gained┼
gained
gained)
CS
$114 0.6798
Glucosamine
$143 0.6824
$29
0.0026
$11,215
Celecoxib
$228 0.6832
$85
0.0008
$106,225
Glucosamine
$250 0.6799
$22
-0.0033
-$6,557*
+ CS
Placebo
$367 0.6775
$118
-0.0024
-$49,041*
*=Dominated therapies
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; QALYs=Quality-adjusted
life-years
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Sensitivity Analysis
In one-way sensitivity analysis, the following parameters were found to impact
the expected value of the cost-effectiveness model: utilities of response and no response
to the treatment at 24-weeks; medications compliance rate; and response rate among
compliant patients on celecoxib and glucosamine therapies. No other model parameters
affect cost-effectiveness ratios.
Table 32 displays the detailed results of probabilistic sensitivity analysis on all
model inputs and Figure 12 presents its scatter plot based on 10000 second-order Monte
Carlo simulations.
Table 32: Probabilistic Sensitivity Analysis Results, in Overall KOA Patients Group from
US Health care Payers’ Perspective and 24-Week Time-Horizon.

Cost

Parame
ters
Mean
SD
Min
2.50%
10%
Median
90%
97.50%
Max

CS
Glucosamine
$114
$143
$14
$27
$65
$59
$88
$95
$96
$110
$114
$141
$133
$178
$144
$199
$178
$275

Glucosamine
+ CS
Celecoxib
$250
$229
$31
$77
$159
$45
$193
$104
$211
$138
$249
$220
$290
$332
$314
$407
$397
$598

QALYs
gained┼

0.6803
0.6828
0.6803
0.6836
Mean
0.0643
0.0667
0.0644
0.0673
SD
0.3380
0.2971
0.3336
0.2872
Min
0.5472
0.5440
0.5475
0.5433
2.50%
0.5968
0.5957
0.5966
0.5956
10%
0.6832
0.6859
0.6832
0.6864
Median
0.7620
0.7673
0.7622
0.7686
90%
0.7967
0.8032
0.7975
0.8048
97.50%
0.8802
0.8804
0.8802
0.8808
Max
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years
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Placebo
$366
$74
$140
$235
$275
$362
$463
$525
$749
0.6779
0.0628
0.3290
0.5486
0.5964
0.6805
0.7584
0.7927
0.8796

Figure 12: Scatter Plot for Probabilistic Sensitivity Analysis Based on 10000 Simulations,
in Overall KOA Patients Group from US Health care Payers’ Perspective and 24-Week
Time-Horizon.

0.46 0.48 0.50 0.52 0.54 0.56 0.58 0.60 0.62 0.64 0.66 0.68 0.70 0.72 0.74 0.76 0.78 0.80 0.82 0.84 0.86

CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years

The above scatter plot can be interpreted as follows: the most cost-effective
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less
expensive) and right hand side from the X-axis (i.e., more effective).
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Figure 13 displays the cost-effectiveness acceptability curve for the above
described analysis, based on 10,000 simulations and variation of willingness-to-pay from
$0 to $500,000 per QALY gained.

Figure 13: Cost-Effectiveness Acceptability Curve, in Overall KOA Patients Group from
US Health care Payers’ Perspective and 24-Week Time-Horizon.

CS=Chondroitin Sulfate
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Cost-Effectiveness of CAM Therapies vs. Celecoxib among KOA Patients with Mild
Pain
In this sub-group analysis, cost-effectiveness of CAM therapies was compared
with celecoxib and placebo in treating KOA among those patients that had mild knee pain
at the baseline, defined by WOMAC pain sub-scale score of 150 to 300. The timehorizon was 24-weeks and study perspective was of the US healthcare payers’.
Table 33 displays the base case results for incremental cost-effectiveness of CAM
therapies with celecoxib and placebo from US health care payers’ perspective and 24week time-horizon, among the KOA patients group with mild baseline. Overall, CAM
therapies were cost-effective than conventional medicines in treating KOA. Specifically,
the incremental cost-effectiveness of glucosamine, in comparison to CS, was found to be
$24,300.00/QALY gained.
CS alone therapy was used as the reference group in this analysis (reason is
described earlier in this chapter) and was found to have the absolute the costeffectiveness ratio of $167.48/QALY gained.
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Table 33: Base Case Results for Cost-Effectiveness Analysis, in Mild Pain Only KOA
Patients Group from US Health care Payers’ Perspective and 24-Week Time-Horizon,
with Chondroitin Sulfate as the Reference Group.
Study
Total Cost Total Incremental Incremental
ICER
Comparator
QALYs
Cost
QALYs
(Cost/QALY
gained┼
gained
gained)
CS
$114 0.6803
Glucosamine
$143 0.6815
$29
0.0012
$24,300
Celecoxib
$228 0.6832
$85
0.0017
$49,988
Glucosamine
$250 0.6769
$22
-0.0063
-$3,434*
+ CS
Placebo
$367 0.6787
$118
0.0018
$65,389
*=Dominated therapies
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; QALYs=Quality-adjusted
life-years
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Sensitivity Analysis
In one-way sensitivity analysis, the following parameters were found to impact
the expected value of the cost-effectiveness model: utilities of response and no response
to the treatment at 24-weeks; medications compliance rate; and response rate among
compliant and non-compliant patients on celecoxib, and among compliant patients on CS
and glucosamine. No other model parameters affect cost-effectiveness ratios.
Table 34 displays the detailed results of probabilistic sensitivity analysis on all
model inputs and Figure 14 presents its scatter plot based on 10000 second-order Monte
Carlo simulations.
Table 34: Probabilistic Sensitivity Analysis Results, in Mild Pain Only KOA Patients
Group from US Health care Payers’ Perspective and 24-Week Time-Horizon.

Cost

Parame
ters
Mean
SD
Min
2.50%
10%
Median
90%
97.50%
Max

CS
Glucosamine
$114
$143
$14
$27
$65
$59
$88
$95
$96
$110
$114
$141
$133
$178
$144
$199
$178
$275

Glucosamine
+ CS
Celecoxib
$250
$229
$31
$77
$159
$45
$193
$104
$211
$138
$249
$220
$290
$332
$314
$407
$397
$598

QALYs
gained┼

0.6803
0.6828
0.6803
0.6836
Mean
0.0643
0.0667
0.0644
0.0673
SD
0.3380
0.2971
0.3336
0.2872
Min
0.5472
0.5440
0.5475
0.5433
2.50%
0.5968
0.5957
0.5966
0.5956
10%
0.6832
0.6859
0.6832
0.6864
Median
0.7620
0.7673
0.7622
0.7686
90%
0.7967
0.8032
0.7975
0.8048
97.50%
0.8802
0.8804
0.8802
0.8808
Max
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years
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Placebo
$366
$74
$140
$235
$275
$362
$463
$525
$749
0.6779
0.0628
0.3290
0.5486
0.5964
0.6805
0.7584
0.7927
0.8796

Figure 14: Scatter Plot for Probabilistic Sensitivity Analysis, in Mild Pain Only KOA
Patients Group from US Health care Payers’ Perspective and 24-Week Time-Horizon.

CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years

The above scatter plot can be interpreted as follows: the most cost-effective
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less
expensive) and right hand side from the X-axis (i.e., more effective).
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Figure 15 displays the cost-effectiveness acceptability curve for the above
described analysis, based on 10,000 simulations and variation of willingness-to-pay from
$0 to $500,000 per QALY gained.

Figure 15: Cost-Effectiveness Acceptability Curve for Cost-Effectiveness Analysis, in
Mild Pain Only KOA Patients Group from US Health care Payers’ Perspective and 24Week Time-Horizon.

CS=Chondroitin Sulfate
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Cost-Effectiveness of CAM Therapies vs. Celecoxib among KOA Patients with
Moderate to Severe Pain
In this sub-group analysis, cost-effectiveness of CAM therapies was compared
with celecoxib and placebo in the treatment of KOA among those patients that had
moderate to severe knee pain at the baseline, defined by WOMAC pain sub-scale score of
301 to 400. The time-horizon was 24-weeks and study perspective was of the US
healthcare payers’.
Table 35 displays the base case results for incremental cost-effectiveness of CAM
therapies with celecoxib and placebo from US health care payers’ perspective and 24week time-horizon, among the KOA patients group with moderate to severe baseline
pain. Overall, CAM therapies were cost-effective than conventional medicines in treating
KOA. Specifically, the incremental cost-effectiveness of glucosamine, in comparison to
CS, was found to be $3,313.63/QALY gained and of combination of glucosamine and CS
was $3,278.78/QALY gained.
CS alone therapy was used as the reference group in this analysis (reason is
described earlier in this chapter) and was found to have the absolute the costeffectiveness ratio of $167.17/QALY gained.
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Table 35: Base Case Results for Cost-Effectiveness Analysis, in Moderate to Severe Pain
KOA Patients Group from US Health care Payers’ Perspective and 24-Week TimeHorizon, with Chondroitin Sulfate as the Reference Group.
Study
Total Cost Total Incremental Incremental
ICER
Comparator
QALYs
Cost
QALYs
(Cost/QALY
gained┼
gained
gained)
CS
$114 0.6775
Glucosamine
$143 0.6863
$29
0.0088
$3,314
Celecoxib
$228 0.6838
$85
-0.0025
-$33,992*
Glucosamine
$250 0.6904
$22
0.0066
$3,279
+ CS
Placebo
$367 0.6732
$118
-0.0172
-$6,843*
*=Dominated therapies
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; QALYs=Quality-adjusted
life-years
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Sensitivity Analysis
In one-way sensitivity analysis, the following parameters were found to impact
the expected value of the cost-effectiveness model: utilities of response and no response
to the treatment at 24-weeks; medications compliance rate; and 24-week cost of treatment
with combination therapy of glucosamine and CS. No other model parameters affect costeffectiveness ratios.
Table 36 displays the detailed results of probabilistic sensitivity analysis on all
model inputs and Figure 16 presents its scatter plot based on 10000 second-order Monte
Carlo simulations.

Table 36: Probabilistic Sensitivity Analysis Results, in Moderate to Severe Pain KOA
Patients Group from US Health care Payers’ Perspective and 24-Week Time-Horizon.

Cost

Parame
ters
Mean
SD
Min
2.50%
10%
Median
90%
97.50%
Max

CS
Glucosamine
$114
$143
$14
$27
$68
$61
$88
$94
$97
$110
$114
$141
$133
$179
$143
$200
$178
$297

Glucosamine
+ CS
Celecoxib
$250
$228
$31
$77
$156
$35
$193
$104
$211
$137
$249
$219
$291
$331
$315
$404
$373
$699

QALYs
gained┼

0.6773
0.6862
0.6902
0.6836
Mean
0.0625
0.0705
0.0746
0.0677
SD
0.4026
0.3535
0.3546
0.3758
Min
0.5482
0.5374
0.5317
0.5419
2.50%
0.5941
0.5919
0.5911
0.5935
10%
0.6803
0.6896
0.6942
0.6870
Median
0.7552
0.7741
0.7824
0.7683
90%
0.7919
0.8138
0.8234
0.8062
97.50%
0.8890
0.9163
0.9208
0.9007
Max
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years
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Placebo
$367
$74
$127
$237
$276
$362
$466
$526
$702
0.6730
0.0604
0.4305
0.5484
0.5926
0.6758
0.7488
0.7853
0.8882

Figure 16: Scatter Plot for Probabilistic Sensitivity Analysis, in Moderate to Severe Pain
KOA Patients Group from US Health care Payers’ Perspective and 24-Week TimeHorizon.

CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years

The above scatter plot can be interpreted as follows: the most cost-effective
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less
expensive) and right hand side from the X-axis (i.e., more effective).
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Figure 17 displays the cost-effectiveness acceptability curve for the above
described analysis, based on 10,000 simulations and variation of willingness-to-pay from
$0 to $500,000 per QALY gained.

Figure 17: Cost-Effectiveness Acceptability Curve for Cost-Effectiveness Analysis, in
Moderate to Severe Pain KOA Patients Group from US Health care Payers’ Perspective
and 24-Week Time-Horizon.

CS=Chondroitin Sulfate
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Section 3: Findings for Study Objective 3:
The third objective of our study was to compare the incremental costeffectiveness of CAM therapies (i.e., glucosamine, CS, and their combination therapy)
with celecoxib and placebo to treat KOA from the patients’ perspective and 24-week
time-horizon. Tables 37 to 42 display results for cost-effectiveness comparison of CAM
therapies with celecoxib and placebo among different study groups of KOA patients.
Cost-Effectiveness of CAM Therapies vs. Celecoxib among Overall KOA Patients
Group
Table 37 displays the base case results for incremental cost-effectiveness of CAM
therapies and conventional medicines among the overall KOA patients group (i.e., KOA
patients with baseline WOMAC pain sub-scale scores between 150 and 400) from
patients’ perspective and 24-week time-horizon. Overall, CAM therapies were costeffective than conventional medicines in treating KOA. Specifically, the incremental
cost-effectiveness of glucosamine, in comparison to CS, was found to be
$11,215.38/QALY gained; whereas, both placebo and combination therapy of
glucosamine and CS were dominated.
CS alone therapy was used as the reference group in this analysis (reason is
described earlier in this chapter) and was found to have the absolute the costeffectiveness ratio of $9,417.63/QALY gained.
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Table 37: Base Case Results for Cost-Effectiveness Analysis, in Overall KOA Patients
Group from Patients’ Perspective and 24-Week Time-Horizon, with Chondroitin Sulfate
as the Reference Group.
Study
Total Cost Total Incremental Incremental
ICER
Comparator
QALYs
Cost
QALYs
(Cost/QALY
gained┼
gained
gained)
CS
$6,402 0.6798
Glucosamine
$6,431 0.6824
$29
0.0026
$11,215
Celecoxib
$6,516 0.6832
$85
0.0008
$106,225
Glucosamine
$6,538 0.6799
$22
-0.0033
-$6,557*
+ CS
Placebo
$6,656 0.6775
$118
-0.0024
-$49,041*
*=Dominated therapies
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; QALYs=Quality-adjusted
life-years
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Sensitivity Analysis
In one-way sensitivity analysis, the following parameters were found to impact
the expected value of the cost-effectiveness model: utilities of response and no response
to the treatment at 24-weeks; medications compliance rate; indirect healthcare costs for
KOA treatment; and response rate among compliant and non-compliant patients on
celecoxib and compliant patients on glucosamine and CS alone therapies. No other model
parameters affect cost-effectiveness ratios.
Table 38 displays the detailed results of probabilistic sensitivity analysis on all
model inputs and Figure 18 presents its scatter plot based on 10000 second-order Monte
Carlo simulations.
Table 38: Probabilistic Sensitivity Analysis Results, in Overall KOA Patients Group from
Patients’ Perspective and 24-Week Time-Horizon.

Cost

Parame
ters
Mean
SD
Min
2.50%
10%
Median
90%
97.50%
Max

CS
Glucosamine
$6,443
$6,472
$5,892
$5,892
$91
$112
$334
$365
$946
$969
$4,674
$4,703
$14,260
$14,288
$22,261
$22,303
$56,070
$56,136

Glucosamine
+ CS
Celecoxib
$6,579
$6,558
$5,892
$5,894
$209
$101
$474
$447
$1,079
$1,054
$4,815
$4,803
$14,397
$14,374
$22,379
$22,361
$56,241
$56,217

QALYs
gained┼

0.6808
0.6834
0.6809
0.6841
Mean
0.0639
0.0663
0.0639
0.0669
SD
0.4042
0.3990
0.4119
0.4019
Min
0.5487
0.5455
0.5486
0.5455
2.50%
0.5975
0.5971
0.5972
0.5968
10%
0.6836
0.6866
0.6837
0.6874
Median
0.7610
0.7664
0.7608
0.7685
90%
0.7981
0.8044
0.7981
0.8051
97.50%
0.8997
0.9002
0.8997
0.9006
Max
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years
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Placebo
$6,697
$5,891
$271
$584
$1,200
$4,939
$14,504
$22,499
$56,350
0.6784
0.0624
0.4087
0.5507
0.5970
0.6807
0.7567
0.7943
0.8991

Figure 18: Scatter Plot for Probabilistic Sensitivity Analysis, in Overall KOA Patients
Group from Patients’ Perspective and 24-Week Time-Horizon.

CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years

The above scatter plot can be interpreted as follows: the most cost-effective
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less
expensive) and right hand side from the X-axis (i.e., more effective).
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Figure 19 displays the cost-effectiveness acceptability curve for the above
described analysis, based on 10,000 simulations and variation of willingness-to-pay from
$0 to $500,000 per QALY gained.

Figure 19: Cost-Effectiveness Acceptability Curve for Cost-Effectiveness Analysis, in
Overall KOA Patients Group from Patients’ Perspective and 24-Week Time-Horizon.

CS=Chondroitin Sulfate
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Cost-Effectiveness of CAM Therapies vs. Celecoxib among KOA Patients with Mild
Pain
In this sub-group analysis, cost-effectiveness of CAM therapies was compared
with celecoxib and placebo in the treatment of KOA among those patients that had mild
knee pain at the baseline, defined by WOMAC pain sub-scale score of 150 to 300. The
time-horizon was 24-weeks and study perspective was of the patients’.
Table 39 displays the base case results for incremental cost-effectiveness of CAM
therapies with celecoxib and placebo from patients’ perspective and 24-week timehorizon, among the KOA patients group with mild baseline. Overall, CAM therapies
were cost-effective than conventional medicines in treating KOA. Specifically, the
incremental cost-effectiveness of glucosamine, in comparison to CS, was found to be
$24,300.00/QALY gained and of celecoxib was $49,988.24/QALY gained.
CS alone therapy was used as the reference group in this analysis (reason is
described earlier in this chapter) and was found to have the absolute the costeffectiveness ratio of $9,410.71/QALY gained.
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Table 39: Base Case Results for Cost-Effectiveness Analysis, in Mild Pain Only KOA
Patients Group from Patients’ Perspective and 24-Week Time-Horizon, with Chondroitin
Sulfate as the Reference Group.
Study
Total Cost Total Incremental Incremental
ICER
Comparator
QALYs
Cost
QALYs
(Cost/QALY
gained┼
gained
gained)
CS
$6,402 0.6803
Glucosamine
$6,431 0.6815
$29.2
0.0012
$24,300
Celecoxib
$6,516 0.6832
$85.0
0.0017
$49,988
Glucosamine
$6,538 0.6789
$21.6
-0.0063
-$3,434*
+ CS
Placebo
$6,656 0.6787
$117.7
0.0018
$65,389
*=Dominated therapies
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; QALYs=Quality-adjusted
life-years

142

Sensitivity Analysis
In one-way sensitivity analysis, the following parameters were found to impact
the expected value of the cost-effectiveness model: utilities of response and no response
to the treatment at 24-weeks; medications compliance rate; indirect healthcare costs of
KOA treatment; and response rate among compliant and non-compliant patients on
celecoxib, and among compliant patients on CS and glucosamine alone therapies. No
other model parameters affect cost-effectiveness ratios.
Table 40 displays the detailed results of probabilistic sensitivity analysis on all
model inputs and Figure 20 presents its scatter plot based on 10000 second-order Monte
Carlo simulations.
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Table 40: Probabilistic Sensitivity Analysis Results, in Mild Pain Only KOA Patients
Group from Patients’ Perspective and 24-Week Time-Horizon.
Parame
ters

CS

Glucosamine

Glucosamine
+ CS
Celecoxib

Placebo

Cost
Mean

6,471

6,500

6,606

6,584

6,724

SD

6,028

6,028

6,028

6,029

6,028

90

114

212

131

245

2.50%

325

359

465

436

572

10%

939

975

1,071

1,042

1,191

4,616

4,645

4,750

4,725

4,873

90%

14,341

14,361

14,463

14,436

14,585

97.50%

22,654

22,698

22,795

22,796

22,839

Max

51,190

51,214

51,294

51,345

51,304

Mean

0.6793

0.6805

0.6759

0.6822

0.6777

SD

0.0650

0.0660

0.0625

0.0674

0.0639

Min

0.4032

0.4032

0.4016

0.4044

0.4024

2.50%

0.5470

0.5464

0.5495

0.5453

0.5480

10%

0.5933

0.5931

0.5934

0.5924

0.5934

Median

0.6816

0.6829

0.6781

0.6850

0.6801

90%

0.7610

0.7637

0.7547

0.7670

0.7577

97.50%

0.7991

0.8026

0.7915

0.8061

0.7953

Min

Median

QALYs
gained┼

Max
0.8873
0.8880
0.8753
0.8915
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years
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0.8763

Figure 20: Scatter Plot for Probabilistic Sensitivity Analysis, in Mild Pain Only KOA
Patients Group from Patients’ Perspective and 24-Week Time-Horizon.
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CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years

The above scatter plot can be interpreted as follows: the most cost-effective
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less
expensive) and right hand side from the X-axis (i.e., more effective).
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Figure 21 displays the cost-effectiveness acceptability curve for the above
described analysis, based on 10,000 simulations and variation of willingness-to-pay from
$0 to $500,000 per QALY gained.
Figure 21: Cost-Effectiveness Acceptability Curve for Cost-Effectiveness Analysis, in
Mild Pain Only KOA Patients Group from Patients’ Perspective and 24-Week TimeHorizon.

CS=Chondroitin Sulfate
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Cost-Effectiveness of CAM Therapies vs. Celecoxib among KOA Patients with
Moderate to Severe Pain
In this sub-group analysis, cost-effectiveness of CAM therapies was compared
with celecoxib and placebo in the treatment of KOA among those patients that had
moderate to severe knee pain at the baseline, defined by WOMAC pain sub-scale score of
301 to 400. The time-horizon was 24-weeks and study perspective was of the patients.
Table 41 displays the base case results for incremental cost-effectiveness of CAM
therapies with celecoxib and placebo from patients’ perspective and 24-week timehorizon, among the KOA patients group with moderate to severe baseline pain. Overall,
CAM therapies were cost-effective than conventional medicines in treating KOA.
Specifically, the incremental cost-effectiveness of glucosamine, in comparison to CS,
was found to be $3,313.63/QALY gained and of combination of glucosamine and CS was
$3,278.78/QALY gained. On the other hand, both celecoxib and placebo were dominated
by CS alone therapy.
CS alone therapy was used as the reference group in this analysis (reason is
described earlier in this chapter) and was found to have the absolute the costeffectiveness ratio of $9,449.60/QALY gained.
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Table 41: Base Case Results for Cost-Effectiveness Analysis, in Moderate to Severe Pain
KOA Patients Group from Patients’ Perspective and 24-Week Time-Horizon, with
Chondroitin Sulfate as the Reference Group.
Study
Total Cost Total Incremental Incremental
ICER
Comparator
QALYs
Cost
QALYs
(Cost/QALY
gained┼
gained
gained)
CS
$6,402 0.6775
Glucosamine
$6,431 0.6863
$29
0.0088
$3,314
Celecoxib
$6,516 0.6838
$85
-0.0025
-$33,992*
Glucosamine
$6,538 0.6904
$22
0.0066
$3,279
+ CS
Placebo
$6,656 0.6732
$118
-0.0172
-$6,843*
*=Dominated therapies
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; QALYs=Quality-adjusted
life-years
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Sensitivity Analysis
In one-way sensitivity analysis, the following parameters were found to impact
the expected value of the cost-effectiveness model: utilities of response and no response
to the treatment at 24-weeks; medications compliance rate; indirect healthcare costs of
treating KOA; and response rate among compliant and non-compliant patients on
celecoxib and compliant patients on glucosamine and CS alone therapies. No other model
parameters affect cost-effectiveness ratios.
Table 42 displays the detailed results of probabilistic sensitivity analysis on all
model inputs and Figure 22 presents its scatter plot based on 10000 second-order Monte
Carlo simulations.
Table 42: Probabilistic Sensitivity Analysis Results, in Moderate to Severe Pain KOA
Patients Group from Patients’ Perspective and 24-Week Time-Horizon.

Cost

Parame
ters
Mean
SD
Min
2.50%
10%
Median
90%
97.50%
Max

CS
Glucosamine
$114
$143
$14
$27
$67
$52
$88
$95
$97
$110
$114
$141
$132
$179
$144
$201
$174
$281

Glucosamine
+ CS
Celecoxib
$250
$230
$32
$78
$154
$39
$191
$101
$210
$137
$249
$221
$291
$332
$315
$404
$382
$717

QALYs
gained┼

0.6775
0.6861
0.6900
0.6836
Mean
0.0627
0.0709
0.0750
0.0680
SD
0.4358
0.4100
0.4101
0.4262
Min
0.5484
0.5395
0.5343
0.5425
2.50%
0.5954
0.5933
0.5910
0.5943
10%
0.6799
0.6897
0.6946
0.6868
Median
0.7567
0.7753
0.7846
0.7692
90%
0.7935
0.8148
0.8239
0.8069
97.50%
0.8660
0.9038
0.8935
0.8905
Max
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years
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Placebo
$369
$74
$143
$240
$278
$363
$467
$526
$761
0.6733
0.0605
0.4461
0.5504
0.5939
0.6750
0.7503
0.7854
0.8623

Figure 22: Scatter Plot for Probabilistic Sensitivity Analysis, in Moderate to Severe Pain
KOA Patients Group from Patients’ Perspective and 24-Week Time-Horizon.

0.48 0.50 0.52 0.54 0.56 0.58 0.60 0.62 0.64 0.66 0.68 0.70 0.72 0.74 0.76 0.78 0.80 0.82 0.84 0.86

CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years

The above scatter plot can be interpreted as follows: the most cost-effective
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less
expensive) and right hand side from the X-axis (i.e., more effective).
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Figure 23 displays the cost-effectiveness acceptability curve for the above
described analysis, based on 10,000 simulations and variation of willingness-to-pay from
$0 to $500,000 per QALY gained.

Figure 23: Cost-Effectiveness Acceptability Curve for Cost-Effectiveness Analysis, in
Moderate to Severe Pain KOA Patients Group from Patients’ Perspective and 24-Week
Time-Horizon.

CS=Chondroitin Sulfate
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Section 4: Findings for Study Objective 4:
The fourth objective of our study was to compare the incremental costeffectiveness of CAM therapies (i.e., glucosamine, CS, and their combination therapy)
with celecoxib and placebo in treating KOA from the US health care payers’ perspective
and 2-year time-horizon. Tables 43 to 48 display results for cost-effectiveness
comparison of CAM therapies with celecoxib and placebo among different study groups
of KOA patients.
Cost-Effectiveness of CAM Therapies vs. Celecoxib among Overall KOA Patients
Group
Table 43 displays the base case results for incremental cost-effectiveness of CAM
therapies and conventional medicines among the overall KOA patients group (i.e., KOA
patients with baseline WOMAC pain sub-scale scores between 150 and 400) from US
health care payers’ perspective and 2-year time-horizon. Overall, CAM therapies were
cost-effective than conventional medicines in treating KOA. Specifically, the incremental
cost-effectiveness of glucosamine, in comparison to CS, was found to be
$11,810.64/QALY gained; whereas, all other therapies were dominated.
CS alone therapy was used as the reference group in this analysis (reason is
described earlier in this chapter) and was found to have the absolute the costeffectiveness ratio of $669.23/QALY gained.
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Table 43: Base Case Results for Cost-Effectiveness Analysis, in Overall KOA Patients
Group from US Health care Payers’ Perspective and 2-Year Time-Horizon, with
Chondroitin Sulfate as the Reference Group.
Study
Total Cost Total Incremental Incremental
ICER
Comparator
QALYs
Cost
QALYs
(Cost/QALY
gained┼
gained
gained)
CS
$434
0.6482
Glucosamine $545
0.6576 $111
0.0094
$11,811
Placebo
$699
0.6492 $155
-0.0084
-$18,406*
Celecoxib
$868
0.6488 $169
-0.0004
-$422,325*
Glucosamine
$951
0.642
$82
-0.0068
-$12,116*
+ CS
*=Dominated therapies
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; QALYs=Quality-adjusted
life-years
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Sensitivity Analysis
In one-way sensitivity analysis, the following parameters were found to impact
the expected value of the cost-effectiveness model: utilities of response and no response
to the treatment at 2-years; medications compliance rate; discount rate; and response rate
among compliant and non-compliant patients on glucosamine. No other model
parameters affect cost-effectiveness ratios.
Table 44 displays the detailed results of probabilistic sensitivity analysis on all
model inputs and Figure 24 presents its scatter plot based on 10000 second-order Monte
Carlo simulations.
Table 44: Probabilistic Sensitivity Analysis Results, in Overall KOA Patients Group from
US Health care Payers’ Perspective and 2-Year Time-Horizon.

Cost

Parame
ters
Mean
SD
Min
2.50%
10%
Median
90%
97.50%
Max

CS
Glucosamine
$434
$545
$56
$103
$263
$191
$331
$366
$364
$417
$432
$539
$506
$681
$550
$761
$719
$1,137

Glucosamine
+ CS
Celecoxib
$951
$866
$122
$294
$542
$153
$731
$393
$798
$515
$946
$834
$1,112
$1,259
$1,208
$1,530
$1,429
$2,302

QALYs
gained┼

0.6485
0.6578
0.6424
1324.98
Mean
0.0620
0.0681
0.0599
0.6491
SD
0.3963
0.3784
0.3964
0.0622
Min
0.5226
0.5187
0.5217
0.3963
2.50%
0.5680
0.5684
0.5650
0.5226
10%
0.6502
0.6604
0.6437
0.5680
Median
0.7270
0.7439
0.7193
0.6508
90%
0.7627
0.7815
0.7528
0.7274
97.50%
0.8646
0.8737
0.8650
0.7638
Max
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years
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Placebo
$699
$143
$315
$452
$523
$689
$889
$1,007
$699
0.6495
0.0623
0.3963
0.5226
0.5682
0.6513
0.7284
0.7643
0.8647

Figure 24: Scatter Plot for Probabilistic Sensitivity Analysis Based on 10000 Simulations,
in Overall KOA Patients Group from US Health care Payers’ Perspective and 2-Year
Time-Horizon.

CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years

The above scatter plot can be interpreted as follows: the most cost-effective
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less
expensive) and right hand side from the X-axis (i.e., more effective).
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Figure 25 displays the cost-effectiveness acceptability curve for the above
described analysis, based on 10,000 simulations and variation of willingness-to-pay from
$0 to $500,000 per QALY gained.

Figure 25: Cost-Effectiveness Acceptability Curve, in Overall KOA Patients Group from
US Health care Payers’ Perspective and 2-Year Time-Horizon.

CS=Chondroitin Sulfate
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Cost-Effectiveness of CAM Therapies vs. Celecoxib among KOA Patients with Mild
Pain
In this sub-group analysis, cost-effectiveness of CAM therapies was compared
with celecoxib and placebo in the treatment of KOA among those patients that had mild
knee pain at the baseline defined by WOMAC pain sub-scale score of 150 to 300. The
time-horizon was 2-years and study perspective was of the US healthcare payers’.
Table 45 displays the base case results for incremental cost-effectiveness of CAM
therapies with celecoxib and placebo from US health care payers’ perspective and 2-year
time-horizon, among the KOA patients group with mild baseline. Overall, CAM therapies
were cost-effective than conventional medicines in treating KOA. Specifically, the
incremental cost-effectiveness of glucosamine, in comparison to CS, was found to be
$9,570.69/QALY gained.
CS alone therapy was used as the reference group in this analysis (reason is
described earlier in this chapter) and was found to have the absolute the costeffectiveness ratio of $668.51/QALY gained.
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Table 45: Base Case Results for Cost-Effectiveness Analysis, in Mild Pain Only KOA
Patients Group from US Health care Payers’ Perspective and 2-Year Time-Horizon, with
Chondroitin Sulfate as the Reference Group.
Study
Total Cost Total Incremental Incremental
ICER
Comparator
QALYs
Cost
QALYs
(Cost/QALY
gained┼
gained
gained)
CS
$434 0.6489
Glucosamine
$545 0.6605
$111
0.0116
$9,571
Placebo
$699 0.6476
$155
-0.0129
-$11985*
Celecoxib
$868 0.6482
$169
0.0006
$281,550
Glucosamine
$951 0.6421
$82
-0.0061
-$13506*
+ CS
*=Dominated therapies
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; QALYs=Quality-adjusted
life-years
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Sensitivity Analysis
In one-way sensitivity analysis, the following parameters were found to impact
the expected value of the cost-effectiveness model: utilities of response and no response
to the treatment at 2-years; medications compliance rate; discount rate; response rate
among compliant and non-compliant patients on glucosamine; and 2-years cost of
glucosamine therapy. No other model parameters affect cost-effectiveness ratios.
Table 46 displays the detailed results of probabilistic sensitivity analysis on all
model inputs and Figure 26 presents its scatter plot based on 10000 second-order Monte
Carlo simulations.
Table 46: Probabilistic Sensitivity Analysis Results, in Mild Pain Only KOA Patients
Group from US Health care Payers’ Perspective and 2-Year Time-Horizon.

Cost

Parame
ters
Mean
SD
Min
2.50%
10%
Median
90%
97.50%
Max

CS
Glucosamine
$433
$545
$56
$102
$260
$188
$331
$364
$363
$421
$430
$540
$506
$678
$550
$763
$717
$1,113

Glucosamine
+ CS
Celecoxib
$951
$870
$122
$298
$551
$117
$731
$387
$799
$518
$944
$837
$1,113
$1,270
$1,208
$1,553
$1,483
$2,365

QALYs
gained┼

0.6493
0.6609
0.6425
0.6486
Mean
0.0619
0.0703
0.0596
0.0616
SD
0.3987
0.3774
0.4089
0.3998
Min
0.5200
0.5121
0.5208
0.5200
2.50%
0.5681
0.5693
0.5648
0.5680
10%
0.6514
0.6642
0.6440
0.6509
Median
0.7275
0.7496
0.7177
0.7263
90%
0.7642
0.7875
0.7561
0.7638
97.50%
0.8457
0.8726
0.8409
0.8460
Max
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years
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Placebo
$697
$144
$249
$445
$521
$687
$886
$1,005
$1,353
0.6480
0.0612
0.3996
0.5198
0.5677
0.6501
0.7253
0.7625
0.8439

Figure 26: Scatter Plot for Probabilistic Sensitivity Analysis, in Mild Pain Only KOA
Patients Group from US Health care Payers’ Perspective and 2-Year Time-Horizon.

CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years

The above scatter plot can be interpreted as follows: the most cost-effective
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less
expensive) and right hand side from the X-axis (i.e., more effective).
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Figure 27 displays the cost-effectiveness acceptability curve for the above
described analysis, based on 10,000 simulations and variation of willingness-to-pay from
$0 to $500,000 per QALY gained.

Figure 27: Cost-Effectiveness Acceptability Curve for Cost-Effectiveness Analysis, in
Mild Pain Only KOA Patients Group from US Health care Payers’ Perspective and 2Year Time-Horizon.

CS=Chondroitin Sulfate
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Cost-Effectiveness of CAM Therapies vs. Celecoxib among KOA Patients with
Moderate to Severe Pain
In this sub-group analysis, cost-effectiveness of CAM therapies was compared
with celecoxib and placebo in the treatment of KOA among those patients that had
moderate to severe knee pain at the baseline defined by WOMAC pain sub-scale score of
301 to 400. The time-horizon was 2-year and study perspective was of the US healthcare
payers’.
Table 47 displays the base case results for incremental cost-effectiveness of CAM
therapies with celecoxib and placebo from US health care payers’ perspective and 2-year
time-horizon, among the KOA patients group with moderate to severe baseline pain.
Overall, with CS as the reference group, the incremental cost-effectiveness of placebo
therapy was found to be $12368.80/QALY gained.
CS alone therapy was used as the reference group in this analysis (reason is
described earlier in this chapter) and was found to have the absolute the costeffectiveness ratio of $672.14/QALY gained.
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Table 47: Base Case Results for Cost-Effectiveness Analysis, in Moderate to Severe Pain
KOA Patients Group from US Health care Payers’ Perspective and 2-Year Time-Horizon,
with Chondroitin Sulfate as the Reference Group.
Study
Total Cost Total Incremental Incremental
ICER
Comparator
QALYs
Cost
QALYs
(Cost/QALY
gained┼
gained
gained)
CS
$434 0.6454
Glucosamine
$545 0.6458
$111
0.0004
$277,550
Placebo
$699 0.6583
$155
0.0125
$12,369
Celecoxib
$868 0.6557
$169
-0.0026
-$64973*
Glucosamine
$951 0.6423
$82
-0.0134
-$6148*
+ CS
*=Dominated therapies
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; QALYs=Quality-adjusted
life-years

163

Sensitivity Analysis
In one-way sensitivity analysis, the following parameters were found to impact
the expected value of the cost-effectiveness model: utilities of response and no response
to the treatment at 24-weeks; discount rate; medications compliance rate; 2-year cost of
treatment with placebo; and response rate among compliant patients on combination of
glucosamine and CS. No other model parameters affect cost-effectiveness ratios.
Table 48 displays the detailed results of probabilistic sensitivity analysis on all
model inputs and Figure 28 presents its scatter plot based on 10000 second-order Monte
Carlo simulations.

Table 48: Probabilistic Sensitivity Analysis Results, in Moderate to Severe Pain KOA
Patients Group from US Health care Payers’ Perspective and 2-Year Time-Horizon.

Cost

Parame
ters
Mean
SD
Min
2.50%
10%
Median
90%
97.50%
Max

CS
Glucosamine
$434
$545
$55
$104
$267
$234
$333
$365
$365
$416
$432
$539
$507
$682
$550
$764
$681
$1,013

Glucosamine
+ CS
Celecoxib
$949
$874
$122
$294
$469
$190
$723
$398
$796
$521
$944
$843
$1,106
$1,272
$1,201
$1,540
$1,498
$2,313

QALYs
gained┼

0.6458
0.6462
0.6426
0.6561
Mean
0.0610
0.0616
0.0602
0.0678
SD
0.4005
0.4001
0.4023
0.3964
Min
0.5218
0.5216
0.5205
0.5183
2.50%
0.5665
0.5662
0.5648
0.5675
10%
0.6473
0.6479
0.6443
0.6581
Median
0.7229
0.7244
0.7192
0.7414
90%
0.7606
0.7615
0.7556
0.7822
97.50%
0.8411
0.8448
0.8393
0.8734
Max
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years
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Placebo
$698
$143
$289
$446
$523
$687
$887
$1,007
$1,379
0.6586
0.0687
0.3877
0.5143
0.5681
0.6612
0.7447
0.7849
0.8607

Figure 28: Scatter Plot for Probabilistic Sensitivity Analysis, in Moderate to Severe Pain
KOA Patients Group from US Health care Payers’ Perspective and 2-Year Time-Horizon.

CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years

The above scatter plot can be interpreted as follows: the most cost-effective
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less
expensive) and right hand side from the X-axis (i.e., more effective).
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Figure 29 displays the cost-effectiveness acceptability curve for the above
described analysis, based on 10,000 simulations and variation of willingness-to-pay from
$0 to $500,000 per QALY gained.

Figure 29: Cost-Effectiveness Acceptability Curve for Cost-Effectiveness Analysis, in
Moderate to Severe Pain KOA Patients Group from US Health care Payers’ Perspective
and 2-Year Time-Horizon.

CS=Chondroitin Sulfate
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Section 5: Findings for Study Objective 5:
The fifth objective of our study was to compare the incremental cost-effectiveness
of CAM therapies (i.e., glucosamine, CS, and their combination therapy) with celecoxib
and placebo to treat KOA from patients’ perspective and 2-year time-horizon. Tables 49
to 54 display results for cost-effectiveness comparison of CAM therapies with celecoxib
and placebo among different study groups of KOA patients.
Cost-Effectiveness of CAM Therapies vs. Celecoxib among Overall KOA Patients
Group
Table 49 displays the base case results for incremental cost-effectiveness of CAM
therapies and conventional medicines among the overall KOA patients group (i.e., KOA
patients with baseline WOMAC pain sub-scale scores between 150 and 400) patients’
perspective and 2-year time-horizon. Overall, CAM therapies were cost-effective than
conventional medicines in treating KOA. Specifically, the incremental cost-effectiveness
of glucosamine, in comparison to CS, was found to be $11,810.64/QALY gained;
whereas, while all other therapies were dominated.
CS alone therapy was used as the reference group in this analysis (reason is
described earlier in this chapter) and was found to have the absolute the costeffectiveness ratio of $40,681.17/QALY gained.
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Table 49: Base Case Results for Cost-Effectiveness Analysis, in Overall KOA Patients
Group from Patients’ Perspective and 2-Year Time-Horizon, with Chondroitin Sulfate as
the Reference Group.
Study
Total Cost Total Incremental Incremental
ICER
Comparator
QALYs
Cost
QALYs
(Cost/QALY
gained┼
gained
gained)
CS
$26,370 0.6482
Glucosamine
$26,481 0.6576
$111
0.0094
$11,811
Placebo
$26,635 0.6492
$155
-0.0084
-$18,406*
Celecoxib
$26,804 0.6488
$169
-0.0004
-$422,325*
Glucosamine
$26,886
0.642
$82
-0.0068
-$12,116*
+ CS
*=Dominated therapies
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; QALYs=Quality-adjusted
life-years
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Sensitivity Analysis
In one-way sensitivity analysis, the following parameters were found to impact
the expected value of the cost-effectiveness model: utilities of response and no response
to the treatment at 2-years; medications compliance rate; discount rate; response rate
among compliant and non-compliant patients on glucosamine; and 2-year cost of
treatment with glucosamine and indirect health care costs. No other model parameters
affect cost-effectiveness ratios.
Table 50 displays the detailed results of probabilistic sensitivity analysis on all
model inputs and Figure 30 presents its scatter plot based on 10000 second-order Monte
Carlo simulations.
Table 50: Probabilistic Sensitivity Analysis Results, in Overall KOA Patients Group from
Patients’ Perspective and 2-Year Time-Horizon.

Cost

Parame
ters
Mean
SD
Min
2.50%
10%
Median
90%
97.50%
Max

CS
Glucosamine
$26,461
$26,570
$6,147
$6,149
$7,047
$7,192
$15,811
$15,990
$18,822
$18,956
$25,965
$26,067
$34,622
$34,761
$39,779
$39,873
$57,455
$57,365

Glucosamine
+ CS
Celecoxib
$26,979
$26,894
$6,149
$6,156
$7,611
$7,482
$16,327
$16,232
$19,353
$19,308
$26,491
$26,402
$35,172
$35,105
$40,281
$40,132
$57,851
$58,291

QALYs
gained┼

0.6487
0.6582
0.6425
0.6493
Mean
0.0624
0.0686
0.0604
0.0627
SD
0.4036
0.3804
0.4009
0.4031
Min
0.5218
0.5175
0.5185
0.5214
2.50%
0.5664
0.5660
0.5634
0.5670
10%
0.6510
0.6624
0.6447
0.6518
Median
0.7271
0.7441
0.7184
0.7278
90%
0.7644
0.7830
0.7557
0.7658
97.50%
0.8635
0.8711
0.8588
0.8643
Max
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years
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Placebo
$26,728
$6,151
$7,497
$16,144
$19,100
$26,232
$34,905
$40,004
$57,269
0.6497
0.0629
0.4034
0.5214
0.5670
0.6521
0.7285
0.7665
0.8646

Figure 30: Scatter Plot for Probabilistic Sensitivity Analysis Based on 10000 Simulations,
in Overall KOA Patients Group from Patients’ Perspective and 2-Year Time-Horizon.

CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years

The above scatter plot can be interpreted as follows: the most cost-effective
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less
expensive) and right hand side from the X-axis (i.e., more effective).
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Figure 31 displays the cost-effectiveness acceptability curve for the above
described analysis, based on 10,000 simulations and variation of willingness-to-pay from
$0 to $500,000 per QALY gained.

Figure 31: Cost-Effectiveness Acceptability Curve, in Overall KOA Patients Group from
Patients’ Perspective and 2-Year Time-Horizon.

CS=Chondroitin Sulfate
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Cost-Effectiveness of CAM Therapies vs. Celecoxib among KOA Patients with Mild
Pain
In this sub-group analysis, cost-effectiveness of CAM therapies was compared
with celecoxib and placebo in the treatment of KOA among those patients that had mild
knee pain at the baseline defined by WOMAC pain sub-scale score of 150 to 300. The
time-horizon was 2-years and study perspective was of the patients’.
Table 51 displays the base case results for incremental cost-effectiveness of CAM
therapies with celecoxib and placebo from patients’ perspective and 2-year time-horizon,
among the KOA patients group with mild baseline. Overall, CAM therapies were costeffective than conventional medicines in treating KOA. Specifically, the incremental
cost-effectiveness of glucosamine, in comparison to CS, was found to be
$9,570.69/QALY gained.
CS alone therapy was used as the reference group in this analysis (reason is
described earlier in this chapter) and was found to have the absolute the costeffectiveness ratio of $40,783.97/QALY gained.
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Table 51: Base Case Results for Cost-Effectiveness Analysis, in Mild Pain Only KOA
Patients Group from Patients’ Perspective and 2-Year Time-Horizon, with Chondroitin
Sulfate as the Reference Group.
Study
Total Cost Total Incremental Incremental
ICER
Comparator
QALYs
Cost
QALYs
(Cost/QALY
gained┼
gained
gained)
CS
$26,465 0.6489
Glucosamine
$26,576 0.6605
$111
0.0116
$9,571
Placebo
$26,730 0.6476
$155
-0.0129
-$11,986*
Celecoxib
$26,899 0.6482
$169
0.0006
$281,533
Glucosamine
$26,982 0.6421
$82
-0.0061
-$13,506*
+ CS
*=Dominated therapies
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; QALYs=Quality-adjusted
life-years
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Sensitivity Analysis
In one-way sensitivity analysis, the following parameters were found to impact
the expected value of the cost-effectiveness model: utilities of response and no response
to the treatment at 2-years; medications compliance rate; discount rate; response rate
among compliant and non-compliant patients on glucosamine; and 2-years cost of
glucosamine therapy and indirect health care costs. No other model parameters affect
cost-effectiveness ratios.
Table 52 displays the detailed results of probabilistic sensitivity analysis on all
model inputs and Figure 32 presents its scatter plot based on 10000 second-order Monte
Carlo simulations.
Table 52: Probabilistic Sensitivity Analysis Results, in Mild Pain Only KOA Patients
Group from Patients’ Perspective and 2-Year Time-Horizon.

Cost

Parame
ters
Mean
SD
Min
2.50%
10%
Median
90%
97.50%
Max

CS
Glucosamine
$26,495
$26,604
$6,099
$6,099
$9,019
$9,117
$16,014
$16,119
$19,169
$19,276
$26,034
$26,147
$34,510
$34,601
$39,997
$40,149
$57,950
$58,024

Glucosamine
+ CS
Celecoxib
$27,011
$26,929
$6,103
$6,111
$9,524
$9,286
$16,514
$16,424
$19,672
$19,595
$26,524
$26,444
$35,006
$34,916
$40,514
$40,450
$58,282
$58,364

QALYs
gained┼

0.6500
0.6616
0.6431
0.6493
Mean
0.0625
0.0708
0.0601
0.0621
SD
0.4209
0.3852
0.4072
0.4215
Min
0.5228
0.5158
0.5219
0.5223
2.50%
0.5674
0.5670
0.5650
0.5673
10%
0.6521
0.6650
0.6451
0.6513
Median
0.7294
0.7511
0.7195
0.7284
90%
0.7666
0.7897
0.7569
0.7655
97.50%
0.8584
0.8853
0.8418
0.8580
Max
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years
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Placebo
$26,761
$6,102
$9,546
$16,243
$19,421
$26,284
$34,779
$40,289
$58,237
0.6486
0.0617
0.4210
0.5226
0.5670
0.6507
0.7272
0.7643
0.8567

Figure 32: Scatter Plot for Probabilistic Sensitivity Analysis, in Mild Pain Only KOA
Patients Group from Patients’ Perspective and 2-Year Time-Horizon.

CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years

The above scatter plot can be interpreted as follows: the most cost-effective
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less
expensive) and right hand side from the X-axis (i.e., more effective).
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Figure 33 displays the cost-effectiveness acceptability curve for the above
described analysis, based on 10,000 simulations and variation of willingness-to-pay from
$0 to $500,000 per QALY gained.

Figure 33: Cost-Effectiveness Acceptability Curve for Cost-Effectiveness Analysis, in
Mild Pain Only KOA Patients Group from Patients’ Perspective and 2-Year TimeHorizon.

CS=Chondroitin Sulfate
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Cost-Effectiveness of CAM Therapies vs. Celecoxib among KOA Patients with
Moderate to Severe Pain
In this sub-group analysis, cost-effectiveness of CAM therapies was compared
with celecoxib and placebo in the treatment of KOA among those patients that had
moderate to severe knee pain at the baseline defined by WOMAC pain sub-scale score of
301 to 400. The time-horizon was 2-year and study perspective was of the patients’.
Table 53 displays the base case results for incremental cost-effectiveness of CAM
therapies with celecoxib and placebo from patients’ perspective and 2-year time-horizon,
among the KOA patients group with moderate to severe baseline pain. Overall, with CS
as the reference group, the incremental cost-effectiveness ratio of placebo was
$12,257.03/QALY gained. While celecoxib and combination therapy of glucosamine and
CS were dominated by CS alone therapy, the incremental cost-effectiveness of
glucosamine alone therapy was $281,984.30/QALY gained.
CS alone therapy was used as the reference group in this analysis (reason is
described earlier in this chapter) and was found to have the absolute the costeffectiveness ratio of $40,891.35/QALY gained.
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Table 53: Base Case Results for Cost-Effectiveness Analysis, in Moderate to Severe Pain
KOA Patients Group from Patients’ Perspective and 2-Year Time-Horizon, with
Chondroitin Sulfate as the Reference Group.
Study
Total Cost
Total
Incremental Incremental
ICER
Comparator
QALYs
Cost
QALYs
(Cost/QALY
gained┼
gained
gained)
CS
$26,417 0.646032
Glucosamine
$26,528 0.646426
$111
0.0004
$281,984
Placebo
$26,683 0.65904
$155
0.0126
$12,257
Celecoxib
$26,852 0.65631
$169
-0.0027
-$61,865*
Glucosamine
$26,934 0.642957
$82
-0.0134
-$6,170*
+ CS
*=Dominated therapies
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; QALYs=Quality-adjusted
life-years
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Sensitivity Analysis
In one-way sensitivity analysis, the following parameters were found to impact
the expected value of the cost-effectiveness model: utilities of response and no response
to the treatment at 2-years; medications compliance rate; discount rate; response rate
among compliant and non-compliant patients on glucosamine; and 2-years cost of
glucosamine therapy. No other model parameters affect cost-effectiveness ratios.
Table 54 displays the detailed results of probabilistic sensitivity analysis on all
model inputs and Figure 34 presents its scatter plot based on 10000 second-order Monte
Carlo simulations.
Table 54: Probabilistic Sensitivity Analysis Results, in Moderate to Severe Pain KOA
Patients Group from Patients’ Perspective and 2-Year Time-Horizon.

Cost

Parame
ters
Mean
SD
Min
2.50%
10%
Median
90%
97.50%
Max

CS
Glucosamine
$434
$545
$56
$103
$253
$245
$333
$363
$366
$417
$432
$538
$507
$681
$551
$762
$646
$1,042

Glucosamine
+ CS
Celecoxib
$949
$873
$122
$292
$541
$121
$725
$397
$800
$526
$942
$839
$1,108
$1,255
$1,204
$1,532
$1,682
$2,183

QALYs
gained┼

0.6460
0.6464
0.6430
0.6563
Mean
0.0612
0.0617
0.0602
0.0683
SD
0.3967
0.3960
0.3998
0.3714
Min
0.5222
0.5208
0.5214
0.5156
2.50%
0.5664
0.5660
0.5643
0.5669
10%
0.6476
0.6478
0.6440
0.6583
Median
0.7238
0.7250
0.7191
0.7413
90%
0.7608
0.7621
0.7564
0.7835
97.50%
0.8525
0.8528
0.8531
0.8697
Max
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years
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Placebo
$702
$146
$252
$447
$521
$692
$894
$1,013
$1,385
0.6590
0.0694
0.3868
0.5156
0.5676
0.6619
0.7459
0.7851
0.8696

Figure 34: Scatter Plot for Probabilistic Sensitivity Analysis, in Moderate to Severe Pain
KOA Patients Group from Patients’ Perspective and 2-Year Time-Horizon.

CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years

The above scatter plot can be interpreted as follows: the most cost-effective
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less
expensive) and right hand side from the X-axis (i.e., more effective).
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Figure 35 displays the cost-effectiveness acceptability curve for the above
described analysis, based on 10,000 simulations and variation of willingness-to-pay from
$0 to $500,000 per QALY gained.

Figure 35: Cost-Effectiveness Acceptability Curve for Cost-Effectiveness Analysis, in
Moderate to Severe Pain KOA Patients Group from Patients’ Perspective and 2-Year
Time-Horizon.

CS=Chondroitin Sulfate
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Structural Sensitivity Analysis
As described in the methods section, structural sensitivity analysis was performed
on the 10-year Markov model to account for the robustness of assumption of no risk of
adverse events associated with CAM therapies.
Structural Sensitivity Analysis of Cost-Effectiveness of CAM Therapies vs.
Conventional Medicines among Overall KOA Patients Group
Table 55 displays the detailed results of probabilistic sensitivity analysis on all
model inputs and Figure 36 presents its scatter plot based on 10000 second-order Monte
Carlo simulations.
Table 55: Probabilistic Sensitivity Analysis Results, in Overall KOA Patients Group from
Healthcare Payers Perspective and 10-Year Time-Horizon.

Cost

Parame
ters
Mean
SD
Min
2.50%
10%
Median
90%
97.50%
Max

CS
Glucosamine
$7,598
$8,057
$1,607
$1,613
$3,175
$3,589
$4,913
$5,352
$5,649
$6,115
$7,441
$7,917
$9,706
$10,169
$11,210
$11,628
$15,984
$16,350

Glucosamine
+ CS
Celecoxib
$9,749
$2,696
$1,680
$665
$5,247
$975
$6,884
$1,585
$7,708
$1,893
$9,609
$2,631
$11,963
$3,572
$13,398
$4,185
$18,067
$6,363

QALYs
gained┼

5.71
5.71
5.71
5.75
Mean
0.51
0.51
0.51
0.55
SD
3.91
3.91
3.91
3.88
Min
4.72
4.72
4.72
4.67
2.50%
5.05
5.05
5.05
5.04
10%
5.70
5.70
5.70
5.75
Median
6.38
6.39
6.39
6.48
90%
6.71
6.72
6.72
6.82
97.50%
7.66
7.67
7.67
7.86
Max
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years
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NSAIDs
$2,696
$665
$967
$1,582
$1,894
$2,630
$3,570
$4,194
$6,366
5.75
0.55
3.89
4.67
5.04
5.75
6.48
6.82
7.86

Figure 36: Scatter Plot for Probabilistic Sensitivity Analysis, in Overall KOA Patients
Group from Healthcare Payers Perspective and 10-Year Time-Horizon.

CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years

The above scatter plot can be interpreted as follows: the most cost-effective
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less
expensive) and right hand side from the X-axis (i.e., more effective).
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Figure 37 displays the cost-effectiveness acceptability curve for the above
described analysis, based on 10,000 simulations and variation of willingness-to-pay from
$0 to $500,000 per QALY gained.

Figure 37: Cost-Effectiveness Acceptability Curve for Cost-Effectiveness Analysis, in
Overall KOA Patients Group from Healthcare Payer’s Perspective and 10-Year TimeHorizon.

CS=Chondroitin Sulfate
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Structural Sensitivity Analysis of Cost-Effectiveness of CAM Therapies vs.
Conventional Medicines among Moderate to Severe KOA Patients Group
Table 56 displays the detailed results of probabilistic sensitivity analysis on all
model inputs and Figure 38 presents its scatter plot based on 10000 second-order Monte
Carlo simulations.
Table 56: Probabilistic Sensitivity Analysis Results, in Moderate to Severe Pain KOA
Patients Group from Healthcare Payers Perspective and 10-Year Time-Horizon.

Cost

Parame
ters
Mean
SD
Min
2.50%
10%
Median
90%
97.50%
Max

CS
Glucosamine
$7,597
$8,056
$1,609
$1,614
$3,175
$3,589
$4,900
$5,350
$5,644
$6,107
$7,441
$7,917
$9,713
$10,179
$11,208
$11,631
$15,984
$16,350

Glucosamine
+ CS
Celecoxib
$9,749
$2,755
$1,681
$683
$5,247
$991
$6,891
$1,616
$7,704
$1,932
$9,607
$2,689
$11,971
$3,654
$13,398
$4,277
$18,067
$6,525

QALYs
gained┼

5.70
5.71
5.73
5.75
Mean
0.51
0.51
0.52
0.55
SD
3.91
3.91
3.91
3.89
Min
4.72
4.72
4.73
4.68
2.50%
5.05
5.05
5.06
5.05
10%
5.70
5.70
5.73
5.75
Median
6.38
6.38
6.42
6.48
90%
6.71
6.72
6.75
6.82
97.50%
7.65
7.66
7.73
7.85
Max
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years
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NSAIDs
$2,755
$683
$984
$1,612
$1,933
$2,689
$3,651
$4,290
$6,517
5.75
0.55
3.90
4.68
5.05
5.75
6.47
6.82
7.84

Figure 38: Scatter Plot for Probabilistic Sensitivity Analysis, in Moderate to Severe Pain
KOA Patients Group from Healthcare Payers Perspective and 10-Year Time-Horizon.

CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years

The above scatter plot can be interpreted as follows: the most cost-effective
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less
expensive) and right hand side from the X-axis (i.e., more effective).
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Figure 39 displays the cost-effectiveness acceptability curve for the above
described analysis, based on 10,000 simulations and variation of willingness-to-pay from
$0 to $500,000 per QALY gained.

Figure 39: Cost-Effectiveness Acceptability Curve for Cost-Effectiveness Analysis, in
Moderate to Severe Pain KOA Patients Group from Healthcare Payer’s Perspective and
10-Year Time-Horizon.

CS=Chondroitin Sulfate
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Structural Sensitivity Analysis of Cost-Effectiveness of CAM Therapies vs.
Conventional Medicines among Mild Pain Only KOA Patients Group
Table 57 displays the detailed results of probabilistic sensitivity analysis on all
model inputs and Figure 40 presents its scatter plot based on 10000 second-order Monte
Carlo simulations.
Table 57: Probabilistic Sensitivity Analysis Results, in Mild Pain Only KOA Patients
Group from Healthcare Payers Perspective and 10-Year Time-Horizon.

Cost

Parame
ters
Mean
SD
Min
2.50%
10%
Median
90%
97.50%
Max

CS
Glucosamine
$7,588
$8,048
$1,602
$1,608
$3,175
$3,589
$4,912
$5,350
$5,644
$6,102
$7,436
$7,911
$9,690
$10,155
$11,199
$11,621
$15,984
$16,350

Glucosamine
+ CS
Celecoxib
$9,740
$2,710
$1,675
$668
$5,247
$979
$6,884
$1,595
$7,707
$1,903
$9,599
$2,646
$11,953
$3,588
$13,391
$4,204
$18,067
$6,401

QALYs
gained┼

5.70
5.71
5.70
5.75
Mean
0.51
0.51
0.51
0.55
SD
3.91
3.91
3.90
3.89
Min
4.71
4.71
4.71
4.67
2.50%
5.05
5.05
5.05
5.04
10%
5.69
5.70
5.69
5.75
Median
6.38
6.39
6.38
6.48
90%
6.72
6.72
6.72
6.83
97.50%
7.65
7.67
7.65
7.86
Max
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years
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NSAIDs
$2,710
$668
$972
$1,593
$1,906
$2,646
$3,584
$4,218
$6,413
5.75
0.55
3.89
4.67
5.04
5.75
6.48
6.83
7.85

Figure 40: Scatter Plot for Probabilistic Sensitivity Analysis, in Mild Pain Only KOA
Patients Group from Healthcare Payers Perspective and 10-Year Time-Horizon.

CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years

The above scatter plot can be interpreted as follows: the most cost-effective
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less
expensive) and right hand side from the X-axis (i.e., more effective).

189

Figure 41 displays the cost-effectiveness acceptability curve for the above
described analysis, based on 10,000 simulations and variation of willingness-to-pay from
$0 to $500,000 per QALY gained.

Figure 41: Cost-Effectiveness Acceptability Curve for Cost-Effectiveness Analysis, in
Mild Pain Only KOA Patients Group from Healthcare Payer’s Perspective and 10-Year
Time-Horizon.

CS=Chondroitin Sulfate
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Summary of Findings
Overall, CS was found to be the most cost-effective option to treat KOA patients, among
all three groups (i.e., overall, mild pain only, and moderate to severe pain). Other CAM therapy
based strategies, i.e. glucosamine alone or in combination with CS, were also found to be costeffective in general. Celecoxib was cost-effective among the mild pain only group of KOA
patients from a 24-week time-horizon and both health care payers’ and patient’s perspectives,
compared to CS as the reference.
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CHAPTER 5: DISCUSSION

This chapter is divided into six main sections. In the first section, we begin by
providing the interpretation of the findings of our study. This section is followed by
discussion on the role of adverse events as a driver of the cost-effectiveness ratios and
QALYs gained as an outcome measure. In the next section, our findings are compared
with the previous literature in the successive section. Proceeding forward in this chapter,
in the next two sections, we discuss implications of our study findings and areas for
future research related to our study. This chapter then ends by discussing the strengths
and limitations of our study in penultimate section trailed by conclusion of our study.

Interpretation of Study Findings
In this section we discuss findings of our study for all five objectives and identify
different cost-effective therapies in treating KOA for different scenarios of time-horizons
and study perspectives. Specifically, we provide details of cost-effectiveness of all study
comparators analyzed in this study, at time-horizons of 10 years, 2 years, and 24 weeks
and from the perspectives of patients and healthcare payers. Table 55 summarizes costeffectiveness of various study comparators during different conditions, as mentioned
previously.
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Table 58: Summary of Cost-Effectiveness Findings with Chondroitin Sulfate as the
Reference Group.
Time
ICER For Study Comparators* (Cost/QALY gained)
Horizon
Glu
Glu + CS
Celecoxib
NSAIDs
Placebo
10 Years (objective 1)
Overall $120367§
$3250047
Dominated Dominated
NA
Group
Mild Pain $86233┼
Dominated
Dominated Dominated
NA
Group
Moderate $962943
$73006┼
Dominated Dominated
NA
to Severe
Pain Group
24 Weeks
Healthcare Payers’ Perspective (objective 2)
Overall $11215‡
Dominated
$106225
NA
Dominated
Group
Mild Pain $24300‡
Dominated
$49988‡
NA
Dominated
Group
Moderate $3313‡
$3278‡
Dominated NA
Dominated
to Severe
Pain Group
Patients’ Perspective (objective 3)
Overall $11215‡
Dominated
$106225
NA
Dominated
Group
Mild Pain $24300‡
Dominated
$49988‡
NA
Dominated
Group
Moderate $3313‡
$3278‡
Dominated NA
Dominated
to Severe
Pain Group
2 Years
Healthcare Payers’ Perspective (objective 4)
Overall $11810‡§
Dominated
Dominated NA
Dominated
Group
Mild Pain $9570‡
Dominated
281550‡
NA
Dominated
Group
Moderate $277550
Dominated
Dominated NA
$12368‡
to Severe
Pain Group
Patients’ Perspective (objective 5)
Overall $11810‡
Dominated
Dominated NA
Dominated
Group
Mild Pain $9570‡
Dominated
281533‡
NA
Dominated
Group
Moderate $281984
Dominated
Dominated NA
$12257‡
to Severe
Pain Group
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*=Chondroitin Sulfate is used as the reference group for incremental cost-effectiveness ratios.

┼=Cost-effective at ICER threshold of $100,000/QALY gained.
‡=Cost-effective at ICER of $50,000/QALY gained.
§=Cost-effectiveness ratio of the overall pain group from 10-years horizon is
substantially higher than 2-years and 24-weeks as the former is the cumulative of annual
cost-effectiveness ratios from year 1 to 10 after discounting at 3%
CS=Chondroitin Sulfate; Glu=Glucosamine; NA=Not applicable; NSAIDs= Non-Steroidal AntiInflammatory Drugs; ICER=Incremental cost-effectiveness ratio
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For Objective 1
The first objective was to compare cost-effectiveness of CAM therapies with
conventional medicines for the treatment of KOA from the US health care payers’
perspective and 10-year time-horizon.
Overall KOA Group
For base case analysis, from US healthcare payers’ perspective and 10-year timehorizon, neither glucosamine (alone or in combination with CS) nor conventional
medicines were incrementally cost-effective. Only CS alone therapy was found to be
cost-effective at the ICER threshold of $100,000/QALY. All these results were robust to
the modeling parameters in the probabilistic sensitivity analysis (Figure 6).
KOA Patients with Mild Knee Pain
For base case analysis, we found that CS alone therapy had the lowest cost/QALY
gained and glucosamine alone therapy was incrementally cost-effective at the societal
acceptability of $100,000/QALY. All other study comparators were dominated by CS
alone therapy in this study group. All findings were reaffirmed in the probabilistic
sensitivity analysis (Figure 8).
KOA Patients with Moderate to Severe Pain
For base case analysis, we found that CS alone therapy had the lowest cost/QALY
gained and its combination therapy with glucosamine was the only incrementally costeffective comparator at the threshold of $100,000/QALY gained. All findings were
robust in the probabilistic sensitivity analysis (Figure 10).
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For Objective 2
The second objective was to compare the cost-effectiveness of CAM therapies
with celecoxib and placebo for the treatment of KOA from the US health care payers’
perspective and 24-week time-horizon.
Overall KOA Group
For base case analysis, we found that CS alone therapy had the lowest cost/QALY
gained, with glucosamine alone therapy being incrementally cost-effective at the
threshold of $100,000/QALY gained. No other therapy was incrementally cost-effective
compared to CS alone therapy. These results of the base case analysis were reaffirmed in
the probabilistic sensitivity analysis (Figure 12).
KOA Patients with Mild Knee Pain
For base case analysis, we found that CS alone therapy had the lowest cost/QALY
gained and only the combination therapy of glucosamine and CS was incrementally costeffective at the threshold of $100,000/QALY gained. In probabilistic sensitivity analysis
as well, while CS was found to be the most cost-effective option (distribution towards
bottom right corner in scatterplot in Figure 14), combination therapy of glucosamine and
CS was incrementally cost-effective.
KOA Patients with Moderate to Severe Pain
For base case analysis, we found that all three CAM therapies based treatment
strategies were cost-effective at the ICER threshold of $100,000/QALY gained.
Specifically, the CS alone therapy had the lowest cost/QALY gained and both
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glucosamine alone and combination of glucosamine and CS were incrementally costeffective at the threshold of $100,000/QALY gained, with cost-effectiveness ratios of
$3,313.63/QALY and $3,278.78/QALY gained, respectively. On the other hand, both
celecoxib and placebo therapies were dominated by CS alone therapy in this group of
KOA patients. All findings were robust to the probabilistic sensitivity analysis (Figure
16).
For Objective 3
The third objective was to compare the cost-effectiveness of CAM therapies with
celecoxib and placebo for treatment of KOA from the US patients’ perspective and 24week time-horizon.
Overall KOA Group
For base case analysis, we found that CS alone therapy had the lowest cost/QALY
gained; whereas, only glucosamine therapy was incrementally cost-effective at the
threshold of $100,000/QALY gained. In probabilistic sensitivity analysis, CS alone
therapy was the most cost-effective option followed by glucosamine and celecoxib (as it
can be seen from the respective scatter distributions in Figure 18)—affirming the results
of base case analysis.
KOA Patients with Mild Knee Pain
For base case analysis, we found that CS alone therapy was the mocst costeffective; both glucosamine alone and celecoxib therapies were incrementally costeffective at the threshold of $100,000/QALY gained with respective cost-effectiveness
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ratios being $24,300.00/QALY and $49,988.24/QALY gained. In probabilistic sensitivity
analysis as well, similar to the overall group of KOA patients, CS alone was the most
cost-effective therapy followed by glucosamine alone and celecoxib therapies (Figure
20).
KOA Patients with Moderate to Severe Pain
For base case analysis, we found that CS alone therapy had the lowest cost/QALY
gained. Therapies of glucosamine alone and its combination with CS were incrementally
cost-effective at the threshold of $100,000/QALY gained. In probabilistic sensitivity
analysis, on the other hand, combination therapy of glucosamine and CS was found to be
incrementally cost-effective based on 10,000 second order Monte Carlo simulations, as is
displayed in Figure 22.
For Objective 4
The fourth objective was to compare the cost-effectiveness of CAM therapies
with celecoxib and placebo for treatment of KOA from the US health care payers’
perspective and 2-year time-horizon.
Overall KOA Group
For base case analysis, we found that CS alone therapy had the lowest cost/QALY
gained, whereas only glucosamine alone therapy was incrementally cost-effective at the
threshold of $100,000/QALY gained. These findings were robust to the modeling
parameters, as found through the probabilistic sensitivity analysis (Figure 24).
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KOA Patients with Mild Knee Pain
Similar to overall KOA group, for base case analysis, we found that CS alone
therapy had the lowest cost/QALY gained and only glucosamine alone therapy was
incrementally cost-effective at the threshold of $100,000/QALY gained. In probabilistic
sensitivity analysis as well, the distribution density of CS alone therapy towards bottom
right hand side of the scatterplot in Figure 26 demonstrates it to be the most cost-effective
option.
KOA Patients with Moderate to Severe Pain
For the base case analysis, we found that CS alone therapy had the lowest
cost/QALY gained. Interestingly, placebo therapy was incrementally cost-effective at the
threshold of $100,000/QALY gained.
Nonetheless, these findings provide only the economic perspective and not the
ethical perspective for practicing medicine. The use of placebo in the real-world clinical
settings to treat patients is deemed unethical and all patients shall be treated with the best
available standard of care.284 All findings were robust to the modeling parameters, as
found in the probabilistic sensitivity analysis (Figure 28).
For Objective 5
The fifth objective was to compare the cost-effectiveness of CAM therapies with
celecoxib and placebo for treatment of KOA from the US patients’ perspective and 2year time-horizon.
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Overall KOA Group
For base case analysis, we found that CS alone therapy had the lowest cost/QALY
gained and only glucosamine alone therapy was found to be incrementally cost-effective
at the threshold of $100,000/QALY gained. In probabilistic sensitivity analysis, based on
10,000 second order Monte Carlo simulations, as can be seen from scatterplot in Figure
30, CS alone therapy was the most cost-effective option—affirming the results of base
case analysis.
KOA Patients with Mild Knee Pain
Similar to the above findings, for base case analysis, we found that CS alone
therapy had the lowest cost/QALY gained and only glucosamine alone therapy was
incrementally cost-effective at $100,000/QALY gained threshold. In probabilistic
sensitivity analysis as well, similar to the overall KOA patient group, CS alone therapy
was found to be the most cost-effective option, followed by glucosamine alone therapy
(Figure 32).
KOA Patients with Moderate to Severe Pain
For base case analysis, we found that CS alone therapy had the lowest cost/QALY
gained. Interestingly, placebo therapy was incrementally cost-effective at the threshold of
$100,000/QALY gained. These findings were robust to the modeling parameters as found
in the probabilistic sensitivity analysis results (Figure 34).
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Adverse Events as a Driver of Cost-Effectiveness Ratios
Risks of serious cardiovascular and GI adverse events associated with NSAIDs
and celecoxib were accounted for in the cost-effectiveness analysis while comparing the
CAM therapies and conventional medicines from the 10-year time-horizon. As described
earlier, we found that neither of the NSAIDs or celecoxib were incrementally costeffective compared to CS in the base case analysis. However, in the structural sensitivity
analysis when the risk of serious adverse events associated with conventional medicines
was excluded, we found that both NSAIDs and celecoxib are highly cost-effective
compared to the CAM therapies (Figures 51 to 56). These findings were valid for all
types of KOA patient population (i.e., overall, mild, and moderate groups), indicating that
the risk of serious adverse events modeled to be associated with conventional medicines
was a key driver of the cost-effectiveness ratios in our study.
The risk of adverse events associated with CAM therapies was not modeled in our
study due to a lack of strong scientific evidence for the same. We conducted both primary
and secondary research to find any data on the adverse events potentially associated with
the CAM therapies. In the primary analysis we searched the FAERS database to identify
safety signals associated with glucosamine and/or CS through the standard Research on
Adverse Drug evens And Reports (RADAR) methodology. No new safety signals
associated with glucosamine and/or CS were found, potentially because of the voluntary
nature of reporting of adverse events to this database. In the secondary analysis, we
reviewed the findings of two recently published meta-analyses that were based on the
previously conducted clinical trials of glucosamine and CS.25, 29 Similar to our primary
analysis, we did not find any significant (p<0.05) risk of adverse events associated with
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CAM therapies from these reviews. To the best of our knowledge, there is no other
published study (interventional or observational) that has examined the safety or efficacy
of glucosamine and/or CS. Based on these data, we conclude a scarcity of evidence for
the safety of CAM therapies.
Recent efforts by the FDA to facilitate the reporting of adverse events associated
with dietary supplements like CAM therapies are intended to broaden the knowledge of
safety of these agents. In one such instance, starting January 13th, 2014, the FDA’s Center
for Food Safety and Applied Nutrition accepts online submission of voluntary and
mandatory dietary supplements adverse events reports through forms 3500A and 3500,
respectively. Previously, only paper versions of these forms were available to report
adverse events associated with dietary supplements to the FDA. Future research
examining these data may be of high scientific importance.
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Comparison with Previous Literature
Only one published cost-effectiveness analysis has previously compared CAM
therapies with conventional medicines in treating KOA.58,59 In this study, costeffectiveness of glucosamine was compared with paracetamol (acetaminophen) and
placebo to treat KOA from 6-month time-horizon and health care payers’ perspective.
The primary outcome measure of effectiveness used in this study was QALY gained.
Only direct healthcare costs were included in the analysis, in accordance to the health
care payers’ perspective. The incremental cost-effectiveness ratios were estimated
utilizing data from a closed out clinical trial.68 This study concluded glucosamine to be
highly cost-effective in treating KOA; glucosamine dominated the paracetamol strategy
and was found to have incremental cost-effectiveness ratio of €4,285/QALY (2009)
gained in comparison to placebo.
The findings of our study are in congruence with the above described costeffectiveness analysis. Specifically, we found CS to be the most cost-effective option in
all analyses and glucosamine to have a low incremental cost-effectiveness ratio in both
24-week and 2-year time-horizon analysis, from health care payers’ as well as patients’
perspectives. From 10-year time-horizon and health care payers’ perspective,
glucosamine alone therapy was cost-effective only among KOA patients that had mild
knee pain at baseline. In moderate to severe baseline knee pain group, however, the
combination of glucosamine and CS was incrementally cost-effective at $100,000/QALY
gained threshold, but glucosamine alone was not
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Our study has several strengths in comparison to this previously published costeffectiveness analysis. First, while Scholtissen et al. conducted their study from only 6month time-horizon, our study is conducted from 6-month (24-week), 2-year, and 10-year
time-horizons to comprehensively compare cost-effectiveness of CAM therapies with
conventional medicines in treating KOA. Second, we examined the cost-effectiveness of
glucosamine and CS alone as well as combination therapies in our study; whereas
Scholtissen et al. examined only glucosamine alone therapy. Third, for the 10 year time
horizon we included two conventional medicines in our analysis, i.e. celecoxib and
NSAIDs, in comparison to only acetaminophen in the previous study. Fourth, we
included risks of several GI and cardiovascular adverse events associated with
conventional medicines in our study—since the comparator was paracetamol no such
inclusion was made in the previous study. Inclusion of such adverse events in our
analysis more closely replicates the clinical scenario of treating KOA with conventional
medicines. Fifth, our estimates of efficacies of the therapies were based on a much larger
sample size from the GAIT study (n=1,583), in comparison to the estimates used in the
previously published cost-effectiveness analysis study that were based on only 318
participants,68 leading to narrower confidence intervals of modeling parameters. Sixth,
the primary focus of our study is on the US population, in comparison to Spanish
population focus of the Scholtissen et al. study; therefore, our results may be more
helpful for health care decision-making in the US.
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Study Implications
The primary aim of conducting any cost-effectiveness analysis study is usually
exploring the optimal ways for allocation of resources. In the light of currently available
data, our results justify use of glucosamine and CS as therapies to treat KOA among the
US population, as we found CAM therapies to be cost-effective compared to
conventional medicines for the treatment of this pathology in general. Specifically,
among the overall group of KOA patients, glucosamine and CS alone therapies were the
most cost-effective. These CAM therapies were also found to be cost-effective from 10year and 2-year time-horizons among the KOA patients that had mild knee pain at the
baseline.
Comparison with GAIT findings24, 33
We found celecoxib to be cost-effective in patients with only mild pain from 24week time-horizon and both health care payers’ and patient’s perspective, at the ICER of
$50,000/QALY gained compared to CS. In congruence to these findings, celecoxib was
reported to be the only significantly better strategy than placebo in treating KOA in the
GAIT study. However in contrast with GAIT, the glucosamine, CS, or combination
treatments were no better than placebo.
Similarly, among patients with moderate to severe pain, the GAIT study found the
combination therapy of glucosamine and CS and celecoxib were significantly better
placebo in treating KOA at 24 weeks. In our study as well, among moderate to severe
pain group, this CAM combination therapy was highly cost-effective in treating KOA
from both health care payers’ and patient’s perspectives, with an ICER of $3,278/QALY
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gained compared to CS alone. Moreover, this combination CAM therapy was notstatistically significant different from placebo in GAIT study in both the overall and mild
only pain groups; in our study as well, this combination therapy was dominated (or had
extremely high ICER) compared to CS in these groups.
The higher incremental cost-effectiveness of conventional medicines, in
comparison to CAM therapies, was primarily driven by their higher drug utilization costs
(for celecoxib) and the associated risks of serious cardiovascular and GI adverse events
that lead to both higher costs and lower number of QALYs gained (for celecoxib and
NSAIDs). The currently available evidence suggests no risk of serious adverse events
associated with glucosamine and CS therapies (please refer to the materials and methods
chapter for more details); however, establishment of such relationships in future may
decrease the cost-effectiveness of CAM therapies.
The findings of our study would be most valuable after more evidence on clinical
efficacy of glucosamine and CS for treating KOA were obtained. As described in the
introduction chapter, a recent meta-analysis of 10 clinical trials reported no significant
differences in joint pain reduction or joint space width narrowing benefits between
placebo and glucosamine, CS, or combination therapy of glucosamine and CS among the
KOA patients.25 On the other hand, this meta-analysis is widely criticized for using
artificially back transforming effect sizes of the included studies to obtain pooled
estimates meta-analysis.26, 27 Furthermore, this study is criticized for not studying the
effect of CAM therapies on TKR surgery rates: a follow-up study of one of the clinical
trials included in this meta-analysis reported glucosamine group of KOA having a
significant risk reduction in TKR surgery (5-year relative risk=0.43; 95% CI=0.2-0.92),
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in comparison to placebo group.28 This, translating into per patient per month (PPPM)
cost saving of $35.44 to the health plan among the KOA patients.216 Moreover, a similar
meta-analysis study reported effect size of 0.35 (95% CI=0.14 to 0.56) in favor of
glucosamine for treating KOA.29 Since the conducted probabilistic sensitivity analysis
accounts for a wide variation in all our model inputs, including the efficacy of
glucosamine and TKR surgery rates, we do not expect these differences to impact our
findings substantially.
QALYs as an Outcome Measure
Amount of QALYs gained by KOA patients varied by treatment strategies and
time-horizon for the analysis (Table 59). A recent systematic review of SF-6D based
QALYs gained reported 0.033 (95% CI=0.029 to 0.037) as the minimal important
difference (MID) in QALYs gained.285 On this basis, only MID found in our study was in
the 10-year time-horizon model. In this model, CAM therapies of CS and glucosamine,
alone as well as together, had meaningfully more QALYs gained than conventional
medicines.
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Table 59: QALYs gained in Different Cost-Effectiveness Models.
Time
QALYs gained
Horizon
CS
Glu
Glu + CS
Celecoxib
10 Years (objective 1)
Overall 5.6833
5.6872
5.6877
4.8567
Group
Mild Pain 5.6799
5.6853
5.6801
4.8560
Group
Moderate 5.6796
5.6801
5.709
4.8545
to Severe
Pain
Group
24 Weeks
Healthcare Payers’ Perspective (objective 2)
Overall 0.6798
0.6824
0.6799
0.6832
n/a
Group
Mild Pain 0.6803
0.6815
0.6769
0.6832
n/a
Group
Moderate 0.6775
0.6863
0.6904
0.6838
n/a
to Severe
Pain
Group
Patients’ Perspective (objective 3)
Overall 0.6798
0.6824
0.6799
0.6832
Group
Mild Pain 0.6803
0.6815
0.6769
0.6832
Group
Moderate 0.6775
0.6863
0.6904
0.6838
to Severe
Pain
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NSAIDs

Placebo

4.7765

n/a

4.7754

n/a

4.7728

n/a

0.6775
0.6787
0.6732

n/a

0.6775

n/a

0.6787

n/a

0.6732

Time
Horizon
CS
Glu
Group
2 Years
Healthcare Payers’ Perspective (objective 4)
Overall 0.6482
0.6576
Group
Mild Pain 0.6489
0.6605
Group
Moderate 0.6454
0.6458
to Severe
Pain
Group
Patients’ Perspective (objective 5)
Overall 0.6482
0.6576
Group
Mild Pain 0.6489
0.6605
Group
Moderate 0.6454
0.6458
to Severe
Pain
Group

QALYs gained
Glu + CS

Celecoxib

NSAIDs

Placebo

0.6420

0.6488

n/a

0.6492

0.6421

0.6482

n/a

0.6476

0.6423

0.6557

n/a

0.6583

0.6420

0.6488

n/a

0.6492

0.6421

0.6482

n/a

0.6476

0.6423

0.6557

n/a

0.6583

CS=Chondroitin Sulfate; Glu=Glucosamine; NA=Not applicable; NSAIDs= Non-Steroidal Anti-Inflammatory Drugs
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It is noteworthy that different PRO instruments used to measure health utilities
values in order to estimate QALYs may yield different results.286, 287 For example, Raisch
et al compared health utilities estimated using the SF-6D, Health Utilities Index, Mark II
and Mark III (HUI2 and HUI3) and the feeling thermometer (FT) among type 2 diabetes
participants in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.283
Poor agreement between different instruments were reported except for two: the intracorrelation cofficients were 0.245 for FT/SF-6D, 0.313 for HUI3/SF-6D, 0.437 for
HUI2/SF-6D, 0.338 for FT/HUI2, 0.337 for FT/HUI3 and 0.751 for HUI2/HUI3 (P <
0.001 for all).
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Areas for Future Research
The sub-sections below discuss several areas for future research that may help in
informing health care decision-making processes related to KOA treatment, in the US as
well as internationally.
Societal Perspective
Some stakeholders recommend using a societal perspective for base case analysis
such as The US Panel on Cost-Effectiveness in Health and Medicine. Future costeffectiveness analyses conducted from societal perspective to compare cost-effectiveness
of CAM therapies with conventional medicines may be helpful to the decision-makers,
because of inclusion of KOA treatment costs to the society in the analysis as well as
utilization of societal health utility values rather than of the patients. The SF-6D is
derived from a British societal perspective, so it could vary from QALY measures using a
US societal perspective.
We chose health care payers’ and patients’ perspectives for the purpose of our
study for the following reasons: (1) All published health utility data currently available
for modeling inputs required to conduct cost-effectiveness analysis like ours are based on
KOA patients rather than societal sample; therefore, using such data for societal
perspective analysis may yield biased estimates of cost-effectiveness ratios, (2) In the US,
health insurance providers (government and commercial), followed by out-of-pocket
payments by patients, are the two largest sources of financing health care services.288 As
a result, it is important to analyze cost-effectiveness from the perspectives of these
stakeholders.
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Analysis in other countries
The ISPOR Good Research Practices Task Force Report on transferability of
health economic evaluations across international jurisdictions (i.e., across different
countries) suggests several reasons for why the cost-effectiveness of health technologies
may vary from place to place.289 These reasons include differences in the incidence and
severity of the disease in question, the availability of health care resources, clinical
practice patterns, and relative prices of health care.290
The primary focus of our study was on the US population. Further, only one
previously published cost-effectiveness analysis has compared CAM therapies with
conventional medicines in treating KOA—this study was focused on Spanish market.
Therefore, future studies focusing on other population groups such as in Europe and
Japan are required to help in informing the clinical decision-making processes in these
respective places.
Inclusion of Other Study Comparators
For our analysis, as CAM therapies, we examined glucosamine and CS alone and
as combination. In addition to these agents, several other types of CAM therapies are
currently available and used in treating KOA. These other CAM therapies include
acupuncture as well as dietary supplements such as methylsulfonylmethane, ridedronate,
and diacerein. Similarly, for conventional medicines, we examined only celecoxib (a
selective COX-2 inhibitor) and NSAIDs; whereas several other agents such as
corticosteroids, hyaluronate injections, and acetaminophen are currently used to treat
KOA. Future cost-effectiveness studies comparing these agents could be beneficial in
informing decision-making process for clinicians.
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Different Therapeutic Doses of Glucosamine and/or CS
Currently, both glucosamine and CS, alone and in combination, do not have an
approved dosage in the US, as these agents are treated as dietary supplements and are not
approved by the US FDA. Previously conducted clinical trials have used different doses
of CS (ranged from 800 mg/day to 1200 mg/day) and glucosamine (ranged from 1200
mg/day to 1500 mg/day).21, 24, 69, 86-98, 105-110
The drug clinical efficacy data utilized in our study were based on the GAIT
clinical trial in which participants were daily given 1500 mg of glucosamine, 1200 mg of
CS, or their combination. Since, as described before, there is no currently approved dose
for glucosamine or CS, future cost-effectiveness studies conducted utilizing clinical
efficacy data based on different doses of these agents than ours may be helpful.
Long Term Clinical Data on Glucosamine and/or CS
Further research is required to examine the long-term clinical efficacy and safety
of CAM therapies such as glucosamine and CS, alone or in combination, to treat KOA.
The currently available longest duration trials for glucosamine and CS alone therapies are
of 162 weeks and 104 weeks durations, respectively.33, 91, 93, 108 Based on these trials, as
well as other similar studies, as described in the literature review chapter of this
manuscript, the effectiveness of glucosamine and CS in treating KOA is currently not
well-established. Therefore, future research examining long-term efficacies and safety of
CAM therapies in treating KOA may be of scientific importance.
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Study Limitations
Although our study is the first to compare cost-effectiveness of glucosamine and
CS with conventional medicines in treating KOA, it has several limitations. First,
sampling uncertainty may exist in our study results. This is because the clinical efficacy
estimates used in our study for CAM therapies as well as conventional medicines were
primarily obtained from the GAIT study in which a single sample was drawn from the
KOA patients population. This issue was addressed in our study by reporting the 95%
confidence intervals around point estimates for average costs and QALYs gained for all
study comparators and by representing the cost-effectiveness results on acceptability
curves.
Second, risks of adverse events associated with studied therapies were not
modeled in the decision-trees. This was done because the primary data source to populate
decision-tree models in our study was GAIT in which the reported adverse events were
mild and similar across all study groups.33, 174 Exclusion of adverse events from the
decision-tree model may lead to overestimation of the cost-effectiveness of drug
therapies, especially for celecoxib which has risks of serious GI and cardiovascular
events.8 In the GAIT study, at 24-week follow-up, only three adverse events were
deemed to be associated with the drugs by the study investigators. These serious adverse
events were: heart failure (in a patient receiving combination of glucosamine and CS),
stroke (in a patient receiving celecoxib), and chest pain (in a patient receiving
glucosamine). Due to the uncommon nature of these events we do not estimate these to
impact our results. Further, no other data is currently available to associate glucosamine
and/or CS with cardiovascular events. Similarly, there were no serious GI adverse events
214

or deaths reported at the 24-week follow-up. In the 2-year GAIT follow-up study, a total
of five serious adverse events were associated with the studied therapies. These events
were myocardial infarction (in a patient receiving the glucosamine/CS combination),
coronary angioplasty (in placebo group), and hip arthroplasty, cerebrovascular accident
and abdominal wall abscess (in celecoxib group).
Third, the time-horizon of our study does not include life-time of the patients, but
extends only to 10-years. This time-period is enough to capture intervention outcomes for
both symptom-modifying and structure-modifying KOA clinical trial studies.291
Nonetheless, some organizations recommend life-time of the patients as the time-horizon
for “reference case” evaluation in cost-effectiveness analyses.34 Extrapolating timehorizon of our study to life-time of the patients may have introduced regression to the
mean as a source of bias in the magnitude of drugs’ efficacies due to the natural course of
KOA.33, 292 The possibility of the effect of regression to the mean was also reported in the
GAIT 2-year follow-up study as well as in a meta-analysis comparing the efficacy of
glucosamine, CS, their combination, and celecoxib.25, 33 Thus, one may get different
results by extending the study time-horizon to the life-time of the patients.
Fourth, the GAIT participants had relatively mild knee pain at baseline. This
factor is different from some other KOA clinical trials in which a criterion for entry in the
study was a disease flare after the discontinuation of NSAIDs.293, 294 For this reason, one
may argue that the GAIT study may have underestimated clinical efficacies of the
therapies under study; this, in turn, may have led to biased estimates of cost-effectiveness
in our study (i.e., parameter uncertainty). To account for this, we conducted costeffectiveness analysis stratifying KOA patients by their baseline knee pain levels into
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mild pain and moderate to severe pain groups. The cost-effectiveness analysis results
from these subgroups were similar to the overall GAIT study population (i.e., overall
KOA group), indicating the robustness of our findings to the severity of baseline pain
level. Further, this robustness of our study findings was confirmed in the one-way and
probabilistic sensitivity analyses.
Fifth, cost of physicians’ office visit is included in both CAM therapies and
conventional medicines groups. One may argue that patients on conventional medicines
would incur more physicians’ office visits in order to obtain prescriptions for celecoxib
or NSAIDs. Nonetheless, from the published literature, we did not find any evidence of
differences in the number of physicians’ office visits between KOA patients on CAM
therapies and conventional medicines. Resultantly, assumption of equal number of
physicians’ office visit in these two groups of KOA patients was made for the purpose of
our study. If at all, this assumption would bias cost-effectiveness ratios against CAM
therapies, because, ceteris paribus, KOA patients on CAM therapies would visit
physicians’ less as they do not need any prescriptions.
Sixth, our Markov cohort model does not account for the risk of revision TKR
surgery, which has both substantial costs and quality-of-life burden.216, 224, 272, 273 In the
US, 52.2% of males and 50.6% who are diagnosed with primary KOA would undergo
TKR surgery during their life-time.3 Currently, an estimated 3,471,300 KOA patients
aged over 50 years live with an intact TKR in the US, with annual revision TKR rates of
only 1.9% in adults aged less than 65 years and 1.0% in older ones.283 Therefore, we do
not expect substantial changes in cost-effectiveness outcomes if such revision TKR
surgery risks were included in the analysis.
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Seventh, one may question why different types of decision-analytic models
(Markov and decision-tree) were used for examining different objectives in this study. As
described earlier in the methods section, the purpose of studying objective 1 was to
compare the long-term (10 years) cost-effectiveness of CAM therapies with conventional
medicines in real-world where a patient may experience adverse events or death during
its treatment journey. To model these adverse events and deaths, a Markov model was
developed to investigate objective 1. The purpose of objectives 2 to 5 was to compare the
cost-effectiveness of KOA treatment strategies by exclusively simulating GAIT clinical
trial settings, which was achieved by building a decision-tree model.
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Conclusion
We compared the cost-effectiveness of CAM therapies (i.e., glucosamine and CS,
alone and in combination), conventional medicines (i.e., celecoxib and NSAIDs), and
placebo in treating KOA from time-horizons of 24 weeks, 2 years, and 10 years and from
perspectives of the US health care payers and patients.
In general, we found that CAM therapies are more cost-effective than
conventional medicines in treating KOA in the US. Specifically, mono-therapies of
glucosamine or CS were the most cost-effective among overall group of KOA patients.
Similarly, among KOA patients with mild knee pain at the baseline, monotherapies of
glucosamine or CS were found to be cost-effective from 10-year and 2-year timehorizons; whereas, from 24-week time-horizon, celecoxib was also cost-effective.
Further, among KOA patients with moderate to severe knee pain at the baseline, in
general, combination therapy of glucosamine and CS was cost-effective in treating KOA
from both 24-week and 2-year time-horizons.
Our study is the first to compare cost-effectiveness of CAM therapies and
conventional medicines in treating KOA among the US population. Results from our
study could help health policy and clinical decision-makers in selecting treatment
modalities for KOA patients. However, future research is required to examine the longterm clinical effectiveness and safety of CAM therapies such as glucosamine and CS to
treat KOA. Our study has several limitations, including potential for sampling uncertainty
in modeling inputs, non-inclusion of risk of CAM therapy associated adverse events in
decision-tree models, lack of a life-time of the patients as the study time-horizon, and
several assumptions in decision-analytic models design and development.
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APPENDICES
Appendix 1: Inclusion and Exclusion Criteria Used in the GAIT Study.
Inclusion Criteria:
1. Male or female, at least 40 years of age, with clinical diagnosis of primary KOA
based on the following clinical and radiographic criteria: (Kellgren and Lawrence
Grades 2-3).80, 295
a. Pain in the affected knee on motion or weight bearing for the majority of
days during the previous month, at least partially relieved by rest, and
b. Tibiofemoral osteophytes of at least 1 mm assessed by the certified reader
at each individual study site.
2. Clinical symptoms of KOA for at least 6 months prior to study entry.
3. Sum of WOMAC pain subscales between 125 and 400 mm inclusive.125
4. American Rheumatism Association’s (ARA) functional class I, II, or III.296
Exclusion Criteria21, 33
1. Concurrent medical/arthritic disease that could confound or interfere with
evaluation of pain or efficacy including: inflammatory arthritis, gout, episodes of
acute monarticular arthritis, psoriatic arthritis clinically consistent with
pseudogout, Paget’s disease affecting the study joint, history of septic arthritis or
avascular necrosis or intra-articular fracture of the study joint, Wilson’s disease,
hemochromatosis, alkaptonuria, or primary osteochondromatosis.
2. Spine or hip pain of sufficient magnitude to interfere with the evaluation of the
index joint.
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3. Kellgren and Lawrence Grade 4 in the contralateral knee. Isolated patellofemoral
disease manifested by primarily anterior knee pain in the absence of tibiofemoral
radiographic finding.
4. History of significant collateral ligament, anterior cruciate ligament or meniscal
injury of the index joint requiring at least one week of non-weight bearing.
5. History of arthroscopy of the affected knee within 6 months prior to study entry.
6. If aminotransferase/alanine aminotransferase (AST/ALT) are greater than two
times normal.
7. Serum creatinine of >1.8 mg/dl.
8. Uncontrolled hypertension, defined by systolic blood pressure of >150 mm Hg or
diastolic blood pressure of >90 mm Hg.
9. Diabetes mellitus, defined by fasting blood glucose of >126 mg/dl.
10. History of any illness that might confound the results of the study or pose
additional risk to the patient, in the opinion of the study investigator.
11. Allergy to or history of significant clinical or laboratory adverse experience
associated with acetaminophen, celecoxib, other NSAIDs, glucosamine or CS.
12. Allergy to shellfish.
13. Female patients must not be pregnant at entry and all study participants must
agree to practice contraception while taking study medications. A urine pregnancy
test was performed at 2nd visit (randomization visit).
14. Inability to understand the study procedures and/or give written informed consent.
15. Alcohol use in excess of 3 mixed drinks/day.297
16. Corticosteroid treatment as follows:
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a. Use of oral corticosteroids within the previous four weeks.
b. Exposure to intramuscular corticosteroids within one month prior to
entering the study.
c. Administration of intra-articular steroids to the joint under study, within 3
months of 2nd visit (randomization visit).
d. Administration of intra-articular steroids to any other joint, within 1 month
of 2nd visit (randomization visit).
17. Sustained use of NSAIDs including aspirin in anti-inflammatory doses
discontinued before study entry in accordance with the washout schedule.
However, aspirin may be discontinued for cardiovascular reasons.
18. Intra-articular injection of hyaluronic acid or congeners into the study joint within
12 months.
19. Topical analgesics administration to the study joint, or any oral analgesics within
2 weeks of 2nd visit.
20. Implementation of any other medical therapy for arthritis within one month prior
to entry.
21. Other medications, unrelated to the patient’s osteoarthritis must have been used at
a stable dosage for at least 1 month. In addition, it was anticipated that the dose of
the concomitant medication is stable during the entire treatment period.
22. Participation in another clinical study with an investigational agent within the last
4 weeks.
23. Exposure to glucosamine within 3 months or CS within 6 months of 2nd visit.
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24. Initiation of physical therapy or muscle conditioning program within 2 months
prior to study entry.
25. Concurrent use of the following medications and dietary supplements:
a. Chronic therapy with tetracycline or tetracycline derivatives.
b. Other complementary or alternative regimens for the treatment of
osteoarthritis.
c. Vitamin C intake in excess of the amount included in one daily multiple
vitamins.
d. Vitamin D intake in excess of the amount included in one daily multiple
vitamins.
26. Allergy to sulfonamides.
27. Use of anticoagulants.
28. Moderately or severely depressed, based on the Beck depression inventory
(summed score >19).298
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Appendix 2: Human Research and Review Committee Study Approval Letter.
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Appendix 3: Main Effects Model.172
OLS
RE
Mean

c
PF2
PF3
PF4
PF5
PF6
RL2
RL3
RL4
SF2
SF3
SF4
SF5
PAIN2
PAIN3
PAIN4
PAIN5
PAIN6
MH2
MH3
MH4
MH5
VIT2
VIT3
VIT4
VIT5
n
Adjusted R2

0.826
−0.009
0.008
−0.036
−0.032
−0.115
−0.023
−0.035
−0.034
−0.015
−0.041
−0.047
−0.085
0.011
0.006
−0.034
−0.065
−0.159
−0.033
−0.025
−0.098
−0.131
−0.043
−0.036
−0.033
−0.077
3518
0.204

Inconsistencies 2

Median

0.833
−0.021
−0.026
−0.065
−0.044
−0.135
−0.027
−0.055
−0.055
−0.034
−0.022
−0.041
−0.089
−0.001
−0.018
−0.026
−0.068
−0.155
−0.019
−0.032
−0.093
−0.106
−0.006
−0.008
−0.011
−0.068
3518
0.2

0.827
−0.014
0.008
−0.027
−0.043
−0.096
−0.019
−0.043
−0.036
−0.027
−0.049
−0.057
−0.073
0.008
−0.001
−0.032
−0.062
−0.149
−0.026
−0.022
−0.095
−0.114
−0.044
−0.037
−0.029
−0.076
249
0.583

0.945
−0.011
0.026
0.001
−0.064
−0.097
−0.026
−0.035
−0.026
−0.029
−0.079
−0.053
−0.113
0.003
0.002
−0.018
−0.102
−0.191
−0.058
−0.043
−0.133
−0.165
−0.051
−0.034
−0.048
−0.090
249
0.577

Constant forced to
unity
RE
Mean
1
1
−0.058 −0.060
−0.051 −0.020
−0.088 −0.060
−0.061 −0.063
−0.160 −0.131
−0.056 −0.057
−0.076 −0.068
−0.078 −0.066
−0.066 −0.071
−0.048 −0.084
−0.066 −0.093
−0.109 −0.105
−0.042 −0.048
−0.046 −0.034
−0.055 −0.070
−0.103 −0.107
−0.178 −0.181
−0.043 −0.057
−0.055 −0.051
−0.115 −0.121
−0.125 −0.140
−0.040 −0.094
−0.030 −0.069
−0.040 −0.069
−0.087 −0.106
3518
249
b
0.508

2

2

3

4

5

LB
333.01 386.63 520.71 560.88 185.3
169.57
a=All models are estimated with White’s heteroscedasticity consistent standard errors.
Estimates shown in bold are significant at p<0.05.
b=No R2 statistics (GEE estimation).
PF=Physical function; RL=Role Limitation; SF=Social functioning; MH=Mental health;
Vit=Vitality; OLS=Ordinary least squares; RE=Random error.
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Appendix 4: Models with Interaction Effects.172
RE
Mean
Constant
Forced to Unity
RE
Mean*
c
0.799 0.788 1
1
PF2
−0.023 −0.015 −0.050 −0.053
PF3
−0.021 0.011 −0.038 −0.011
PF4
−0.054 −0.018 −0.069 −0.040
PF5
−0.035 −0.034 −0.046 −0.054
PF6
−0.119 −0.084 −0.145 −0.111
RL2
−0.030 −0.021 −0.051 −0.053
RL3
−0.042 −0.030 −0.058 −0.055
RL4
−0.041 −0.024 −0.063 −0.050
SF2
−0.030 −0.023 −0.054 −0.055
SF3
−0.012 −0.040 −0.032 −0.067
SF4
−0.025 −0.042 −0.044 −0.070
SF5
−0.071 −0.058 −0.096 −0.087
PAIN2
−0.005 0.005 −0.037 −0.047
PAIN3
−0.013 0.004 −0.034 −0.025
PAIN4
−0.020 −0.025 −0.040 −0.056
PAIN5
−0.055 −0.049 −0.081 −0.091
PAIN6
−0.141 −0.136 −0.167 −0.167
MH2
−0.022 −0.030 −0.036 −0.049
MH3
−0.028 −0.019 −0.045 −0.042
MH4
−0.085 −0.089 −0.099 −0.109
MH5
−0.098 −0.109 −0.115 −0.128
VIT2
−0.006 −0.044 −0.032 −0.086
VIT3
−0.002 −0.031 −0.019 −0.061
VIT4
−0.001 −0.019 −0.022 −0.054
VIT5
−0.054 −0.064 −0.073 −0.091
MOST
−0.052 −0.041 −0.084 −0.070
LEAST
0.049 0.048
n
3518
249
3518
249
Adjusted R2 0.201 0.591 b
0.526
LB
388.3 524.64 164.18 189.87
*=Recommended model to derive preference-based scores for using in health economic
evaluations.
a=All models are estimated with White’s heteroscedasticity consistent standard errors.
Estimates shown in bold are significant at p<0.05.
b=No R2 statistics (GEE estimation).
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PF=Physical function; RL=Role Limitation; SF=Social functioning; MH=Mental health;
Vit=Vitality; RE=Random error.
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